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ABSTRACT
Signaling lipids such as diacylglycerol (DAG) and the phosphatidylinositol
polyphosphates (PIPns) play crucial roles in numerous cellular pathways. However,
characterization of their activities is hindered by the complexity of associated signaling
pathways and of the membrane environment.

To address this issue, we have

developed lipid probes that are effective for characterizing biological events using
different applications, including activity-based probing (PIPns and DAG) and microarray
analysis (PIPns). The activity-based probes have been applied to label receptor targets
in multiple cancer cell proteomes through photocrosslinking followed by click reactions.
The probes were found to label several proteins, as judged by on-gel fluorescence, and
labeling was abrogated through various controls, such as heat denaturation and
competition. Proteomic studies have been successfully performed to identify protein
targets through biotin enrichment followed by mass spectrometric analysis.

For

microarray analysis, functionalized PIPn probes were synthesized and applied to
develop a high throughput microarray analysis to measure protein-lipid binding affinity.
These approaches will be invaluable for characterizing PIPn/DAG-regulated events and
their involvement in disease. The design, synthesis and application of these lipid probes
are included in this dissertation. In addition, the design and synthesis of other lipid
probes

are

discussed,

such

as

bis(monoacylglycero)phosphate

lysophophatidylcholine (LPC) analogs.

iv

(BMP),

and
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1. CHAPTER 1 Introduction
Cell membranes consist of a complex array of molecules including lipid bilayers and
membrane proteins. Different membranes of cellular compartments possess different
lipid compositions, which is regulated by lipid metabolism and trafficking. The lipid
molecules can be classified into two categories by their roles in membranes: bulk lipids
and signaling lipids. Bulk lipids as the major composition primarily serve a structural
role, while signaling lipids as the minor composition serve as site-specific ligands.
Therefore, despite the minimal amounts of signaling lipids that are present in the
membrane, they have been actively studied by many scientists in order to understand
their activities in important processes include membrane-protein interactions. Examples
of important signaling lipids include phosphatidic acid (PA), diacylglycerol (DAG) and
the phosphatidylinositol polyphosphates (PIPns) (figure 1.1).
Protein-membrane binding interactions represent crucial molecular recognition
events that control key cellular processes including signal transduction events, viral cell
entry as well as other processes, and defects in binding have been linked to several
diseases.1,2 For instance, DAG is involved in the onset of cancer3-5 and diabetes,5 etc.
Another prominent example involves the conversion of PI-(4,5)-P2 to PIP3 by
phosphotidyl 3-kinase (PI-3K), which then binds and activates Akt, activating numerous
events that regulate the cell cycle (figure 1.2). The reverse conversion is promoted by
PTEN. As a result, enzymes that interconvert PI-(4,5)-P2 and PIP3 are among the most
heavily mutated proteins in cancer.6 Due to the key roles that lipids play in cancer and
other diseases, it is necessary to characterize binding activities to fully understand their
biological ramifications.
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Figure 1.1 Membrane lipids include signaling lipids and bulk lipids: even though
signaling lipids are the minor components comparing to other lipids, they act as the sitespecific ligands for the binding of peripheral proteins onto membrane.

It is well-documented that many proteins have binding sites that are specific to a
particular signaling lipid. For example, C1 domains are an important family of DAG
binding domains. C1 domains were named after “conserved region-1” in protein kinase
C (PKC). The C1 domains are cysteine-rich modules whose distinct motif is
HX12CX2CXnCX2CX4HX2CX7C (H is histidine, C is cysteine, X is any other amino acid).
C1 domains were originally identified in protein kinase C (PKC) isozymes and thus were
named after “conserved region-1” in PKC. Up to date, C1 domains have been also
identified in protein kinase D (PKD) isozymes, chimaerins, RasGRPs, diacylglycerol
kinases (DGKs) and etc. Because the lipid-protein binding is site-targeting, these
2

proteins were all found to be DAG receptors7. Similarly, it is evident that the PIPns also
interact with a number of specific binding protein domains. Very diverse domains have
been reported to bind PIPns: for instance, the PH, PX, FYVE, ENTH, ANTH, FERM,
Tubby and PROPPIN domains8-11.
Through the elucidation of these lipid-targeting domains, efforts were made to
unravel the mechanism by which the cytosolic proteins with these domains were
recruited into the cell membranes.1 Cytosolic proteins can be categorized into three
classes by the their relative position when interacting with membranes (see figure 1.3):
1) S-type proteins: positioned at the membrane surface and outside the lipid backbone,
thus interact primarily through the binding of polar lipid headgroups; 2) I-type proteins:
penetrate into the interfacial region and interact with both lipid headgroups and
backbones; 3) H-type proteins: insert deep into lipid bilayers and interact with both lipid
headgroups and hydrophobic backbones. Therefore, some proteins only require the
presence of polar lipid headgroups for the binding events whereas others require both
the headgroup and the membrane environment. The PH domains, in particular, bind to
the membrane primarily through its association to the polar lipid headgroups. The
crystal structures of PH domains have a binding pocket outlining the minimal regions for
membrane penetration.10 Even though we have begun to understand some of these
binding events, the research of lipid-protein interaction is still in its childhood. The
challenges we are facing include the elucidation of lipid binding receptors, the analysis
of lipid-protein binding affinities and many others.

3

Figure 1.2 Example of the key roles that lipids (PIPns) play in cellular signaling
evengs events: PI-3K converts PI-(4,5)-P2 to PIP3, which binds and activates Akt. This
activated Akt protein regulates the cell survival cycle.

4

Figure 1.3 Three types of peripheral proteins categorized by their relative position
to the membrane: S-type proteins sit on the membrane surface and interaction mainly
with the lipid headgroups; I-type and H-type proteins penetrate the interfacial region and
hydrocarbon core to certain extent, thus they interact with both lipid headgroups and
lipid backbones.

Besides the signaling lipids, other lipids serve important roles in biological
processes in different fashions. For example, bis(monoacylglycero)phosphate (BMP) as
a minimal component of cellular phospholipid content, has emerged as an important
lipid in the regulation of biological pathways. In one of the studies, BMP was found to be
one of the best stimulators of glucosylceramide hydrolysis.12 BMP was also reported to
regulate endosomal cholesterol levels under the control of Alix/AlP1, a LBPA-interacting
protein involved in sorting into multivesicular endosomes.13 Another recent proteomic
study revealed that the association of Alix with late endosomal BMP plays a vital role in
dengue virus infection in human endothelial cells.14
Another example is lysophosphatidic acid (LPA), which is found responsible for
various cellular responses.15-17 It has been reported to facilitate cell proliferation and
migration, neurite retraction, platelet aggregation, smooth muscle contraction, actin
stress formation, cytokine and chemokine secretion, etc.17 LPA is produced from LPC
by the enzyme autotaxin. 
5

All in all, lipids are critical to human health in numerous aspects. They have been
hot research topics among biologists in order to fully understand many cellular
processes. In recent years, chemistry techniques were employed in this field and
proven to be highly effective in solving many issues, which are rather difficult to solve if
solely relying on biological tools. A major application of chemical tools in this field is to
develop lipid probes. Lipid probes are implemented lipid compounds that are developed
to characterize lipid recognition events. For example, our group has developed a set of
diacylglycerol (DAG) probes bearing various reporter groups to characterize DAG
binding interactions.18 The precursor of these probes contains an azide tag at the sn-1
position of the headgroup, which was then derivatized into various fluorophores
(naphthyl, dansyl, coumarin, CBF) and photoactive group (benzophenone group) by
click reaction. The binding efficacy of these lipid probes was analyzed with a known
DAG receptor, PKC. In the SPR equilibrium binding analysis, these probes showed
similar binding affinity to natural DAG lipids. Therefore, these DAG probes can be used
to serve desired analytical functions while mimicing the binding of natural DAG lipids. In
the same manner, we also developed PA probes bearing reporter groups.19
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Scheme 1.1 DAG probes bearing various reporter groups

Some valuable PIPn probes have been developed to characterize PIPn binding. For
example, Holmes and coworkers developed PIPn probes bearing amino tag, which can
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be immobilized onto Affi-Gel 10 to purify out and identify the binding protein receptors
(figure 1.4 A).20 Photoactive radio-labeled PIPn probes were also developed (figure 1.4
B, C), as well as biotinylated PIPn probes (figure 1.4 D).21
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2. CHAPTER 2. Design, Synthesis and Application of
Phosphatidylinositol Polyphosphate (PIPn) Activity Probes as
Chemical Tools to Characterize Protein-Membrane Binding
Interactions.
1. Introduction
The family of phosphatidylinositol polyphosphates (PIPns), also known as
phosphoinositides, is an important signaling lipid family with seven naturally existing
isomers. These isomers only vary by the number and position of the phosphate groups,
and include every combination of phosphate at the 3,4 and 5 position of the D-myoinositol ring. The myo-inositol ring is a cyclitol that consists of one axial group and five
equatorial groups (figure 2.1). As the axial group is assigned as the 2-position, the
numbering system is assigned D- for counterclockwise rotation and L- for clockwise
rotation. As the PIP lipid backbone is connected to the inositol ring at the 1-position
through a phosphadiester, a PIP molecule can be generally denoted as PI(a,b,c)Pn, in
which the position and total number of phosphates on the inositol ring are indicated by
“a,b,c” and “n” respectively (“n” is usually omitted if equals to 1). Thus the PIPn isomers
are written as follows: PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, PI(4,5)P2, PI(3,4,5)P3
(figure 2.2).
Surprisingly, with the minimal differences in structures, the PIP isomers bind protein
receptors with very different specificity and affinity1,10. The consistent efforts made by
scientists to elucidate these protein–PIPn interactions have yielded many important
details: a great number of PIPn-binding protein modules have been identified, including
but not limited to the PH, PX, FYVE, ENTH, ANTH, FERM, Tubby, and PROPPIN
domains. However, further efforts are required to fully characterize these complex
events. For instance, if we consider PH domain only, there are more than 250 PHdomain-containing proteins, which can each exhibit different protein binding properties.
Thus, the structural variations of PIPns lead to variations of both affinity and specificity
of the binding to different family members. On the other hand, different proteins require
8

different motif of the PIPns to bind, with some requiring the presence of the membrane
bilayers whereas others have been shown to bind strongly to soluble headgroups. In
particular, outside of the membrane context, the PH domains exhibit binding interactions
that are primarily driven by headgroup association. As a result of the structural
complexity of the PIPns, the soluble headgroups themselves were shown to possess
comparable binding affinities to the cognate natural lipids22-24. Based on this fact, we
have targeted simplified headgroup analogs lacking the lipid backbone to study
binding.25-27
The PIPns play vital roles in many cellular events, such as lipid signaling, cell
signaling, membrane trafficking and the regulation of protein functions.8,9,28 For
example, one of the most actively studied PIPns binding proteins is Akt since this is
among the most heavily mutated proteins in cancer.6,29-31 However, the studies of lipidprotein binding are often hindered by the complex cellular environment and the kinetic
binding of protein receptors. The goal of the research discussed herein is to develop
activity-based probes corresponding to different PIP isomers that are effective for
identifying and characterizing cognate protein binding targets from cell extracts (figure
2.3).

Figure 2.1 Structure and numbering of D-myo-inositol ring: the axial position is
assigned as 2-position and D- indicates a counter-clockwise numbering system.

9

Figure 2.2 Seven isomers of PIPns family: PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2,
PI(4,5)P2, PI(3,4,5)P3.

Figure 2.3 Cartoon depiction of the use of activity-based probe to fish out
cognate binding proteins from cell extract using synthetic PIPns probes.

Activity-based protein profiling
The development of the activity-based probe strategy, along with complementary
proteomic studies has revolutionized the understanding of protein activity events at the
molecular level. In 1999, Cravatt and coworkers described a universally applicable
strategy, namely activity-based protein profiling (ABPP), through the development of
probes for the serine hydrolase superfamily.32 In this strategy (figure 2.4 a), an active
site-directed chemical probe was used to assess the functional state of enzymes in
biological systems.33 Activity-based probes usually contain two motifs: a probing group
10

(yellow ball) and a detection tag. The probing group targets a specific set of enzymes by
forming covalent bonds with the targets. The covalent binding is necessary for the
bounded complex to survive latent analytical procedures. The detection tag can be a
fluorophore, for example rhodamine so that the active enzyme can be labeled then
visualized through SDS-PAGE. If a biotin tag is used, the labeled proteins can be
purified by biotin-avidin affinity chromatography. The purified proteins are then digested
on beads by trypsin and identified by LC/MS/MS.

On the other hand, ABPP is

invaluable in evaluating the potency and selectivity of enzyme inhibitors in native
biological samples through a competition strategy (figure 2.4 b). Inhibitors were
incubated with the proteome first to compete with activity-based probes for enzyme
targets, and this competition is read out by loss of fluorescence (for fluorophoreconjugated probes) or mass spectrometry signals (for biotinylated probes).
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Figure 2.4 Demonstration of activity-based protein profiling: (a) an activity probe
contains a probing motif (yellow ball) and a detection tag which can be rhodamine for ingel analysis or biotin for protein enrichment and LC/MS/MS analysis in order to indentify
the proteins; (b) ABPP used as a strategy to study enzyme inhibitor potency: cell
extracts are subjected to inhibitors first, followed by labeling with rhodamine-tagged
probe. The suppression of the fluorescent signal on SDS-PAGE is a scale to measure
the inhibiting potency of inhibitors.

12

Bio-orthogonal reactions
Bio-orthogonal reactions are a set of reactions that are performed between
functional groups that show limited or no reactivities with any other bio-molecules. At
the same time, these reactions occur under ambient conditions. Their application to the
labeling of biological molecules has revolutionized the field of chemical biology.34-40
Examples of well-studied bio-orthogonal reactions are the azide-alkyne 1,3-dipolar
cycloaddition (click reaction), copper-free azide-cyclooctyne ring strain-promoted
cycloaddition (copper-free click reaction) and the Staudinger ligation (figure 2.5).34,41
The conventional click reaction requires the presence of copper, which is toxic to live
cells in most cases whereas the copper-free click reaction is driven solely by the ring
strain of cyclooctyne and can be carried out without any other additives. However, the
conventional click reaction occurs with a faster reaction rate (usually complete within an
hour) and the synthesis of the probes is considerably simpler.
Scientists are under active study to improve both types of click reactions. For
example, modification of the cyclooctyne has been made to speed up the copper-free
click reaction.42
In a conventional click reaction, Cu(II) is usually added rather than the direct
addition of the active form, Cu(I). Thus, the presence of a reducing reagent is required,
such as sodium ascorbate and tris(2-carboxyethyl)phosphine (TCEP). Furthermore,
ligands are often required for a transition metal-catalyzed reaction (figure 2.6). The
most commonly used ligand for click reation is tris[(1-benzyl-1H-1,2,3-triazol-4yl)methyl]amine

(TBTA).43,44

A

water-soluble

ligand

tris(3-

hydroxypropyltriazolylmethyl)amine (THPTA) has also been developed.45 Most recently,
Soriano del Amo and Wu developed a tris(triazolylmethyl)amine-based ligand (BTTES)
to form a Cu(I) complex which rapidly promotes click reaction without toxicity to living
systems.46
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Figure 2.5 Examples of bio-orthogonal reactions: 1,3-dipolar cycloaddition, namely
“click” reaction and copper-free “click” reaction driven by cyclooctyne ring strain.
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Figure 2.6 Click reaction ligands: TBTA, THPTA, BTTES

These bio-orthoganol reactions can be applied to activity-based protein profiling to
minimize the non-specific interactions between activity probes and the biological
samples induced by the detection tag (fluorophore, biotin, etc.).37,39 For example, biotin
is known to covalently bind to the epsilon-amino group of specific lysine residues in
14

some carboxylases.

47

Therefore, instead of directly attaching the detection tag to the

activity probe, a small bioorthogonal tag, generally as azide or alkyne, can be appended
to avoid any non-specific interactions. Upon the completion of the probing, the
azide/alkyne group can be derivatized to introduce reporter groups used for detection by
click reaction with an alkyne/azide-tagged detection group (figure 2.7). The
conventional copper-promoted click reaction is a good choice for applications using cell
extracts in which toxicity is not problematic.

Figure 2.7 Latent labeling of the alkyne/azido-tagged proteins using click
reaction: To minimize non-specific interactions, the probe can be labeled with a
minimal and bioorthogonal azide/alkyne group. After the probing event, this group can
be derivatized into a detection tag by performing a click reaction with an alkyne or
azide-tagged fluorophore or biotin.

Photoactive groups and photo-cross-linking
As was mentioned above, protein-membrane interactions are primarily non-covalent,
which is often too weak to survive processing. Thus, it is necessary to enforce covalent
15

labeling for successful labeling. To address this issue, the phenomenon of “crosslinking” can be implemented. This method was originally used to “fix” live cells at a
desired phase by cross-linking nearby proteins via chemical reactions or photolysis.
Formaldehydes and NHS esters (DSG, DSS) are the most commonly used chemicals in
chemical-induced cross-linking by creating “zero-distance” covalent bonds among
nearby proteins.48 Photons can also trigger such reactions when photoreactive groups
prior to photolysis, referred to as photo-cross-linking. Photo-cross-linking has several
advantages over chemical-cross-linking such as lower background, higher reaction rate
and yield, etc.49 Especially since two photoreactive amino acids (L-photo-leucine and Lphoto-methionine) recently became commercially available (Thermo Sci. Inc.), it is
expected that this strategy can be more robustly and widely applied. Examples of wellstudied photoreactive groups include diazirine, phenylazide and benzophenone (figure
2.8). When these groups absorb photons, diazirine and phenylazide release nitrogen
gas and generates a carbene or nitrene to react with protein backbones. Benzophenone
results in cross-linking by generating stabilized radicals to react with proteins in
proximity (figure 2.9).50 The photo-cross-linking strategy can be applied to ABPP,
amending this protein profiling strategy to be suitable to probe non-covalent binding
interactions such as sugar-protein binding and lipid-protein binding.

Figure 2.8 Common photoreactive groups: photoreactive groups include diazirine,
phenylazide, benzophenone and others.
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Figure 2.9 Photo-cross-linking mechanism by benzophenone: first, benzophenone
(BP) absorbs photons during photolysis and generates two radicals; second, the radical
on the oxygen rapidly undergoes hydrogen abstraction from the nearby protein
backbone while the other radical at the benzylic position is stabilized by resonance; the
remaining radical on the BP then recombines with the radical on the protein in proximity
yielded from hydrogen abstraction, thus forming a covalent bond between BP and the
protein.

Modified ABPP strategy
More specific ligands typically do not react with active site residues, so it is difficult to
enforce covalent labeling. Therefore, ABPP strategy was extended to study
receptorligand binding interactions by the introduction of a photoreactive group to
capture the non-covalent binding and a detection handle (fluorophore for visualization or
biotin for purification), which can also be installed at a latent stage by click chemistry to
minimize the non-specific interactions. This bifunctional activity probing method was
successfully used for probing carbohydrate-galectin binding interactions by Pieters and
coworkers (figure 2.10).51,52 In this approach, the probe was designed to include a
lactose binding moiety, a photoreactive group (benzophenone) to capture noncovalently bound proteins by generating a covalent bond to the nearby protein following
photolysis, and an azide tag that can undergo a click reaction with rhodamine-alkyne for
in-gel analysis of carbohydrate-galectin binding events.
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Figure 2.10 Illustration of activity-based probing mechanism for characterization of
carbohydrate-receptor binding interactions.

2. Results and discussion
2.1. Design of PIPn activity-based probes
Our lipid activity-based probes consist of the ligand moiety, a photoactive group and
a functional tag (a tag used to perform a specific function). As was discussed earlier,
some proteins primarily bind to the PIPn headgroups. Therefore, we designed this
probing strategy using solely the PIPn headgroup as binding motifs. We then chose
lysine as a “Y” shaped linker attaching to the headgroup, with one of the ends modified
into a benzophenone photoactive group and the other into a functional tag. This can be
a fluorophore for in-gel visualization, a biotin for protein enrichment or an alkyne/azide
for latent derivatization by click chemistry (figure 2.11).
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Figure 2.11 Design of PIPn activity-based probes: the probes consist of a binding
moiety, PIPn headgroup; a Y-shaped lysine linker; photoaffinity group, benzophone
group, and a functional tag that can be a fluorophore, biotin, alkyne or azide.

The mechanism by which these probes fish out cognate protein binding targets is as
follows (figure 2.12). First of all, the proteins or proteomes are incubated with the
probe. During the incubation, the PIPn probe binds to the cognate protein receptors,
however, these interactions are non-covalent. The presence of a photoaffinity group
(the benzophenone group) allows the capturing of these interactions through photolysis,
which promotes covalent cross-linking between the probe and nearby proteins. With the
secondary functional tag, labeled proteins can be visualized on a protein gel by
introducing a fluorophore tag, identified in mass spectrometry by labeling with isotopes,
or purified and then characterized by attaching to a biotin tag. Alternatively, to minimize
the size of the label and avoid non-specific protein labeling, a latent secondary tag can
be derivatized by performing a click reaction between azido (alkyne)-tagged proteins
and alkyne (azido)-tagged functional groups after the protein-lipid binding phase.
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Figure 2.12 Illustration of the mechanisms of various PIPns probes: The lipidprotein binding event is captured by photoreactive benzophenone group through
radiation, followed by derivatization of the secondary functional tag with click chemistry
into fluorophore for in-gel analysis or biotin for protein enrichment to identify proteins
using multi-dimensional mass spectrometry.

2.2. Synthesis of PIPn activity-based probes
In order to develop chemical approaches to investigate the biological roles of PIPns,
the initial requrement is the design and synthesis of natural or modified lipids. To
accomplish this, issues to be addressed include the selective installation of phosphate
groups onto the inositol ring and choices of protecting groups. Many groups have made
significant contributions to the synthesis of phosphoinositides, leading to a number of
reported syntheses.21,53,54 In 2009, our lab reported the synthesis of modifiable PIPn
isomers corresponding to all seven PIPns. In this study, PIPn-amine conjugates were
20

efficiently modified to produce multiple analogues through coupling reactions55. With
these amine-tagged PIPns in hand, several PIPn functional probes described in the
chapter were synthesized in an efficient manner (scheme 2.1).
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Scheme 2.1 Modular syntheses of various PIPn lipid probes

By following a reported procedure from our group.55 I have synthesized the aminotagged PI(4,5,)P2 and PI(3,4,5)P3 headgroups. The synthetic routes to the two
compounds only differ by whether a third benzyl group is installed at the 3-position of
compound 2.1.5. With this step performed, amino-tagged PI(3,4,5)P3 headgroup 2.2.6 is
synthesized, while without this benzyl group, an amino-tagged PI(4,5,)P2 headgroup is
instead generated. The synthesis of amino-tagged PI(3,4,5)P3 is illustrated in scheme
2.2. This began with the protection of diol D-myo-inositol using a camphor acetal to
2.1.2, followed by selective TBDPS protection of the hydroxyl at 6-position to form
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compound 2.1.3. This selectivity is generated from the higher reactivity of the alcohol at
3-position than others caused by its proximity to the axial position. The alcohols at the 3
and 4 position were then protected by benzyol group (Bz) to yield 2.1.4, leaving only the
5-position as a free alcohol due to the steric hindrance from the bulky TBDPS group
nearby. The camphor group was then removed with TFA to obtain 2.1.5. The less
sterically hindered alcohol at 3-position was then selectively protected by Bz to form
2.1.6. Next, the remaining alcohols were protected by BOM ether, followed by the
deprotection of all the Bz groups to obtain three free alcohols, which then were
phosphorylated to yield 2.1.9. Deprotection of TBDPS by TBAF then released the
alcohol at the 1-position. Phosphoramidite chemistry was performed at this position to
generate the fully-protected PI(3,4,5)P3 headgroup, followed by global deprotection
using hydrogenolysis to produce the amino-tagged PI(3,4,5)P3 headgroup 2.2.6.

Scheme 2.2 Synthesis of amino-tagged PI(3,4,5)P3.
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The second stage of the probe synthesis includes the functionalization of the lysine
and the combination of the modified lysine and the headgroup (scheme 2.3). This
synthesis of the bifunctional tag portions of these probes began with fully protected
lysine 2.2.1 (Chem-Impex International, Inc.), which after Cbz group removal, was
coupled to 4-benzoylbenzoic acid to produce Boc protected 2.2.2 (scheme 2.3). This
product was then treated with trifluoroacetic acid to deprotect the Boc-protected amino
group, which was coupled to carboxylic acids containing benzyl, benzyl (D5),
carboxyfluorescein, azide, alkyne and biotin to form intermediates of 2.2.3a-e, g. In an
alternative route, a diazo transfer reaction was used to yield 2.2.3f. Intermediates
2.2.3a-f were subjected to ester hydrolysis under basic conditions to 2.2.4a-f which
were then coupled to the desired amino-tagged PIPn headgroup to generate probes
2.2.5a-f. Specifically, a set of PI(3,4)P2 probes 2.2.5a-d were obtained by coupling
amino-tagged PI(3,4)P2 2.2.5 to 2.2.4a-d. PI(3,4,5)P3 probes 2.2.6e and 2.2.6g were
generated by the coupling of amino-tagged PI(3,4,5)P3 2.2.6 to 2.2.4e and 2.2.4g
respectively. PI(3,5)P2 probe 2.2.7e was formed by the coupling of amino-tagged
PI(3,5)P2 to 2.2.4e.
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Scheme 2.3
 Synthesis of various PIPns bifunctional probes

Since it has been reported in many other studies that successful cross-linking can
depend on the location of photoaffinity tag52, a PI(3,4,5)P3 probe with a longer linker
(2.2.10) was also synthesized with a slightly modified scheme (scheme 2.4).
Functionalized lysine acid 2.2.4e was first coupled with 6-aminocaproic acid methyl
ester hydrochloride to yield 2.2.8, followed by ester hydrolysis to generate acid 2.2.9.
Acid 2.2.9 was then converted into the corresponding NHS ester and coupled to aminotagged PI(3,4,5)P3 2.2.6 to form probe 2.2.10.
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Scheme 2.4 Synthesis of PI(3,4,5)P3 probe with longer linker

2.3 Synthesis of click reagents
In order to perform the click reaction with the described probes, many clickable tags
are needed, such as biotin-N3, biotin-alkyne, rhodamine-N3, rhodamine-alkyne, the
ligand for click reaction, etc. The syntheses of these clickable tags are discussed below
(scheme 2.5).
Azido-biotin 2.3.3 was obtained by the coupling of activated biotin 2.3.1 with 6azidohexyl amine 2.3.2 (figure 2.3). Azido-rhodamine 2.3.4 was also obtained in a
similar manner. Another azido rhodamine (2.3.8) was kindly donated by Dr. Anna
Speers from The Scripps Research Institute. A nucleophilic replacement of the chlorine
of NBD chloride by the amino group of 2.3.2 to the formation of azido NBD 2.3.5. Lastly,
in order to optimize the click reaction conditions of the probes, a previously reported
water-soluble ligand, 2.3.7, was synthesized to compare with the commercially available
ligand TBTA (tris-[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl]amine). The synthesis of 2.3.7
was accomplished by performing a click reaction between 3-Azido-1-propanol 2.3.6 and
tripropargylamine.45
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Scheme 2.5 Synthesis of various click reagents

2.4 Initial labeling of purified Akt protein bearing PH domain
The initial labeling studies were performed by incubating the synthetic probes with
the GST-tagged PH domain of Akt, expressed and purified as described previously by
Nathan Lucas in the lab of our collaborator, Dr. Wonhwa Cho.56 One of the probes used
was a PI(3,4)P2 probe directly conjugated with fluorescein (2.2.5c) (lane 1-3 in figure
2.13). The general labeling procedures are as follows: the Akt protein was generally
incubated with probe 2.2.5c for 1 hour at room temperature, followed by photolysis on
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ice under 360 nm UV exposure for 1 hour. The samples were then subjected to 1D
SDS-PAGE for in-gel fluorescent analysis. The results showed that the Akt protein (final
concentration 60 ug/mL) (lane 2) was labeled compared to the heat denatured control
(lane 3) and the no light control (lane 1). The other probe used was the PI(3,4,5)P3
alkyne probe 2.2.6e, which requires derivatization of the probe after cross-linking
through the attachment of rhodamine onto the alkyne by a click reaction (the red
labeling in figure 2.13). The same click reaction conditions were applied to both lanes 4
& 5 whereas only lane 4 with active Akt protein was labeled by rhodamine. This reveals
that the labeling of the Akt protein is specific to the active site binding and that the
photolysis procedure and the photo-affinity group are critical for the effective labeling.
To further verify that the lipid headgroup is the responsible motif for protein labeling,
competition studies were also performed using a soluble lipid headgroup lacking the
bifunctional linker (2.2.6) as a binding competitor. Interestingly, when following the
typical competition study protocol to incubate the inhibitor (2.2.6) with Akt for 1 hour
prior to probe incubation, we found no suppression of the labeling with up to 400x
inhibitor concentration (data not shown). We then attempted the competition study with
an extended inhibitor
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Figure 2.13 Labeling of Akt protein bearing PH domain
(fluorescent gel image)

incubation time. After incubating the inhibitor with Akt protein overnight prior to the
probe incubation, apparent suppression of labeling was observed with only 40x excess
of the inhibitor, and increased with larger competitor concentration (figure 2.14, lane14). On the other hand, to rule out the possibility that the bifunctional lysine linker is the
cause of the labeling, compound 2.2.3e was incubated with Akt protein in a separate
sample and treated otherwise the same as lane1. The result showed no labeling of the
Akt protein. However, it slightly labeled an impurity that exists in this Akt protein sample.
More results of the labeling in cell lysate (result in section 2.5) showed that 2.2.3e
labeled a different set of proteins from what the probe labeled. This might be due to the
extra methoxy group that 2.2.3e bears, or its hydrophobicity, since the properties of this
molecule differ significantly from the hydrophilic PIPn probes.
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Figure 2.14 Competition studies of Akt protein labeling (fluorescent gel image): In
lanes 1-4, incubation of Akt protein with excess inhibitor (2.2.6, PIP headgroup lacking
bifunctional lysine motif) prior to the incubation of probe 2.2.6e generated suppressed
fluorescent signals of the Akt protein, indicating the suppressed labeling of the Akt
protein due to the preoccupation of the binding sites. In lane 5, the bifunctional lysine
lacking the PIP headgroup did not label the Akt protein.
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2.5 PIPns probe labeling in cell extracts
After achieving the successful labeling of the known binding protein Akt, the probes
were applied in a more complex environment, cancer cell extracts, to label and identify
protein targets. The labeling experiments of the soluble fraction of human MDA-MB-435
cancer cell extracts (all the cell extracts were prepared as previously described by Dr.
Anna Speers in Dr. Benjamin Cravatt’s lab)36 were performed with various
concentrations of probe and azido-rhodamine (for latent labeling) (figure 2.15). Heat
denatured proteome samples were used as positive controls and were treated
otherwise the same. The results showed that certain bands disappeared in the heatdenatured samples, particularly in the low mass range. It is worthwhile to mention that
some of the bands do get enriched in heat-denatured samples, particularly in the higher
mass range. However, it is difficult to judge whether these enriched proteins were the
same ones that were labeled in a regular sample. Images of coomassie blue stained
gels showed identical bands for all lanes (data now shown), indicating the presence of
the same amount of proteins in each sample. Probe concentrations of 25 uM or 50 uM
were chosen for each of the following labeling studies considering the balance between
high-intensity labeling and low-intensity background.
Next, both alkyne-labeled probe 2.2.6e and fluorecein-labeled probe 2.2.5c were
used in the labeling studies with the human MDA-MB-435 cell extract (soluble fraction)
(figure 2.16). The labeling with fluorescein-labeled probe 2.2.5c (lane1,2) appeared to
have higher backgrounds than the labeling with alkyne probe 2.2.6e (lane 4-9). This is
believed to be caused by the non-specific labeling yielded from the direct attachment of
fluorescein. The result of a heat-denatured control with probe 2.2.6e (lane 5) remained
the same at probe concentration of 25 uM, compared to labeling with a 50 uM
concentration in figure 2.11. Also consistant with what was found in Akt protein labeling
studies in section 2.4 (figure 2.13), the probe itself was responsible for the labeling
rather than the azido-rhodamine, as no labeling was apparent in the no-probe control
(lane 6).
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Figure 2.15 Probe concentration screening using MDA-MB-435 cancer cell extract
(soluble fraction) (Fluorescent gel image). Concentrations ranging from 200 nM to
1nM were used to label the same amount of the cell extracts with heat-denatured
controls performed for each protein concentration. From the labeling result, probe
concentrations of 50 and 25 uM were selected for other labeling studies.
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Again, the photolysis step was crucial to the successful labeling (lane 3 & 8), since
no labeling was observed without photolysis. To optimize the click reaction conditions,
the synthetic click reaction ligand 2.3.7 (described in section 2.3) was used to replace
TBTA43, the traditional click ligand. The two samples (lane 5 and lane 9) showed very
similar labeling to one another. Therefore, the commercially available TBTA (SigmaAldrich) was used in all of the following labeling studies.
We then applied this labeling strategy to multiple cancer cell proteomes (MDA-MB435, MDA-MB-231, MCF7, T47D, prepared using a previously reported procedure36 by
Dr. Anna Speers from Dr. Benjamin Cravatt’s lab) to test its global feasibility. Both the
soluble portion and membrane portion of the cell extracts were tested and compared
(figure 2.17). Heat denatured proteomes were used as positive controls. The results
showed that most of the labeling occurred with the soluble portion of the proteomes,
which is consistent with the fact that the majority of the PIP headgroup-binding proteins
are soluble peripheral proteins. The results also indicate that this lipid-binding protein
labeling strategy is universally applicable.

Figure 2.17 Labeling of various cancer cell proteomes
(fluorescent gel image)
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2.6 Exploring the effects of PIPns probe linker length on labeling
It is well documented that the nature of a linker can affect the efficiency of the
labeling and in some cases is even critical.51,52,57 For example, different linker lengths
can cause noticeable differences in protein labeling. To explore how the linker length of
these PIPns probes affects the labeling, we synthesized and then compared probe
2.2.6e and probe 2.2.9 in terms of labeling Akt protein and cell extracts. We found that
probe 2.2.9 with the longer linker labeled neither Akt protein (figure 2.18) nor cell
extracts (figure 2.19, lane 1,2). This could be rationalized as follows: even though the
longer linker provides more flexibility for the bifunctional lysine motif, the benzophenone
photoaffinity group can only interact with proteins in proximity, and this flexibility may
provide too much freedom such that the benzophenone can move away from the bound
protein. Again, as was mentioned in section 2.4, compound 2.2.3e labeled a very
different set of proteins (figure 2.19, lane 3), which might be caused by its increased
hydrophobicity compared to the polar PIPn probes.
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Figure 2.19 MDA-MB-435 Cancer cell extracts labeling with probe 2.2.6e and
probe 2.2.9 (fluorescent gel image)

2.7 Proteomics studies of the PIP probe labeled proteins in MDA-MB-435 cancer
cell extracts
Finally, proteomic studies were performed with alkyne PI(3,4,5)P3 probe 2.2.6e.
From cytosolic MDA-MB-435 cancer cell extracts, we identified 107 proteins that
specifically bind to PI(3,4,5)P3 comparing to the results generated from lysine linker
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2.2.3e as a negative control (Table 2.1). These proteins include a number of actinbinding proteins. This is consistent with the results generated from PI(3,4,5)P3 beads
without membrane context.58 Many kinases were also identified as expected, such as
phosphoglycerate kinase 1&2, ribose-phosphate pyrophosphokinase 1. Other proteins
identified were classified as oxidoreductases, transferases, hydrolases, chaperone,
transport proteins and binding proteins. A complete list of proteins identified is affiliated
in attachment (File 2. List of PI(3,4,5)P3 binding proteins).
Accession

Protein

number

ID

Protein Name

Protein Function

P61160

ARP2

Actin-related protein 2

Actin binding

P12814

ACTN1

Alpha-actinin-1

Actin binding

O43707

ACTN4

Alpha-actinin-4

Actin binding

P21333

FLNA

Filamin-A

Actin binding

P04075

ALDOA

Fructose-bisphosphate aldolase A

Actin binding

P35579

MYH9

Myosin-9

Actin binding

P35241

RADI

Radixin

Actin binding

Q13813

SPTA2

Spectrin alpha chain, brain

Actin binding

P30153

2AAA

Serine/threonine-protein phosphatase 2A 65 kDa

Antigen binding

regulatory subunit A alpha isoform
P26038

MOES

Moesin

Cell adhesion

Q93052

LPP

Lipoma-preferred partner

Cell adhesion,
protein binding

P61221

ABCE1

ATP-binding cassette sub-family E member 1

Chaperone

P56537

IF6

Eukaryotic translation initiation factor 6

Chaperone

P06748

NPM

Nucleophosmin

Chaperone

Q99832

TCPH

T-complex protein 1 subunit eta

Chaperone

P06744

G6PI

Glucose-6-phosphate isomerase

Cytokin

P16104

H2AX

Histone H2A.x

Enzyme binding

P06576

ATPB

ATP synthase subunit beta,mitochondrial

Hydrolase

Q92820

GGH

Gamma-glutamyl hydrolase

Hydrolase

P28070

PSB4

Proteasome subunit beta type-4

Hydrolase

P13010

XRCC5

X-ray repair cross-complementing protein 5

Hydrolase

36

Q99497

PARK7

Protein DJ-1

Hydrolase,
Chaperone

Q14240

IF4A2

Eukaryotic initiation factor 4A-II

Hydrolase,
Helicase

P11586

C1TC

C-1-tetrahydrofolate synthase, cytoplasmic

Hydrolase,
Ligase,
Oxidoreductase

P49327

FAS

Fatty acid synthase

Hydrolase, Lyase,
Oxidoreductase,
Transferase

P48147

PPCE

Prolyl endopeptidase

Hydrolase,
Protease

P31939

PUR9

Bifunctional purine biosynthesis protein PURH

Hydrolase,
Transferase

P38606

VATA

V-type proton ATPase catalytic subunit A

Hydrolase,
Transport

P21281

VATB2

V-type proton ATPase subunit B, brain isoform

Hydrolase,
Transport

P54819

KAD2

Adenylate kinase 2, mitochondrial

Kinase

P00568

KAD1

Adenylate kinase isoenzyme 1

Kinase

P15531

NDKA

Nucleoside diphosphate kinase A

Kinase

P00558

PGK1

Phosphoglycerate kinase 1 OS=Homo sapiens

Kinase

GN=PGK1 PE=1 SV=3
P07205

PGK2

Phosphoglycerate kinase 2

Kinase

P30085

KCY

UMP-CMP kinase

Kinase

P68400

CSK21

Casein kinase II subunit alpha

Kinase,
Transferase

P19784

CSK22

Casein kinase II subunit alpha'

Kinase,
Transferase

Q9HA64

KT3K

Ketosamine-3-kinase

Kinase,
Transferase

P60891

PRPS1

Ribose-phosphate pyrophosphokinase 1

Kinase,
Transferase

37

P17931

LEG3

Galectin-3

lgE binding

P49915

GUAA

GMP synthase [glutamine-hydrolyzing]

Ligase

Q99798

ACON

Aconitate hydratase, mitochondrial

Lyase

Q04760

LGUL

Lactoylglutathione lyase

Lyase

P33176

KINH

Kinesin-1 heavy chain

Motor protein

P15121

ALDR

Aldose reductase

Oxidoreductase

P16152

CBR1

Carbonyl reductase [NADPH] 1

Oxidoreductase

O75828

CBR3

Carbonyl reductase [NADPH] 3

Oxidoreductase

P09417

DHPR

Dihydropteridine reductase

Oxidoreductase

P11413

G6PD

Glucose-6-phosphate 1-dehydrogenase

Oxidoreductase

P04406

G3P

Glyceraldehyde-3-phosphate dehydrogenase

Oxidoreductase

P40926

MDHM

Malate dehydrogenase, mitochondrial

Oxidoreductase

P30041

PRDX6

Peroxiredoxin-6

Oxidoreductase

P49748

ACADV

Very long-chain specific acyl-CoA dehydrogenase,

Oxidoreductase

mitochondrial
P12268

IMDH2

Inosine-5'-monophosphate dehydrogenase 2

Oxidoreductase,
Protein binding

P04083

ANXA1

Annexin A1

Phospholipase
A2 Inhibitor

P07355

ANXA2

Annexin A2

Phospholipase
Inhibitor

P30086

PEBP1

Phosphatidylethanolamine-binding protein 1

Protease inhibitor

P62191

PRS4

26S protease regulatory subunit 4

Protein binding

Q00610

CLH1

Clathrin heavy chain 1

Protein binding

P21399

ACOC

Cytoplasmic aconitate hydratase

Protein binding

P30084

ECHM

Enoyl-CoA hydratase, mitochondrial

Protein binding

P02533

K1C14

Keratin, type I cytoskeletal 14

Protein binding

P08779

K1C16

Keratin, type I cytoskeletal 16

Protein binding

P35527

K1C9

Keratin, type I cytoskeletal 9

Protein binding

P13647

K2C5

Keratin, type II cytoskeletal 5

Protein binding

O95983

MBD3

Methyl-CpG-binding domain protein 3

Protein binding

Q15365

PCBP1

Poly(rC)-binding protein 1

Protein binding

P26599

PTBP1

Polypyrimidine tract-binding protein 1

Protein binding
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O60568

PLOD3

Procollagen-lysine,2-oxoglutarate 5-dioxygenase

Protein binding

P61289

PSME3

Proteasome activator complex subunit 3

Protein binding

Q92597

NDRG1

Protein NDRG1

Protein binding

Q92616

GCN1L

Translational activator GCN1

Protein binding

P23381

SYWC

Tryptophanyl-tRNA synthetase, cytoplasmic

Protein binding

P31150

GDIA

Rab GDP dissociation inhibitor alpha

Protein binding,
Lyase

P46940

IQGA1

Ras GTPase-activating-like protein IQGAP1

Protein
Phosphatase
binding, Ras
GTPase activator

P14868

SYDC

Aspartyl-tRNA synthetase, cytoplasmic

Synthetase,
Ligase

Q9BWD

THIC

Acetyl-CoA acetyltransferase, cytosolic

Transferase

P53396

ACLY

ATP-citrate synthase

Transferase

P06737

PYGL

Glycogen phosphorylase, liver form

Transferase

Q9Y617

SERC

Phosphoserine aminotransferase

Transferase

P34897

GLYM

Serine hydroxymethyltransferase, mitochondrial

Transferase

Q06210

GFPT1

Glucosamine--fructose-6-phosphate

Transferase,

aminotransferase [isomerizing] 1

Aminotransferase

Nicotinamide phosphoribosyltransferase

Transferase,Glyc

1

P43490

NAMPT

osyltransferase
Q16831

UPP1

Uridine phosphorylase 1

Transferase,Glyc
osyltransferase

P25705

ATPA

ATP synthase subunit alpha, mitochondrial

Transport

P53621

COPA

Coatomer subunit alpha

Transport

Q14204

DYHC1

Cytoplasmic dynein 1 heavy chain 1

Transport

P55060

XPO2

Exportin-2

Transport

P62826

RAN

GTP-binding nuclear protein Ran

Transport

P68133

ACTS

Actin, alpha skeletal muscle

P63261

ACTG

Actin, cytoplasmic 2

O00429

DNM1L

Dynamin-1-like protein
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Q9NRV9

HEBP1

Heme-binding protein 1

P42704

LPPRC

Leucine-rich PPR motif-containing protein,
mitochondrial

Q9UL46
Q15019

PSME2

Proteasome activator complex subunit 2

2-Sep Septin-2

P02768

ALBU

Serum albumin

P17987

TCPA

T-complex protein 1 subunit alpha

P50991

TCPD

T-complex protein 1 subunit delta

P50990

TCPQ

T-complex protein 1 subunit theta

P40227

TCPZ

T-complex protein 1 subunit zeta

Q8NBS9

TXND5

Thioredoxin domain-containing protein 5

P23193

TCEA1

Transcription elongation factor A protein 1

Q71U36

TBA1A

Tubulin alpha-1A chain

P68371

TBB2C

Tubulin beta-2C chain

Q13509

TBB3

Tubulin beta-3 chain OS=Homo sapiens
GN=TUBB3 PE=1 SV=2

Q9BUF5

TBB6

Tubulin beta-6 chain

Table 2.1 Summery of proteins by functions

Furthermore, a number of known PIP-binding domains were identified, such as
Annexin, FERM, Filamin-A, HEAT, PH, PX, Septin. This result further validated this
protein identification method.
Domains

Protein ID

Protein Name

Actin

ARP2

Actin-related protein 2

ACTS

Actin, alpha skeletal muscle

ACTG

Actin, cytoplasmic 2

ANXA1

Annexin A1

ANXA2

Annexin A2

ACTN1

Alpha-actinin-1

Annexin

CH
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FERM

Filamin-A

ACTN4

Alpha-actinin-4

FLNA

Filamin-A

IQGA1

Ras GTPase-activating-like protein IQGAP1

MOES

Moesin

RADI

Radixin

K1C14

Keratin, type I cytoskeletal 14

K1C16

Keratin, type I cytoskeletal 16

K1C9

Keratin, type I cytoskeletal 9

K2C5

Keratin, type II cytoskeletal 5

FLNA

Filamin-A

Serine/threonine-protein phosphatase 2A 65 kDa
HEAT

2AAA

regulatory subunit A alpha isoform

GCN1L

Translational activator GCN1

SPTA2

Spectrin alpha chain, brain

ACTN1

Alpha-actinin-1

ACTN4

Alpha-actinin-4

Septin

2-Sep

Septin-2

PH

SPTB2

Spectrin beta chain, brain 1

PX

SNX4

Sorting nexin-4

Spectrin

Table 2.2 Summery of proteins by domains
3. Materials and methods
3.1 Synthesis of PIPn activity-based probes
General Experimental. Generally, reagents were purchased from Acros, Aldrich or
FisherSci and used as received. Dry solvents were obtained from a Pure Solv solvent
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delivery system purchased from Innovative Technology, Inc. Column chromatography
was performed by using 230-400 mesh silica gel purchased from Sorbent Technologies
and C18 (17%) reverse phase column (6 mL, 2 g) purchased from Silicycle. NMR
spectra were obtained by using a Varian Mercury 300 spectrometer. Mass spectra were
obtained with ABI DE Pro MALDI spectrometers with high-resolution capabilities.
Benzophenone-Lys-OMe (2.2.2). Cbz-Lys(Boc)-OMe (2.2.1) (262 mg, 0.664 mmol)
was dissolved in 5 mL methanol. Palladium(II) hydroxide (26 mg, 10% wt) was added to
the solution. The reaction was stirred under hydrogen atmosphere overnight. Then
reaction solution was filtered through a pad of cellite and the filtrate was concentrated to
yield Lys(Boc)-OMe, which was used in the next step without further purification.
Lys(Boc)-OMe was dissolved in 10 mL DMF. To this solution was added 4-benzoyl
benzoic acid (150 mg, 0.664 mmol), EDCI (153 mg, 0.797 mmol), DMAP (97 mg, 0.791
mmol), NMM (0.26 mL, 2.32 mmol). The solution was stirred at room temperature
overnight and then concentrated under reduced pressure. The crude was purified by
silica gel column chromatography with a solvent system of 50% ethyl acetate to
hexanes to yield benzophenone-Lys(Boc)-OMe as a white foam (279 mg, 90% over 2
steps).

The characterization of benzophenone-Lys(Boc)-OMe matches with the
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literature . Benzophenone-Lys(Boc)-OMe was then dissolved in 4 mL of TFA/CH2Cl2
(v/v 1:1). The reaction was allowed to stir at room temperature for 2 hours and then was
concentrated under reduced pressure to yield benzophenone-Lys-OMe (2.2.2) as a
yellowish gum (quantitative yield).
1

H NMR (300MHz, CDCl3)  7.88 (d, J = 9Hz, 1H), 7.70-7.67 (m, 4H), 7.57-7.52 (m, 2H),

7.44-7.40 (m, 2H), 4.67-4.65 (m, 1H), 3.66 (s, 3H), 2.89-2.87 (m, 2H), 1.86-1.64 (m, 4H),
1.46-1.43 (m, 2H).
Benzophenone-Lys(benzoyl)-OMe (2.2.3a). Benzophenone-Lys-OMe (2.2.2) (64 mg,
0.178 mmol) was combined with benzoyl chloride (0.041 mL, 0.356 mmol) along with
triethyl amine (1 mL) in 10 mL dichloromethane. The reaction was allowed to stir at
room temperature overnight. The solvent was then removed under reduced pressure.
The crude was purified by column chromatography with a gradient solvent system of 20-

42

70% ethyl acetate to hexanes to yield benzophenone-Lys(benzoyl)-OMe (2.2.3a) as a
white foam (33 mg, 39%).
1

H NMR (300MHz, CDCl3)  7.94-7.92 (m, 2H), 7.77-7.70 (m, 5H), 7.62-7.59 (m, 1H),

7.51-7.34 (m, 5H), 7.26-7.24 (m, 2H), 6.53-6.51 (m, 1H), 4.80-4.73 (m, 1H), 3.76 (s, 3H),
3.54-3.52 (m, 1H), 3.44-3.42 (m, 1H), 2.00-1.96 (m, 2H), 1.72-1.66 (m, 2H), 1.54-1.48
(m, 2H).
Benzophenone-Lys(benzoyl D5)-OMe (2.2.3b). Benzophenone-Lys-OMe (2.2.2) (120
mg, 0.249 mmol) was combined with benzoic acid D5 (32 mg, 0.249 mmol), EDCI (62
mg, 0.324 mmol), DMAP (40 mg, 0.324 mmol), NMM (0.27 mL, 2.49 mmol) in 10 mL
dichloromethane. The reaction was allowed to stir at room temperature overnight. The
solvent was then removed under reduced pressure. The crude was purified by column
chromatography with a gradient solvent system of 40-60% ethyl acetate to hexanes to
yield benzophenone-Lys(benzoyl D5)-OMe (2.2.3b) as a white foam (64 mg, 54%).
1

H NMR (300MHz, CDCl3)  7.93-7.90 (m, 2H), 7.75-7.71 (m, 3H), 7.62-7.57 (m, 1H),

7.49-7.44 (m, 2H), 7.38-7.35 (m, 1H), 6.74-6.73 (m, 1H), 4.76-4.69 (m, 1H), 3.74 (s, 3H),
3.53-3.48 (m, 1H), 3.42-3.36 (m, 1H), 1.70-1.62 (m, 2H), 1.52-1.46 (m, 2H).
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C NMR

(300MHz, CDCl3)  196.2, 173.1, 168.5, 167.0, 140.3, 134.5, 133.1, 130.3, 130.2, 128.7,
127.5, 53.0, 52.7, 39.1, 31.6, 29.3, 22.7. MALDI-HRMS [M + H]+ calcd for 500.2182;
found 500.2247.
Benzophenone-Lys(5(6)-carboxy fluorescein)-OMe (2.2.3c). Benzophenone-LysOMe (2.2.2) (175 mg, 0.475 mmol) was combined with 5(6)-carboxy fluorescein (197
mg, 0.522 mmol), EDCI (118 mg, 0.618 mmol), DMAP (70 mg, 0.570 mmol), NMM (0.21
mL, 1.90 mmol) in 8 mL dry DMF. The reaction was allowed to stir at room temperature
overnight. The solvent was then removed under reduced pressure. The crude was
dissolved in 50 mL methanol/chloroform (v/v 1:4) and extracted by 50 mL 2N HCl
aqueous solution. The aqueous layer was washed twice by methanol/chloroform (v/v
1:4), 50 mL each time. The organic layers were collected, dried by magnesium sulfate,
concentrated and then purified by column chromatography with a gradient solvent
system of 5-10% methanol to chloroform to yield benzophenone-Lys(5(6)-carboxy
fluorescein)-OMe (2.2.3c) as an orange solid (159 mg, 46%).
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1

H NMR (300MHz, CD3OD/CDCl3 (v/v 1:2))  8.40-8.39 (m, 1H), 8.03-7.98 (m, 2H),

7.95-7.83 (m, 2H), 7.85-7.75 (m, 3H), 7.66-7.69 (m, 1H), 7.54-7.49 (m, 2H), 7.25-7.22
(m, 1H), 6.72-6.70 (m, 2H), 6.57-6.53 (m, 4H), 4.76-4.72 (m, 1H), 3.80 (s, 3H), 3.503.48 (m, 1H), 3.36-3.35 (m, 1H), 2.67 (bs, 1H), 2.06-1.94 (m, 2H), 1.74-1.46 (m, 4H).
Benzophenone-Lys(TEG-N3)-OMe (2.2.3d). Benzophenone-Lys-OMe (2.2.2) (162 mg,
0.584 mmol) was combined with N3-TEG-COOH (272 mg, 0.738 mmol), EDCI (146 mg,
0.759 mmol), DMAP (93 mg, 0.759 mmol), NMM (0.19 mL, 1.752 mmol) in 20 mL
methanol/chloroform (v/v 1:4). The reaction was allowed to stir at room temperature
overnight. The solvent was then removed under reduced pressure. The crude was
purified by column chromatography with a gradient solvent system of 30-90% ethyl
acetate to hexanes to yield benzophenone-Lys(TEG-N3)-OMe (2.2.3d) as a colorless
gum (241 mg, 66%).
1

H NMR (300MHz, CDCl3)  8.04-8.01 (m, 2H), 7.85-7.78 (m, 3H), 7.66-7.60 (m, 1H),

7.53-7.48 (m, 2H), 7.39-7.37 (m, 1H), 7.14 (t, J = 6Hz, 1H), 4.78-4.71 (m, 1H), 4.00-3.87
(m, 2H), 3.78 (s, 3H), 3.67-3.63 (m, 12H), 3.39-3.36 (m, 2H), 3.33-3.28 (m, 2H), 2.59
(bs, 1H), 1.99-1.94 (m, 2H), 1.62-1.45 (m, 4H).
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C NMR (300MHz, CDCl3)  196.2,

173.0, 170.6, 166.7, 140.3, 133.1, 130.3, 130.1, 128.6, 127.6, 71.1, 70.8, 70.7, 70.6,
70.5, 70.3, 70.2, 53.1, 52.7, 50.8, 38.0, 31.3, 29.4, 22.7. MALDI-HRMS [M + Na]+ calcd
for 650.2796; found 650.3725.
4-Oxo-4-(2-propyn-1-ylamino) butanoic acid (2.4.1). Propargyl amine (0.50 mL, 7.29
mmol) was dissolved in 10 mL mixture of acetonitrile/DMF (v/v 1:1) at 0 °C under
nitrogen. Succinic anhydride (in 10 mL acetonitrile) was added to this solution. The
mixture was stirred at room temperature overnight. The solvent was then removed
under reduced pressure. The residue was washed with hexanes then ethyl ether
several times to generate 2.4.1 as a white solid (305 mg, 27%).
1

H NMR (300MHz, CD3OD)  3.94 (d, J = 3Hz, 1H), 2.61-2.56 (m, 2 H), 2.49-2.44 (m,

2H).
Benzophenone-Lys(alkyne)-OMe (2.2.3e). Benzophenone-Lys-OMe (2.2.2) (911 mg,
1.890 mmol) was combined with 4-oxo-4-(2-propyn-1-ylamino) butanoic acid (293 mg,
1.89 mmol), EDCI (543 mg, 2.83 mmol), DMAP (346 mg, 2.83 mmol), NMM (2.08 mL,
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18.9 mmol) in 10 mL methanol/chloroform (v/v 1:4). The reaction was allowed to stir at
room temperature overnight. The solvent was then removed under reduced pressure.
The crude was purified by column chromatography with a gradient solvent system of 50100% acetone to hexanes to yield benzophenone-Lys(alkyne)-OMe (2.2.3e) as a
colorless crystal (760 mg, 80%).
1

H NMR (300MHz, CDCl3)  7.99-7.96 (m, 2H), 7.81-7.75 (m, 3H), 7.61-7.57 (m, 1H),

7.50-7.42 (m, 3H), 6.81-6.79 (m, 1H), 6.55-6.51(m, 1H), 4.74-4.67 (m, 1H), 3.95-3.93 (m,
2H), 3.75 (s, 3H), 3.27-3.15 (m, 2H), 2.42-2.41 (m, 4H), 2.17-2.14 (m, 1H), 1.90-1.86 (m,
2H), 1.53-1.42 (m, 4H). MALDI-HRMS [M + Na]+ calcd for 528.2105; found 528.2134.
Benzophenone-Lys(N3)-OMe (2.2.3f). Benzophenone-Lys-OMe (2.2.2) (219 mg, 0.595
mmol) was dissolved in 10 mL methanol. To this solution was added potassium
carbonate aqueous solution (1.26 mL, 0.804 M), copper sulfate aqueous solution (6 mL,
0.010 M) and imidazole-1-sulfonyl azide hydrochloride (150 mg, 0.714 mmol). The
reaction was allowed to stir at room temperature overnight. The solvent was then
removed under reduced pressure. The crude was dissolved in ethyl acetate (50 mL)
and extracted by 2N HCl aqueous solution (50 mL x 2). The organic layer was collected,
dried by magnesium sulfate, concentrated and then purified by column chromatography
with a solvent system of 50% ethyl acetate to hexanes to yield benzophenone-Lys(N3)OMe (2.2.3f) as a colorless glass (233 mg, 99%). The characterization matches the
literature59.


Benzophenone-Lys(TEG-NHBoc)-OMe (2.9.2). Benzophenone-Lys-OMe (2.2.2) (237
mg, 0.491 mmol) was combined with compound 2.9.1 (157 mg, 0.447 mmol), which was
prepared from our previously reported procedure60, EDCI (129 mg, 0.671 mmol), DMAP
(109 mg, 0.894 mmol), NMM (0.50 mL, 4.47 mmol) in 10 mL methanol/chloroform (v/v
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1:4). The reaction was allowed to stir at room temperature overnight. The solvent was
then removed under reduced pressure. The crude was purified by column
chromatography with a gradient solvent system of 50-100% acetone to hexanes to yield
benzophenone-Lys(TEG-NHBoc)-OMe (2.9.2) as a colorless oil (167 mg, 54%).
1

H NMR (300MHz, CDCl3)  8.05-8.02 (m, 2H), 7.85-7.78 (m, 4H), 7.65-7.60 (m, 1H),

7.53-7.50 (m, 2H), 7.33-7.31 (m, 1H), 7.20-7.18 (m, 1H), 5.11-5.10 (m, 1H), 4.78-4.71
(m, 1H), 3.95-3.78 (m, 2H), 3.78 (s, 3H), 3.65-3.61 (m, 12H), 3.54-3.50 (m, 2H), 3.363.28 (m, 4H), 1.99-1.95 (m, 2H), 1.60-1.56 (m, 2H), 1.50-1.43 (m, 11H).

13

C NMR

(300MHz, CDCl3)  196.0, 172.8, 170.4, 166.4, 140.1, 137.0, 132.9, 130.1, 130.0, 128.4,
127.4, 105.0, 71.0, 70.5, 70.4, 70.3, 70.1, 52.9, 52.5, 40.3, 37.7, 31.1, 29.3, 28.4, 22.4.
Benzophenone-Lys(biotin)-OMe

(2.2.3g).

Benzophenone-Lys(TEG-NHBoc)-OMe

(2.9.2) (167 mg, 0.243 mmol) was dissolved in 5 mL TFA/dichloromethane (v/v 1:1).
The solution was stirred at room temperature for 3 hours before it was concentrated to
yield the Boc deprotected product benzophenone-Lys(TEG-NH2)-OMe. The crude was
dissolved in 20 mL dry DMF. To this solution was added 2 mL triethylamine and biotinpentafluorophenyl ester (100 mg, 0.243 mmol) (2.9.3). The resulting solution was stirred
at room temperature overnight and then concentrated. The crude was purified by
column chromatography with a gradient solvent system of 5-10% methanol to
dichloromethane to yield benzophenone-Lys(biotin)-OMe (2.2.3g) as a yellowish gum
(198 mg, 100%).
1

H NMR (300MHz, CD3OD/CDCl3 (v/v 1:4))  8.22 (d, J = 6 Hz, 1H), 8.05-8.02 (m, 2H),

7.87-7.79 (m, 4H), 7.68-7.63 (m, 1H), 7.55-7.50 (m, 1H), 4.71-4.70 (m, 1H), 4.54-4.50
(m, 1H), 4.05-4.03 (m, 2H), 3.79 (s, 3H), 3.72-3.66 (m, 12H), 3.58-3.57 (m, 2H), 3.433.42 (m, 2H), 3.29-3.27 (m, 2H), 3.18 (m, 1H), 2.94-2.89 (m, 1H), 2.75-2.71 (m, 1H),
1.98-1.91 (m, 2H), 1.63-1.56 (m, 6H), 1.47-1.41 (m, 4H).

13

C NMR (300MHz,

CD3OD/CDCl3 (v/v 1:4))  196.9, 173.3, 171.2, 167.7, 140.4, 137.3, 133.3, 130.3, 130.1,
128.7, 127.7, 70.5, 70.2, 70.0, 60.4, 55.8, 53.3, 52.6, 49.6, 49.3, 49.0, 48.7, 48.4, 40.4,
38.8, 35.8, 31.2, 31.0, 29.0, 28.6, 25.7, 23.2. MALDI-HRMS [M + Na]+ calcd for
850.3673; found 850.4567.
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Benzophenone-Lys(benzoyl)-OH (2.2.4a). Compound 2.2.3a (33 mg, 0.070 mmol)
was dissolved in a mixture of 5 mL ethanol and 2 mL methanol. To this solution was
added 5 mL of 2M NaOH aqueous solution. The reaction was stirred at room
temperature for 3 hours and then was quenched by adjusting the pH to neutral with
addition of 2N HCl aqueous solution. The alcohols were removed from the solution by
rotary evaporation. The resulting solution was extracted by 2N HCl aqueous
solution/dichloromethane. The aqueous layer was washed with dichloromethane (100
mL x 2). The combined organic layers were dried by magnesium sulfate and
concentrated to yield benzophenone-Lys(benzoyl)-OH (2.2.4a) as a colorless oil (28 mg,
87 %). 
1

H NMR (300MHz, CDCl3)  7.83-7.26 (m, 14H), 6.74-6.76 (m, 1H), 4.85-4.83 (m, 1H),

3.64-3.60 (m, 1H), 3.48-3.38 (m, 1H), 2.00-1.98 (m, 2H), 1.68-1.64 (m, 2H), 1.55-1.51
(m, 2H).
Benzophenone-Lys(benzoyl D5)-OH (2.2.4b). Compound 2.2.3b (64 mg, 0.134 mmol)
was dissolved in 2 mL ethanol. To this solution was added 2 mL of 2M NaOH aqueous
solution. The reaction was stirred at room temperature for 40 minutes and then was
extracted by 2N HCl aqueous solution (50 mL)/dichloromethane (100 mL). The aqueous
layer was washed with dichloromethane (50 mL x 2). The combined organic layers were
dried by magnesium sulfate and concentrated to yield benzophenone-Lys(benzoyl D5)OH (2.2.4b) as a colorless oil (58 mg, 93 %). 
1

H NMR (300MHz, CDCl3)  7.88-7.86 (m, 1H), 7.79-7.76 (m, 2H), 7.69-7.66 (m, 2H),

7.57-7.55 (m, 2H), 7.47-7.42 (m, 2H), 7.01-6.99 (m, 1H), 4.82-4.80 (m, 1H), 3.58-3.54
(m, 1H), 3.34-3.32 (m, 1H), 1.96-1.92 (m, 2H), 1.64-1.46 (m, 4H). 13C NMR (300MHz,
CDCl3)  196.3, 174.8, 169.3, 167.5, 167.0, 140.2, 137.1, 136.8, 134.0, 133.2, 130.3,
128.7, 127.4, 52.9, 39.4, 31.4, 30.0, 29.2, 22.5.
Benzophenone-Lys(5(6)-carboxy fluorescein)-OH (2.2.4c). Compound 2.2.3c (36 mg,
0.050 mmol) was suspended in 5 mL methanol. To this solution was added 5 mL of 2M
NaOH aqueous solution. The reaction was stirred at room temperature for 10 minutes
and then was added 2N HCl aqueous solution (30 mL). A orange solid was formed
immediately upon addition of the acid. The solid was filtered and washed with 2N HCl
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aqueous solution (10 mL x 2) to yield the crude compound 2.2.4c. The crude was
dissolved in acetonitrile/water and purified on a C18 reverse phase column (2g) with a
gradient solvent system of 0-80% acetonitrile/water. Compound 2.2.4c came out with
the elution of 45-60% acetonitrile/water. The collected fractions were concentrated by
rotary evaporation to remove acetonitrile. Water was removed by lyophilization to yield
benzophenone-Lys(5(6)-carboxy fluorescein)-OH (2.2.4c) as a yellow powder (19 mg,
53%).
1

H NMR (300MHz, CD3CN/D2O (v/v 1:1))  8.73-8.71 (m, 1H), 8.42-8.29 (m, 4H), 8.14-

8.07 (m, 4H), 7.92-7.87 (m, 2H), 7.53-7.50 (m, 1H), 7.10 (s, 2H), 6.97-6.93 (m, 4H),
4.95-4.85 (m, 1H), 3.82-3.80 (m, 1H), 3.67-3.65 (m, 1H), 2.40-2.38 (m, 2H), 1.94-1.80
(m, 4H). MALDI-HRMS [M + H]+ calcd for 713.2130; found 713.2072.
Benzophenone-Lys(TEG-N3)-OH (2.2.4d). Compound 2.2.3d (117 mg, 0.186 mmol)
was dissolved in 5 mL ethanol. To this solution was added 5 mL of 2M NaOH aqueous
solution. The reaction was stirred at room temperature for 2 hours and then was
extracted by 2N HCl aqueous solution (50 mL)/dichloromethane (100 mL). The aqueous
layer was washed with dichloromethane (50 mL x 2). The combined organic layers were
dried by magnesium sulfate and concentrated to yield benzophenone-Lys(TEG-N3)-OH
(2.2.4d) as a colorless oil (114 mg, 100 %). 
1

H NMR (300MHz, CDCl3)  7.96-7.88 (m, 3H), 7.72-7.67 (m, 3H), 7.63-7.58 (m, 1H),

7.50-7.41 (m, 3H), 4.96-4.94 (m, 1H), 3.98 (dd, J1 = 3Hz, J2 = 18 Hz, 2H), 3.66-3.56 (m,
13H), 3.37 (t, J = 6 Hz, 2H), 3.24-3.23 (m, 1H), 1.97-1.96 (m, 2H), 1.59-1.43 (m, 4H).
MALDI-HRMS [M + Na]+ calcd for 636.2640; found 636.2403.
Benzophenone-Lys(alkyne)-OH (2.2.4e). Compound 2.2.3e (135 mg, 0.267 mmol)
was dissolved in a mixture of 5 mL methanol and 5 mL ethanol. To this solution was
added 8 mL of 2M NaOH aqueous solution. The reaction was stirred at room
temperature for 15 minutes and then was extracted by 2N HCl aqueous solution (100
mL)/dichloromethane

(200

mL).

The

aqueous

layer

was

washed

with

methanol/chloroform (v/v 1:4) (50 mL x 3). The combined organic layers were dried by
magnesium sulfate, filtered and concentrated to yield benzophenone-Lys(alkyne)-OH
(2.2.4e) as a white solid (94 mg, 72 %).
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1

H NMR (300MHz, CD3OD)  8.01-7.99 (m, 2H), 7.84-7.76 (m, 4H), 7.65-7.63 (m, 1H),

7.55-7.53 (m, 2H), 4.59-4.57 (m, 1H), 3.95-3.93 (m, 1H), 3.65-3.61 (m, 2H), 3.21-3.19
(m, 2H), 2.57-2.45 (m, 5H), 1.99.92 (m, 2H), 1.56-1.54 (m, 4H).
Benzophenone-Lys(N3)-OH (2.2.4f). Compound 2.2.3f (233 mg, 0.591 mmol) was
dissolved in 2 mL methanol. To this solution was added 2 mL of 2M NaOH aqueous
solution. The reaction was stirred at room temperature for 30 minutes and then was
extracted by 2N HCl aqueous solution (50 mL)/dichloromethane (50 mL). The aqueous
layer was washed with dichloromethane (60 mL x 2). The combined organic layers were
dried by magnesium sulfate, filtered and concentrated to yield benzophenone-Lys(N3)OH (2.2.4f) as a colorless oil (216 mg, 96 %).
Benzophenone-Lys(Biotin)-OH (2.2.4g). Compound 2.2.3g (270 mg, 0.308 mmol)
was dissolved in 3 mL methanol. To this solution was added 1 mL of 2M NaOH
aqueous solution. The reaction was stirred at room temperature for 30 minutes and then
was added proton resin to adjust the pH to ~4. The resin was afterwards filtered off.
The filtrate was concentrated to yield benzophenone-Lys(Biotin)-OH (2.2.4g) as a
colorless gum (204 mg, 81%).
1

H NMR (300MHz, CD3OD/CDCl3 (v/v 1:1))  8.01 (d, J = 6 Hz, 1H), 7.86-7.78 (m, 4H),

7.67-7.62 (m, 1H), 7.55-7.50 (m, 2H), 4.70-4.68 (m, 1H), 4.52-4.50 (m, 1H), 4.34-4.32
(m, 1H), 3.99-3.97 (m, 2H), 3.67-3.64 (m, 12H), 3.55-3.53 (m, 2H), 3.41-3.40 (m, 2H),
3.29-3.27 (m, 2H), 3.18-3.19 (m, 1H), 2.94-2.90 (m, 1H), 2.75-2.71 (m, 1H), 2.23-2.18
(m, 2H), 1.98-1.90 (m, 2H), 1.64-1.42 (m, 10H).

13

C NMR (300MHz, CD3OD/CDCl3 (v/v

1:4))  196.6, 174.4, 170.8, 167.2, 140.0, 137.1, 136.8, 133.1, 130.0, 130.0, 128.4,
128.2, 127.4, 70.6, 70.3, 70.2, 70.0, 69.9, 69.7, 60.2, 55.6, 49.0, 48.8, 48.5, 40.2, 39.1,
38.4, 35.6, 31.1, 28.9, 28.3, 28.0, 25.4, 22.9.
General procedure for the synthesis of 2.2.5 a,b,d,f and 2.2.6 g. The acid 2.2.4 a-g
was dissolved in 5 mL THF. To this stirred solution was added DCC and then N-hydroxy
succinimide. The reaction was stirred for 8 hours and then concentrated. The crude was
washed by hexane, ethyl ether, and hexane/ethyl ether mixture. The yielded NHS ester
was then stirred in 1 mL DMF. To this solution was added 2.2.5 or 2.2.6 in 1 mL TEAB
(1 M, pH=7.5). 0.5-1 mL of THF was added to enhance the solubility. The reaction was
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allowed to stir at room temperature overnight. The solvent was then removed under
reduced pressure. The crude product solid was washed by acetone (20 mL x3) and
then dissolved in deionized water to stir with 500 mg sodium form at room temperature
for 2 hours.

The reaction solution was directly loaded onto a C18 reversed-phase

column (2 g) and the column was eluted by deionized water (20 mL). The water elution
was lyophilized to yield 2.2.5 a,b,d,f and 2.2.6 g.
General procedure for the synthesis of 2.2.5 e, 2.2.6 e, 2.2.7 e, 2.2.10. The acid
2.2.4 a-g or 2.2.9 was dissolved in 5 mL THF. To this stirred solution was added EDCI
and then N-hydroxy succinimide. The reaction was stirred for 8 hours and then
concentrated. The crude was dissolved in 30 mL chloroform and washed by water (20
mL x 3). The organic layer was concentrated and added ethyl ether (30 mL). The white
precipitate was filtered and redissolved in chloroform (15 mL). The solution was filtered
and the filterate was concentrated to yield the NHS ester as a colorless oil. The NHS
ester was then stirred in 1 mL DMF. To this solution was added 2.2.5 or 2.2.6 in 1 mL
TEAB (1 M, pH=7.5). 0.5-1 mL of THF was added to enhance the solubility. The
reaction was allowed to stir at room temperature overnight. The solvent was then
removed under reduced pressure. The crude product solid was washed by acetone (20
mL x3) and then dissolved in deionized water to stir with 500 mg sodium form at room
temperature for 2 hours.

The reaction solution was directly loaded onto a C18

reversed-phase column (2 g) and the column was eluted by deionized water (20 mL).
The water elution was lyophilized to yield 2.2.5 e, 2.2.6 e or 2.2.7 e.
Benzophenone-Lys(benzyol)-PI(3,4)P2 (2.2.5a). Acid 2.2.4a (41 mg, 0.090 mmol), Nhydroxy succinimide (12 mg, 0.108 mmol), DCC (22 mg, 0.108 mmol) and aminotagged PI(3,4)P2 2.2.5 (13 mg, 0.025 mmol) were used to yield 2.2.5a as a white solid
(8.2 mg, 34%).
1

H NMR (300MHz, D2O)  7.68-7.22 (m, 14 H), 4.22-4.12 (m, 3H), 3.78-3.68 (m, 6H),

3.38 (t, J = 9 Hz, 2H), 3.05-2.90 (m, 2H), 1.49-1.21 (m, 14H). 31P NMR (121.5 MHz, D2O)
 3.47, 2.52, 1.04.
Benzophenone-Lys(benzyol D5)-PI(3,4)P2 (2.2.5b). Acid 2.2.4b (50 mg, 0.108 mmol),
N-hydroxy succinimide (15 mg, 0.129 mmol), DCC (27 mg, 0.129 mmol) and amino50

tagged PI(3,4)P2 2.2.5 (10 mg, 0.0193 mmol) were used to yield 2.2.5b as a white solid
(8.3 mg, 45%).
1

H NMR (300MHz, CD3OD/D2O (v/v 1:1)):  7.69-7.43 (m, 9 H), 4.22-4.12 (m, 3H),

3.88-3.68 (m, 6H), 3.36-3.30 (m, 2H), 2.80 (t, J = 9 Hz, 2H), 1.53-1.09 (m, 14H).

31

P

NMR (121.5 MHz, CD3OD/D2O (v/v 1:1)): 4.60, 3.10, 1.32. MALDI-HRMS [M + H]+
calcd for 987.2619; found 987.5374.
Benzophenone-Lys(5(6)carboxy fluorescein)-PI(3,4)P2 (2.2.5c). The acid 2.2.4c (28
mg, 0.039 mmol) was dissolved in 4 mL DMF/THF (v/v 1:2). To this stirred solution was
added DCC (16 mg, 0.078 mmol) and then N-hydroxy succinimide (9 mg, 0.078 mmol).
The reaction was stirred for 8 hours at room temperature and then filtered. The filtrate
was concentrated to ~0.5 mL and was added 50 mL ethyl ether. An orange precipitate
was formed and filtered. The solid was redissolved in 10 mL THF and filtered. The
filtrate was concentrated to yield the NHS ester which was then stirred in 1 mL DMF. To
this solution was added amino-tagged PI(3,4)P2 2.2.5 (10 mg, 0.019 mmol) in 1 mL
TEAB (1 M, pH=7.5) and 0.5 mL of THF. The reaction was allowed to stir at room
temperature overnight. The solvent was then removed under reduced pressure. The
crude product solid was washed by acetone (20 mL x3) and then dissolved in deionized
water to stir with 500 mg sodium form at room temperature for 2 hours. The reaction
solution was directly loaded onto a C18 reversed-phase column (2 g) and the column
was eluted by deionized water (20 mL). The water elution was lyophilized to yield 2.2.5c
as a yellow solid (8.0 mg, 35%).
1

H NMR (300MHz, CD3OD/D2O (v/v 1:1))  7.75-7.00 (m, 12 H), 6.55 (s, 2 H), 6.30-6.28

(m, 2H), 5.89-5.86 (s, 2 H), 4.30-4.28 (s, 2 H), 4.02-3.98 (m, 2H), 3.72-3.31 (m, 14H),
1.53-1.04 (m, 14H). 31P NMR (121.5 MHz, CD3OD/D2O (v/v 1:1)): 5.05, 3.64, 1.09, 0.12.
MALDI-HRMS [M + H]+ calcd for 1214.2696; found 1214.7771.
Benzophenone-Lys(TEG-N3)-PI(3,4)P2 (2.2.5d). Acid 2.2.4d (12 mg, 0.0192 mmol), Nhydroxy succinimide (2.2 mg, 0.0192 mmol), DCC (4 mg, 0.0192 mmol) and aminotagged PI(3,4)P2 2.2.5 (5 mg, 0.0096 mmol) were used to yield 2.2.5d as a yellowish
solid (6.0 mg, 56%).
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1

H NMR (300MHz, D2O)  8.00-7.75 (m, 9 H), 3.94-3.60 (m, 33 H), 2.26-2.24 ( m, 4 H), ,

1.83-1.66 (m, 13 H), 1.40-1.28 (m, 13 H)..
Benzophenone-Lys(alkyne)-PI(3,4)P2 (2.2.5e). Acid 2.2.4e (15 mg, 0.0305 mmol), Nhydroxy succinimide (4.6 mg, 0.040 mmol), EDCI (7.7 mg, 0.040 mmol) and aminotagged PI(3,4)P2 2.2.5 (5.0 mg, 0.0096 mmol) were used to yield 2.2.5d as a yellowish
solid (3.0 mg, 31%).
Benzophenone-Lys(N3)-PI(3,4)P2 (2.2.5f). Acid 2.2.4f (14 mg, 0.038 mmol), N-hydroxy
succinimide (5.3 mg, 0.046 mmol), DCC (10.4 mg, 0.046 mmol) and amino-tagged
PI(3,4)P2 2.2.5 (10 mg, 0.019 mmol) were used to yield 2.2.5f as a white solid (10.6 mg,
63%).
Benzophenone-Lys(alkyne)-PI(3,4,5)P3 (2.2.6e). Acid 2.2.4e (47 mg, 0.096 mmol), Nhydroxy succinimide (22 mg, 0.192 mmol), EDCI (37 mg, 0.192 mmol) and aminotagged PI(3,4,5)P3 2.2.6 (10 mg, 0.0167 mmol) were used to yield 2.2.6e as a white
solid (11 mg, 61%).
1

H NMR (300MHz, D2O)  7.71-7.52 (m, 7H), 7.37 (t, J = 6 Hz, 2 H), 4.24-4.18 (m, 3H),

3.88-3.63 (m, 10H), 3.03-2.97 (m, 4H), 2.79 (t, J = 6 Hz, 2H), 2.10-2.05 (t, J = 6Hz, 2H),
1.67-1.68 (m, 1 H), 1.46-1.34 (m, 10H), 1.22-1.16 (m, 9H).

31

P NMR (121.5 MHz, D2O):

+

1.33, 1.02, 0.40, -0.89. MALDI-HRMS [M+Na] calcd for 1095.2178; found 1095.2285
Benzophenone-Lys(bitoin)-PI(3,4,5)P3 (2.2.6g). Acid 2.2.4g (138 mg, 0.173 mmol), Nhydroxy succinimide (40 mg, 0.345 mmol), DCC (71 mg, 0.345 mmol) and aminotagged PI(3,4,5)P3 2.2.6 (5 mg, 0.0083 mmol) were used to yield 2.2.6g as a white solid
(2.0 mg, 17%).
1

H NMR (300MHz, CD3OD/D2O (v/v 1:1))  7.98-7.80 (m, 9H), 4.46-4.43 (m, 4H), 4.12-

3.93 (m, 10H), 3.73-3.71 (m, 2H), 2.98 (t, J = 6 Hz, 2H), 2.41-2.35 (m, 4H), 1.88-1.89 (m,
2H), 1.66-1.64 (m, 6H), 1.47-1.43 (m, 5H). MALDI-HRMS [M + Na]+ calcd for 1417.37;
found 1417.40.
Benzophenone-Lys(alkyne)-PI(3,5)P2 (2.2.7e). Acid 2.2.4e (47 mg, 0.096 mmol), Nhydroxy succinimide (22 mg, 0.192 mmol), EDCI (37 mg, 0.192 mmol) and aminotagged PI(3,5)P3 2.2.7 (11 mg, 0.0212 mmol) were used to yield 2.2.7e as a white solid
(9.0 mg, 43%).
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1

H NMR (300MHz, CD3OD/D2O (v/v 1:1))  8.05-7.68 (m, 9H), 3.95-3.86 (m, 13 H),

3.22-3.18 (m, 4H), 2.78-2.65 (m, 2H), 1.67-1.39 (m, 20H).

31

P NMR (121.5 MHz,

CD3OD/D2O (v/v 1:1)): 4.28,3.63, -0.60. MALDI-HRMS [M + Na]+ calcd for 1015.2520;
found 1015.2452.
Benzophenone-Lys(alkyne)-hexanoate (2.2.8). Acid 2.2.4e (144 mg, 0.293 mmol)
was combined with 5-aminocaproic acid methyl ester hydrochloride (69 mg, 0.381
mmol), EDCI (72 mg, 0.381 mmol), DMAP (47 mg, 0.381 mmol), NMM (0.32 mL, 2.92
mmol) in 15 mL methanol/chloroform (v/v 1:4). The reaction was allowed to stir at room
temperature overnight. The solvent was then removed under reduced pressure. The
crude was purified by column chromatography with a gradient solvent system of 50100% acetone to hexanes to yield compound 2.2.8 as a colorless crystal (91 mg, 50%).
1

H NMR (300MHz, CDCl3)  8.00-7.97 (m, 2H), 7.83-7.77 (m, 4H), 7.64-7.59 (m, 1H),

7.52-7.47 (m, 2H), 7.21-7.19 (m, 1H), 6.83-6.81(m, 1H), 4.68-4.66 (m, 1H), 3.98-3.96 (m,
2H), 3.64 (s, 3H), 3.25-3.23 (m, 4H), 2.54-2.48 (m, 4H), 2.29 (t, J = 6 Hz, 2H), 2.21-2.18
(m, 1H), 1.92-1.83 (m, 2H), 1.62-1.34 (m, 10H).

13

C NMR (300MHz, CDCl3)  196.1,

174.1, 172.5, 172.4, 171.7, 166.8, 140.3, 136.9, 133.0, 130.1, 130.0, 128.5, 127.4, 79.7,
71.31, 53.7, 51.6, 39.4, 33.8, 31.3, 29.1, 26.3, 24.4, 22.8. MALDI-HRMS [M + Na]+ calcd
for 641.2951; found 641.2953.
Benzophenone-Lys(alkyne)-hexyl-PI(3,4,5)P3 (2.2.10). Compound 2.2.8 (80 mg,
0.129 mmol) was dissolved in 2 mL methanol. To this solution was added 2 mL of 2M
NaOH aqueous solution. The reaction was stirred at room temperature overnight and
then was added proton resin to adjust the pH to ~4. The resin was then filtered off. The
filtrate was concentrated to yield acid 2.2.9 as a colorless gum (68 mg, 87%). Acid 2.2.9
(68 mg, 0.112 mmol), N-hydroxy succinimide (26 mg, 0.224 mmol), EDCI (43 mg, 0.224
mmol) and amino-tagged PI(3,4,5)P3 2.2.6 (8 mg, 0.0106 mmol) were used to yield
2.2.7e as a white solid (11.2 mg, 93%).
1

H NMR (500MHz, D2O)  7.86-7.80 (m, 4H), 7.76-7.74 (m, 2H), 7.67 (t, J = 3 Hz, 1H),

7.53-7.50 (m, 2H), 4.36-4.33 (m, 3H), 4.03-4.02 (m, 1H), 3.96-3.95 (m, 2H), 3.83-3.79
(m, 3H), 3.16-3.02 (m, 5H), 3.02-2.78 (m, 2H), 2.35-2.31 (m, 4H), 2.09-2.06 (m, 2H),
53

1.80-1.78 (m, 2H), 1.51-1.18 (m, 18H).

31

P NMR (202.5 MHz, D2O): 0.70, 0.31, -0.28,

-0.90.
N-Biotinyl-6-azidohexanamide (2.3.3). 6-Azido-1-hexylamine (2.3.2) was prepared
according to a previously reported procedure. Biotin-pentafluorophenyl ester (750 mg,
1.83 mmol) and 6-azido-1-hexylamine 2.3.2 (390 mg, 2.74 mmol) were combined in 10
mL methanol, along with triethylamine (1.27 mL, 9.15 mmol). The solution was stirred at
room temperature overnight. The solvent was removed under reduced pressure. The
crude was purified by column chromatography with a gradient solvent system of 1-10%
methanol to dichloromethane to yield compound 2.3.3 as a colorless crystal (527 mg,
78%).
1

H NMR (300MHz, CDCl3)  6.19-6.18 (m, 1H), 5.94-5.92 (m, 1H), 5.31-5.30 (m, 1H),

4.54-4.50 (m, 1H), 4.34-4.30 (m, 1H), 3.29-3.15 (m, 3H), 2.92 (dd, J1 = 12Hz, J2 = 6 Hz,
1H), 2.74 (d, J = 12 Hz, 1H), 2.21 (t, J = 6 Hz, 2H), 1.72-1.58 (m, 8H), 1.51-1.36 (m, 8H).
MALDI-HRMS [M + Na]+ calcd for 391.1887; found 391.1825.
N-rhodamine-6-azidohexanamide (2.3.4). Lissamine rhodamine B sulfonyl chloride
was dissolved in 0.5 mL dry dichloromethane. To this solution was added 6-azido-1hexylamine 2.3.2 (62 mg, 0.433 mmol) and triethylamine (60 ul, 0.433 mmol). The
solution was stirred at room temperature overnight. The solvent was then removed and
the crude was purified by column chromatography with a gradient solvent system of 530% ethanol to ethyl acetate to yield compound 2.3.4 as a red solid (13 mg, 23%).
1

H NMR (300MHz, CDCl3)  8.68-8.67 (m, 1H), 8.06-8.03 (m, 1H), 7.31 (t, J = 9 Hz, 1H),

7.16 (t, J = 9 Hz, 2H), 6.87 (dd, J1 = 9 Hz, J2 = 3 Hz, 2H), 6.77-6.76 (m, 2H), 3.61 (q, J
= 6 Hz, 8H), 3.36-3.35 (m, 1H), 3.30 (t, J = 6 Hz, 2H), 3.02 (t, J = 6 Hz, 2H), 1.63-1.60
(m, 4H), 1.43-1.41 (m, 4H), 1.32 (t, J = 6 Hz, 12H).

13

C NMR (300 MHz, CDCl3): 158.2,

157.5, 155.8, 146.8, 142.5, 133.9, 133.0, 130.5, 128.0, 114.4, 113.9, 96.0, 51.6, 46.1,
43.3, 29.9, 29.8, 28.9, 26.5, 26.3, 12.6. MALDI-HRMS [M + H]+ calcd for 683.2685;
found 683.2690.
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N-NBD-6-azidohexanamide (2.3.5). NBD-Cl was dissolved in 2 mL dry DMF. To this
solution was added 6-azido-1-hexylamine 2.3.2 (55 mg, 0.385 mmol) and triethylamine
(0.27 mL, 1.925 mmol). The solution was stirred at room temperature overnight. The
solvent was then removed and the crude was purified by column chromatography with a
gradient solvent system of 10-20% acetone to hexanes to yield compound 2.3.5 as an
orange solid (75 mg, 64%).
1

H NMR (300MHz, CDCl3)  8.47 (d, J = 9 Hz, 1H), 6.50 (bs, 1H), 6.19 (d, J = 9 Hz, 1H),

3.57-3.53 (m, 2H), 3.30 (t, J = 6 Hz, 2H), 1.88-1.84 (m, 2H), 1.67-1.51 (m, 6H).
Ligand 2.3.7. The ligand 2.3.7 was prepared exactly according to the published
procedure45 and the characterization matched.
1

H NMR (300MHz, CD3OD)  8.00 (s, 3H), 4.52 (t, J = 6 Hz, 6H), 3.75 (s, 6H), 3.57 (t, J

= 6 Hz, 6H), 2.16-2.07 (m, 6H). MALDI-HRMS [M + Na]+ calcd for 457.2395; found
457.2876.
3.2 Labeling of Akt protein and proteomes.
General Materials. The GST-tagged PH domain of Akt was expressed and purified as
described previously by Nathan Lucas in the lab of our collaborator, Dr. Wonhwa Cho.56
All the cell extracts were prepared as previously described36 by Dr. Anna Speers in Dr.
Benjamin Cravatt’s lab.
General procedure for the labeling of proteins. In a 96-well plate, Akt protein (10 ul
of 300 ug/mL stock) or proteome samples (50 ul or 43 ul of 1.0 mg/mL protein in PBS,
50 ul for samples without click chemistry labeling, 43 ul for samples with click chemistry
labeling) were incubated with synthetic PIPns probes for 1 hr at room temperature. For
heat-denatured controls, Akt protein or proteome samples were heated at 90°C for 5
min and cooled to room temperature before the addition of probes. For amino-tagged
PIPns competition samples, the corresponding amino-tagged PIPn was incubated with
the samples overnight at 4 °C prior to the incubation of probes. After the probe
incubation, the 96-well plate was placed on ice and photolyzed for 1 hour under 350 nm
UV lamp.

Click reaction was then performed to the samples with alkyne-tagged

PI(3,4,5)P3 probes (2.2.6e, 2.2.7e). Samples with fluorescein-tagged PI(3,4)P2 probe
(2.2.5c) were directly quenched by SDS-PAGE sample buffer (2x). The proteins were
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separated by 1D SDS-PAGE (30 ul of quenched sample/gel lane) and visualized in-gel
by a Hibachi FMBio lle flatbed laser-induced fluorescence scanner (MiraiBio, Alameda,
CA).
General procedure of click reactions to derivatize alkyne tag into reporter group.
The procedure follows a reported protocol36,37,39,61 developed by Dr. Anna Speers in Dr.
Benjamin Cravatt’s lab. After the photolysis procedure, to each sample was added 50
uM rhodamine-N3 (2.3.8) (50x stock solution in DMSO), 1mM TCEP (50x stock in H2O),
100 uM ligand (TBTA or ligand 2.3.7) (17 x stock in DMSO:t-butanol 1:4) and 1mM
CuSO4 (50x stock in water). The samples were shaken for 30 seconds after each
addition. After all the addition, the samples were incubated at room temperature for 1
hour before being quenched by adding 50 ul of SDS-PAGE sample buffer (2x) to each
well. Same as described above, the proteins were separated by 1D SDS-PAGE (30 ul
of quenched sample/gel lane) and visualized in-gel by a Hibachi FMBio lle flatbed laserinduced fluorescence scanner (MiraiBio, Alameda, CA).
LC/MS/MS sample preparation.
The procedure follows a reported protocol36,37,39,61 developed by Dr. Anna Speers in Dr.
Benjamin Cravatt’s lab. Cytosolic MDA-MB-435 cancer cell extracts 1 mg/mL in PBS
(900 ul) were incubated with 20 ul alkyne PI(3,4,5)P3 probe 2.2.6e (5 mM in H2O, gives
a final concentration of 100 uM) for 1 hour, followed by photolyzing on ice at 350 nm for
1 hour. Next, 6ul of biotin-azide 2.2.3 (50 mM in DMSO, gives a final concentration of
300 uM) was added, followed by 20 ul TCEP (50 mM in H2O, gives a final concentration
of 1 mM), 66 ul of TBTA Ligand (1.67 mM in 1:4 DMSO/t-BuOH, giving a final
concentration of 100 uM) and 20 ul CuSO4 (50 mM in H2O, gives a final concentration of
1 mM). The mixture was incubated at room temperature for 1 hour. Each sample was
transferred into three centrifuge tubes containing MeOH (4mL, 4 x volume). CHCl3 (1mL,
1x volume) was added and vortexed. H2O (3mL, 3x volume) was next added and the
mixture was vortexed, then centrifuged. The top and bottom layers were removed,
leaving the protein pallet. The pallet was then transfered into microcentrifuge tube in
600ul MeOH. 150ul CHCl3 and 600ul H2O were added, vortexed, then centrifuged at
14,000 rpm for 3 min. Top and bottom layers were removed, leaving protein interface.
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MeOH (600 ul) was added, sonicated with probe sonicator for 10sec. The mixture was
centrifuged at 14,000 rpm for 5 min to pellet the protein and MeOH was removed. The
pellet was re-suspended in 500 ul of 6 M urea/25 mM ammonium bicarbonate. The
volume was brought up to 1 mL with mQ water. The mixture was heated (65 °C x 5min)
to re-suspend pellet. TCEP (50ul 100x (0.1M), giving a final concentration of 10 mM)
was added. The mixture was incubated at 65 °C for 15min, then cooled to room
temperature. IAA (40ul, 0.55M, giving 40mM IAA) was added and the solution was
Incubated at 37 °C for 30min in the dark. 140ul of 10% SDS (giving a final concentration
of 2%) was added. The mixture was heated to 65 °C for 5min. The sample was diluted
to ~0.2% SDS with 3mL PBS and 3.5mL 50mM Tris buffer. 100ul aliquot of 50% slurry
was removed and washed 3x with PBS. Avidin beads was transfered to sample using
minimal volume buffer or sample. The beads were incubated with sample room
temperature, rotating 1 hrs. The mixture was spinned at 4000rpm for 3 min to pellet,
~90% of supernant was removed. The beads were washed with 2 x 8mL 1% SDS buffer,
then 2 x 6 M urea, 3 x 10mL DPBS. The beads were next transfered to a tube in 200ul
2M Urea/25mM ammonium bicarbonate. 2ul of 100x (100mM) CaCl2 was added, giving
a final concentration of 1mM CaCl2. Trypsin (4ug) was added. The sample was
incubated at 37 °C overnight. The beads were then removed and washed with 100ul
PBS. The solution were combined and acidified to 5% formic acid for LC/MS/MS
analysis. A separate sample was prepared with Lysine linker 2.2.3e under the same
condition and the results were used as a background control.
Digested peptide mixtures were pressure-loaded on to a biphasic (strong cation
exchange/reverse phase) capillary column and analyzed by two-dimensional liquid
chromatography (2D-LC) separation in combination with tandem mass spectrometry as
previously described62-64 using an Agilent 1100-series quaternary pump and Thermo
Scientific LTQ ion trap mass spectrometer. The proteomic data search was performed
by Dr. Sherry Niessen from The Scripps Research Institute. The total proteomic data
was then filtered to display only proteins (Table 1) with more than 5-fold higher spectral
counts in PIPn probe proteomes compared to lysine negative control proteomes.
Proteins that were identified in at least two out of three cell extract samples were
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considered as PIPn binding receptors. Another list of proteins (in attachment, file 2) with
more than 2-fold but less than 5-fold higher spectral counts in PIPn probe proteomes
than in lysine negative control proteomes.
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3. CHAPTER 3. Design, Synthesis and Application of
Diacylglycerol (DAG) Activity Probes as Chemical Tools to
Characterize Protein-Membrane Binding Interactions

1. Background and significance
Diacylglycerol (DAG), also known as diglyceride, consists of a glycerol molecule in
which two hydroxyls have been esterified with fatty acid chains (figure 3.1 left). In
biological systems, diacyglycerols are synthesized from glycerol-3-phosphate chains65
(figure 3.1 right). Glycerol-3-phosphate is first acylated by acyl-coenzyme A (acyl-CoA)
to yield lysophosphatidic acid and then acylated by another molecule of acyl-CoA to
generate phosphatidic acid. Lastly, phosphatidic acid is de-phosphorylated to form
diacylglycerol by phosphatidic acid phosphohydrolases (PAP). The reverse reaction of
the last step can be promoted by diacyglycerol kinase (DGK).

Figure 3.1 An example of DAG: 1-palmitoyl-2-oleoylglycerol (left);
biosynthesis of DAG (right).
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Although DAG has the simplest structure among all the signaling lipids, it plays
critical roles in several biological pathways66-73. DAG acts as an intracellular second
messenger, generally by binding to protein receptors containing hydrophobic domains,
that subsequently regulates protein functions.74 A particularly important example is the
DAG activation of protein kinase C enzyme family (PKCs), which are known to regulate
proliferation, differentiation and malignant transformation. The understanding of DAGPKCs binding interactions is also essential to cancer research as it was found that
tumour-promoting phorbol esters activate PKCs by mimicking the activity of DAGs.
Further investigation into these binding events reveals that DAG mainly binds to the
highly conserved cysteine-rich C1 domain.2,7,69,75,76 C1 domains are generally
composed of ~50 amino acids with a distinctive motif. It was originally identified in PKC
isozymes and then found in many other signaling families as well, such as protein
kinase Ds (PKDs), chimaerins, RasGRPs and others. The binding of DAG and PKDs, a
family of cytosolic serine-threonine kinases, regulates transport of proteins to the cell
surface, and thus the absence of DAGs blocks the protein transportation. It is also
worthwhile to mention that calcium ions are necessary in DAG-receptor binding process
as they are necessary for the interactions of the C2 domains of the PKCs in the
recruitment to the inner leaflet of the plasma membrane.
A significant amount of work has been invested in understanding DAG-binding
proteins. However, we are still lacking an effective tool in identifying these proteins.
This field would benefit from an approach for efficient and collective labeling of DAGbinding proteins. As was described in the previous chapter, the application of activitybased probes may fulfill this purpose using a similar approach. As a result, we set out to
design DAG activity probes. Considering that the alkyne-tagged PIP activity probes
described in the previous chapter provided the best signal-to-noise ratio (see section
2.5), we only synthesized alkyne-tagged DAG activity probes. Three DAG activity
probes were designed with different connection formats (triazole v.s. amide) or linker
lengths (figure 3. 2).
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Figure 3.2 Structures of DAG activity probes
2. Results and discussion.
2.1 Syntheses of DAG activity probes.
We originally attempted to synthesize DAG activity probes bearing ester-linked acyl
chains. However, we consistantly encountered significant problems with acyl chain
migration, as has previously been a problem.18 We then designed probes with ether tails
to avoid this migration problem, and additionally to prevent the enzymatic hydrolysis
(scheme 3.1). The initial attempt to synthesize these probes began with the protection
of the hydroxyl groups of (4R,5R)- 2,2-dimethyl-1,3-dioxolane-4,5-dimethanol (3.1,
synthesized in two steps according to a reported procedure77) to yield 3.2. The
acetonide was then deprotected to 3.3 in order to install the two ether tails of 3.4. The
PMB groups were next deprotected to 3.5, and one of the resulting alcohols was
converted into a tosylate leaving group to produce 3.6. However, the desired
substitution of tosylate 3.6 into azide 3.7 was hindered by the cyclization to form the
five-membered ring of 3.9. Our group has successfully performed this tosylate into azide
reaction when the two secondary alcohols were tied by acetonide. Therefore, we
propose that the promotion of the cyclization is due to the free rotation of the bond
between the two secondary alcohols.
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Scheme 3.1 Initial attempt to synthesize the DAG activity probes.

To circumvent this probe, we next designed an alternative route to synthesize DAG
activity probes (scheme 3.2). Using the same starting material (4R,5R)- 2,2-dimethyl1,3-dioxolane-4,5-dimethanol 3.1.1, the synthesis began with the selective tosylation of
one of the two alcohols to generate a mono-tosyl intermediate, which was then
converted into azide 3.1.2 by nucleophilic substitution. Next, the remaining free alcohol
was protected with a PMB group to form 3.1.3 and the acetonide was deprotected to
yield diol 3.1.4. The alcohols were alkylated using standard Williamson ether synthesis
condition to yield compound 3.1.5.

The PMB group was then deprotected to form

compound 3.1.6. For the route to synthesize probes 3.1.8 and 3.1.9, the azido moiety of
compound 3.1.6 was reduced into an amino group by hydrolysis. The amine of 3.1.7
was then coupled with acid 2.2.4e to yield probe 3.1.8 or with acid 2.2.9 to yield probe
3.1.9. In a different route to synthesize a triazole-linked DAG probe, azide 3.1.6 was
clicked to alkyne 3.1.11 to form a triazole between the DAG moiety and the linker. The
amine of the intermediate was then coupled to 4-oxo-4-(2-propyn-1-ylamino)butanoic
acid to yield probe 3.1.10.
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Scheme 3.2 Synthetic routes to DAG activity probes.
As is required by the competition studies, we also synthesized DAG lacking the
bifunctional linker. To the PMB-protected glycerol 5.2.3 (synthesis described in chapter
5) was installed two ether tails to form 3.1.11, and then the PMB was deprotected to
generate DAG 3.1.12.

Scheme 3.3 Synthetic route to DAG.
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2.2 Labeling of SKOV3 cancer cell extract (cytosol) using DAG activity probes.
All three DAG probes (3.1.8, 3.1.9, 3.1.10) were used to label DAG binding proteins
in Skov 3 cancer cell extracts (figure 3.3. lanes 1-3: DAG probe 3.1.10; lanes 4-6: DAG
probe 3.1.9; lanes 7-9: DAG probe 3.1.8). As discussed previously, the labeling process
consists of three stages: probe-protein binding, photo-cross linking and latent functional
labeling by click reaction. Each labeling was compared with a DAG competition control
(lanes 2, 5, 8) and heat-denatured control (lanes 3, 6, 9). For the competition studies,
DAG 3.1.11 (10x) was incubated with proteome sample 1 hour prior to probe incubation.
The same volume of heat-denatured proteome samples were used as the heatdenatured control, which were otherwise treated the same. The gel results showed that
DAG probe 3.1.9 labeled the least amount of proteins. DAG probe 3.1.8 and 3.1.10
gave similar results, however, DAG probe 3.1.8 labeled slightly more proteins. In the
competition studies, consistent with all three probes, a band at mass ~60kDa was
heavily competed off. Though a heavier band at the same position showed up in the
heat-denatured control, it is hard to say if this is the same protein that was enriched in
heat-denatured samples.
In similar fashion to previous results, bifunctional lysine linker 2.2.3e as a probe
labeled a different set of proteins (lane 10). Because all probes were dissolved in
DMSO, a control study was performed where DMSO itself was used as a probe under
the same labeling conditions (lane 11) and no labeling was observed, indicating that
DMSO does not cause the labeling.
Next, DAG probe 3.1.8 was used to label the membrane fraction of cancer cell
extracts ((MDA-MB-435, MDA-MB-231, MCF7, T47D) and barely any labeling was seen
(data now shown). Lastly, DAG probe 3.1.8 was subjected to live cells for labeling
studies. However, the cells immediately aggregated upon the addition of the probe. We
believe this is due to the toxicity of the unnatural ether lipid tails. On the other hand,
these DAG probes also suffer from their low solubility in the cell extracts. Further
research will focus on incorporating this DAG probe into liposomes and using these
liposomes as probes to fish out protein receptors from live cells. In these liposome
probes, the ether linkages are not exposed to the live cells and thus we expect them to
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have lower to none toxicity to the living system. Furthermore, since the majority of the
liposome

composition

is

water

soluble,

such

as

phosphatidylcholine

(PC),

phosphatidylethanoamine (PE), these probes will have greatly increased solubility in the
cell extracts.
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Figure 3.3 Labeling of SKOV3 cancer cell extract (cytosol) using DAG activity probes.
(Fluorescent gel image)
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3. Materials and methds
3.1 Synthesis of DAG activity-based probes.
General Experimental. Generally, reagents were purchased from Acros, Aldrich or
FisherSci and used as received. Dry solvents were obtained from a Pure Solv solvent
delivery system purchased from Innovative Technology, Inc. Column chromatography
was performed by using 230-400 mesh silica gel purchased from Sorbent Technologies.
NMR spectra were obtained by using a Varian Mercury 300 spectrometer. Mass spectra
were obtained with ABI DE Pro MALDI spectrometers with high-resolution capabilities.
((4S,5S)-5-(Azidomethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-methanol
Compound

3.1.2

was

prepared

according

to

a

reported

(3.1.2).

procedure18.

The

characterization matched with the literature.
(2S,3S)-1-Azido-4-(4-methoxybenzyloxy)butane-2,3-diol (3.1.4). To the stirred cold
100 mL DMF solution of compound 3.1.2 (2.86 g, 15.3 mmol) was added sodium
hydride (1.22 g, 30.6 mmol, 60 %). The solution was stirred at 0 °C for 30 minutes.
PMBCl (4.17 mL, 30.6 mmol) was then added to this solution. The reaction was stirred
at room temperature for 2.5 hours before it was quenched by 3 mL methanol. The
solvent was removed under reduced pressure. Ethyl acetate (250 mL) was added to
dissolve the crude and the solution was extracted by saturated ammonium chloride
solution (200 mL), brine (200 mL), then water (200 mL). The organic layer was dried by
magnesium sulfate, filtered and concentrated to yield the crude product 3.1.3. The
crude 3.1.3 was used in the next reaction without further purification. Crude 3.1.3 was
re-dissolved in 10 mL methanol. To this solution was added 0.40 g H+ resin. The
reaction was stirred at room temperature overnight. The resin was then filtered off and
the filtrate was concentrated to yield the crude 3.1.4. The crude was purified by column
chromatography with a gradient solvent system of 40-80% ethyl acetate to hexanes to
yield compound 3.1.4 as a colorless oil (1.925 g, 47% from 3.1.2). The characterization
of the compound matched that was the previously reported18.
1-(((2S,3S)-4-azido-2,3-bis(hexadecyloxy)butoxy)methyl)-4-methoxybenzene
(3.1.5). To a cold solution of diol 3.1.4 (74 mg, 0.277 mmol) in 10 mL dry DMF was
added sodium hydride (66 mg, 1.66 mmol, 60%). The solution was stirred at 0 °C for 30
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minutes under nitrogen. Then 1-bromohexadecane (0.34 mL, 1.11 mmol) and TBAI
(catalytic) were added to the solution which was stirred at room temperature overnight.
The reaction was then quenched by 2 mL methanol. Ethyl acetate (150 mL) was added
to the solution and extracted by saturated sodium chloride (100 mL), brine (100 mL) and
water (100 mL). The organic layer was dried by magnesium sulfate, filtered and
concentrated to yield the crude product. The crude was purified by column
chromatography with a gradient solvent system of 2-20% ethyl acetate to hexanes to
yield compound 3.1.5 as a colorless oil (190 mg, 96%).
1

H NMR (300MHz, CDCl3)  7.23 (d, J = 9 Hz, 2H), 6.86 (d, J = 9 Hz, 2H), 4.44 (s, 2H),

3.79 (s, 3H), 3.59-3.46 (m, 8H), 3.32-3.30 (m, 2H), 1.56-1.54 (m, 4H), 1.25-1.23 (m,
52H), 0.87 (t, J = 6 Hz, 3H).

13

C NMR (300MHz, CDCl3)  159.2, 130.1, 129.3, 113.7,

79.0, 78.5, 73.0, 71.8, 71.4, 68.6, 55.2, 51.2, 31.9, 30.1, 29.7, 29.6, 29.5, 29.4, 26.1,
22.7, 14.1. MALDI-HRMS [M + Na]+ calcd 738.6125; found, 738.6169.
(2S,3S)-4-azido-2,3-bis(hexadecyloxy)-1-butanol (3.1.6). Compound 3.1.5 (189 mg,
0.264 mmol) was dissolved in 3 mL dichloromethane. To this solution was added DDQ
(90 mg, 0.396 mmol) and 0.3 mL water. The reaction was stirred at room temperature
for 3 hours. Ethyl ether (150 mL) was added and then extracted by by saturated sodium
chloride (100 mL), brine (100 mL) and water (100 mL). The organic layer was dried by
magnesium sulfate, filtered and concentrated to yield the crude product. The crude was
purified by column chromatography with a gradient solvent system of 10-20% ethyl
acetate to hexanes to yield compound 3.1.6 as a white solid (115 mg, 73%).
1

H NMR (300MHz, CDCl3)  3.80-3.74 (m, 1H), 3.64-3.54 (m, 7H), 3.39-3.35 (m, 2H),

2.20 (t, J = 6Hz, 1H), 1.62-1.55 (m, 4H), 1.28-1.24 (m, 52H), 0.88 (t, J = 6 Hz, 6H).

13

C

NMR (300MHz, CDCl3)  79.5, 78.7, 71.6, 71.1, 61.1, 50.8, 31.9, 30.0, 29.7, 29.6, 29.5,
29.4, 29.3, 26.1, 26.0, 22.7, 14.1. MALDI-HRMS [M + Na]+ calcd 618.5550; found,
618.5639.
(2S,3S)-4-amino-2,3-bis(hexadecyloxy)-1-butanol (3.1.7). Compound 3.1.6 (132 mg,
0.221 mmol) was dissolved in 10 mL ethyl acetate. To this solution was added
palladium on carbon (26 mg, 20% by w.t.). The reaction was stirred under a hydrogen
gas atmosphere overnight. The palladium over carbon was then filtered and washed by
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ethyl acetate. The combined filtrate was concentrated under reduced pressure to yield
amine 3.1.7 (110 mg, 87%).
1

H NMR (300MHz, CDCl3)  3.68-3.60 (m, 3H), 3.53-3.45 (m, 5H), 3.01-2.96 (m, 1H),

2.85-2.81 (m, 1H), 1.57-1.53 (m, 4H), 1.26-1.24 (m, 52H), 0.87 (t, J = 6 Hz, 6H).

13

C

NMR (300MHz, CDCl3)  80.0, 79.2, 70.5, 70.1, 58.9, 39.4, 31.9, 30.1, 30.0, 29.7, 29.6,
29.5, 29.3, 26.2, 26.1, 22.7, 14.1. MALDI-HRMS [M + H]+ calcd 570.5825; found,
570.5822.
Bifunctional Benzophenone/Alkyne DAG Probe (3.1.8). Amine 3.1.7 (56 mg, 0.098
mmol) was combined with acid 2.2.3e (48 mg, 0.098 mmol), EDCI (24 mg, 0.127 mmol),
DMAP (16 mg, 0.127 mmol), NMM (22 ul, 0.196 mmol) in 5 mL dry dichloromethane.
The reaction was allowed to stir at room temperature for 3 hours. The solvent was then
removed under reduced pressure. The crude was purified by column chromatography
with a gradient solvent system of 45-75% acetone to chloroform to yield DAG probe
3.1.8 as a colorless solid (32 mg, 31%).
1

H NMR (300MHz, CDCl3)  8.01-7.98 (m, 2H), 7.85-7.79 (m, 4H), 7.65-7.60 (m, 1H),

7.53-7.48 (m, 2H), 7.17-7.09 (m, 1H), 6.77-6.76 (m, 1H), 6.48-6.46 (m, 1H), 4.57-4.56
(m, 1H), 4.00-3.98 (m, 2H), 3.79-3.78 (m, 1H), 3.69-3.67 (m, 1H), 3.58-3.45 (m, 7H),
3.27-3.24 (m, 2H), 3.01-2.96 (m, 1H), 2.55-2.44 (m, 4H), 1.94-1.93 (m, 1H), 1.56-1.48
(m, 8H), 1.25-1.23 (m, 52H), 0.88 (t, J = 6 Hz, 6H). 13C NMR (300MHz, CDCl3)  196.0,
172.6, 171.9, 171.6, 166.6, 140.2, 136.8, 132.9, 130.1, 129.9, 128.4, 127.3, 71.4, 71.0,
53.7, 31.9, 31.4, 30.1, 29.7, 29.6, 29.5, 29.3, 29.1, 26.1, 22.7, 14.1. MALDI-HRMS [M +
Na]+ calcd 1081.7908; found, 1081.7811.
Bifunctional Benzophenone/Alkyne DAG Probe with hexyl carbon chain linker
(3.1.9) Amine 3.1.7 (45 mg, 0.079 mmol) was combined with acid 2.2.9 (62 mg, 0.103
mmol), EDCI (20 mg, 0.103 mmol), DMAP (13 mg, 0.103 mmol), NMM (13 ul, 0.118
mmol) in 5 mL methanol/chloroform mixture (v/v 1:4). The reaction was allowed to stir at
room temperature overnight. The solvent was then removed under reduced pressure.
The crude was purified by column chromatography with a gradient solvent system of 60100% acetone to hexane to yield DAG probe 3.1.9 as a colorless solid (40 mg, 44%).
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1

H NMR (300MHz, CDCl3 )  8.02-7.99 (m, 2H), 7.88-7.79 (m, 4H), 7.68-7.53 (m, 3H),

7.12-7.11 (m, 1H), 4.56 (t, J = 6 Hz, 1H), 3.95-3.94 (m, 2H), 3.67-3.53 (m, 8H), 3.393.36 (m, 2H), 3.2-3.18 (m, 4H), 2.46 (m, 4H), 2.31-2.29 (m, 1H), 2.20 (t, J = 6 Hz, 2H),
1.88-1.77 (m, 2H), 1.60-1.54 (m, 10H), 1.27-1.25 (m, 56H), 0.88 (t, J = 6 Hz, 6H). 13C
NMR (300MHz, CDCl3)  196.9, 174.3, 173.2, 173.1, 172.8, 172.4, 167.3, 140.3, 137.2,
136.9, 133.3, 130.2, 128.6, 127.5, 80.8, 79.4, 71.4, 71.3, 60.8, 53.8, 49.7, 49.4, 49.2,
48.9, 48.6, 48.3, 48.0, 36.3, 32.0, 31.3, 30.2, 29.8, 29.7, 29.5, 29.0, 26.5, 26.2, 25.4,
22.8, 14.1. MALDI-HRMS [M + Na]+ calcd 1178.8436; found, 1178.8686.
Bifunctional Benzophenone/Alkyne DAG Probe with triazole linker (3.1.10). Alkyne
3.1.11 (69 mg, 0.175 mmol) (the synthesis of 3.1.11 was described in Matt’s
dissertation) was dissolved in 1.5 mL THF. To this solution was added copper sulfate
pentahydrate (43 mg, 0.175 mmol), sodium ascorbate (35 mg, 0.350 mmol), azide 3.1.6
(104 mg, 0.175 mmol) and water (0.5 mL). The reaction was stirred at room
temperature overnight. The solvent was then removed. The crude was dried on high vac
for 8 hours before it was dissolved in 3 mL dry DMF. To this DMF solution was added 4oxo-4-(2-propyn-1-ylamino) butanoic acid (33 mg, 0.210 mmol), EDCI (82 mg, 0.43
mmol), DMAP (21 mg, 0.175 mmol), NMM (96 ul, 0.875 mmol). The reaction was
allowed to stir at room temperature overnight. Ethyl acetate (150 mL) was added to the
solution and then extracted by saturated sodium chloride aqueous solution (100 mL x3).
The organic layer was dried by magnesium sulfate, filtered and concentrated to yield the
crude product. The crude was purified by column chromatography with a gradient
solvent system of 50-100% acetone to hexanes to yield DAG probe 3.1.10 as a
colorless gum (55 mg, 28%).
1

H NMR (300MHz, CDCl3)  8.00-7.95 (m, 3H), 7.83-7.77 (m, 4H), 7.62-7.59 (m, 1H),

7.52-7.47 (m, 2H), 7.14-7.13 (m, 1H), 6.89-6.88 (m, 1H), 4.66-4.35 (m, 3H), 4.00-3.98
(m, 2H), 3.87-3.74 (m, 3H), 3.56-3.41 (m, 5H), 3.22-3.19 (m, 3H), 2.75-2.74 (m, 1H),
2.52 (s, 4H), 2.24 (m, 1H), 1.90-1.80 (m, 2H), 1.58-1.40 (m, 6H), 1.26-1.24 (m, 52H),
0.87 (t, J = 6 Hz, 6H). 13C NMR (300MHz, CDCl3)  196.0, 172.7, 172.3, 172.0, 166.6,
140.2, 137.1, 136.9, 133.0, 130.1, 130.1, 130.0, 128.8, 128.5, 127.3, 124.0, 79.7, 78.9,
78.6, 71.9, 71.8, 71.4, 71.1, 60.4, 53.6, 50.9, 38.9, 31.9, 30.1, 29.7, 29.5, 29.4, 26.1,
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26.0, 22.7, 22.5, 19.5, 14.2. MALDI-HRMS [M + Na]+ calcd 1146.7922; found,
1146.7859.
(S)-2,3-bis(hexadecyloxy)1-propanol (3.1.12). To a cold solution of diol 5.2.3 (714
mg, 3.364 mmol) in 10 mL dry DMF was added sodium hydride (807 mg, 20.2 mmol,
60%). The solution was stirred at 0 °C for 30 minutes under nitrogen. Then 1bromohexadecane (4.11 mL, 13.46 mmol) and TBAI (catalytic) were added to the
solution which was stirred at room temperature overnight. The reaction was then
quenched by 2 mL methanol. Ethyl acetate (250 mL) was added to the solution and
extracted by saturated sodium chloride (150 mL), brine (150 mL) and water (150 mL).
The organic layer was dried by magnesium sulfate, filtered and concentrated to yield the
crude product 3.1.11. The crude was purified by column chromatography with a gradient
solvent system of 0-10% ethyl acetate to hexanes to yield compound 3.1.11 which was
then dissolved in 10 mL dichloromethane. To this solution was added DDQ ( 1.145 g,
5.05 mmol) and water (1.0 mL). The reaction was stirred at room temperature overnight.
Ethyl acetate (150 mL) was added and then extracted by by saturated sodium chloride
(100 mL), brine (100 mL) and water (100 mL). The organic layer was dried by
magnesium sulfate, filtered and concentrated to yield the crude product 3.1.12. The
crude was purified by column chromatography with a gradient solvent system of 10-20%
ethyl acetate to hexanes to yield compound 3.1.12 as a white solid (1.10 mg, 60% from
5.2.3).
1

H NMR (300MHz, CDCl3)  3.75-3.70 (m, 1H), 3.63-3.60 (m, 2H), 3.53-3.41 (m, 6H),

2.25 (bs, 1H), 1.58-1.53 (m, 4H), 1.26-1.24 (m, 52H), 0.88 (t, J = 6 Hz, 6H). MALDIHRMS [M + Na]+ calcd 563.5379; found 563.5425
3.2 Labeling of proteomes by DAG activity probes.
General procedure for the labeling of proteomes. SKOV 3 proteome was prepared
by Dr. Sherry Niessen from The Scripps Research Institute. In a 96-well plate, SKOV 3
proteome samples (43 ul of 1.0 mg/mL protein in PBS) were incubated with synthetic
DAG probes for 1 hr at room temperature. For heat-denatured controls, proteome
samples were heated at 90oC for 5 min and cooled to room temperature before the
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addition of probes. For DAG competition studies, the DAG 3.1.12 was incubated with
the samples 1 hour in room temperature prior to the incubation of probes. After the
probe incubation, the 96-well plate was placed on ice and photolyzed for 1 hour under
350 nm UV lamp.
General procedure of click reactions to derivatize alkyne tag into reporter group.
After the photolysis procedure, to each sample was added 50 uM rhodamine-N3 (2.3.8)
(50x stock solution in DMSO), 1mM TCEP (50x stock in H2O), 100 uM TBTA ligand (17
x stock in DMSO:t-butanol 1:4) and 1mM CuSO4 (50x stock in water). The samples
were shaken for 30 seconds after each addition. After all the addition, the samples were
incubated at room temperature for 1 hour before being quenched by adding 50 ul of
SDS-PAGE sample buffer (2x) to each well. The proteins were separated by 1D SDSPAGE (30 ul of quenched sample/gel lane) and visualized in-gel by a Hibachi FMBio lle
flatbed laser-induced fluorescence scanner (MiraiBio, Alameda, CA).
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4. CHAPTER 4. Analysis of Akt PH Domain Binding via a Rapid
Microplate Assay Employing Synthetic Biotinylated Analogs of
all Seven Phosphatidylinositol Polyphosphate Headgroup
Isomers

1. Background and significance
Signaling lipids such as phosphatidylinositol polyphosphates (PIPns) play vital role in
molecular recognition events. These lipid molecules act as ligands in receptor binding
events, resulting in the recruitment of protein receptors onto membrane surfaces, which
regulates both protein subcellular localization and function. The characterization of
these lipid-receptor binding interactions is important for understanding numerous lipidrelated biological pathways at molecular level.1 The PIPns represent an important
signaling lipid family that controls many key cellular pathways. This is exemplified by the
conversion of PI(4,5)P2 to PIP3 by PI-3K, which acts as the hub that controls several
biological pathways involved in cell survival cycle. The family of PIPns consists of seven
naturally existing isomers (PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, PI(4,5)P2,
PI(3,4,5)P3), which possess different protein binding properties. This fact, along with the
complex cell environment, complicates the study of PIP-receptor bindings to a great
extent.
One of the strategies to elucidate these complex binding interactions is to build
model systems. The conventional strategies include surface plasmon resonance (SPR)
analysis using both membrane and individual lipid motifs, fluorescence quenching and
polarization,
calorimetry.

monolayer

78,79

penetration,

vesicle

pelleting,

overlay

assays,

and

In addition, innovative approaches for generating PIPn-presenting

materials have been reported, such as the polymerized liposomes reported by
Prestwich and co-workers,80 and dendrimers studied by Oakley and co-workers.81-83
Though these approaches have provided significant amount of information on the
binding events at molecular level, their disadvantages can be summarized as follows:
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the inability to perform high-throughput analysis, expensive and inaccessible
instrumentation, and/or detection that can be limited to specific systems. Additionally,
since the membrane environment is simplified in these models, it would be ideal to
perform analysis in different contexts that mimic different aspects of the cell membrane
to fully investigate binding. Finally, it will be beneficial to have broadly accessible and
applicable assays that have the potential for high-throughput screening.
Microarray analysis has provided an invaluable method for probing receptor–ligand
binding interactions, such as with carbohydrate studies.84,85 In one example,86 a library
of diverse glycans with amino tags was immobilized onto amino-reactive glass surfaces
to profile their binding specificities with various glycan binding proteins. Microarray
research has also been used to determine the structural requirements of recognition
among receptors, to quantify the effect that multivalency has on receptor affinity by
controlling ligand density on the surface, and to detect receptor variations associated
with disease from cell extracts.87,88 Here, we extend the application of this platform to
study

lipid-receptor

binding

interactions,

particularly

the

PIP-receptor

binding

interactions.
2. Results and Discussion
As was addressed previously, different types of proteins require different lipid motifs
for recognition. Some proteins (S-type) interact primarily with the lipid polar headgroups
while others (I-type and H-type) require the membrane context.89,90 PIPn-protein
bindings particularly belong to the former situation due to their highly-charged
headgroups.25,91-94 With this fact in mind, we once again utilized soluble headgroups
corresponding to all seven PIPn isomers to probe protein binding.
Previously, our group has also developed a platform using immobilized whole
liposomes to detect diacylglycerol (DAG) recognition in a format that mimics cellular
membranes, which we first used to analyze Protein Kinase C.95 We have also modified
the assay via the immobilization of isolated PIPn headgroups motifs for rapid
characterization of receptors that bind with high affinity to these moieties without the
membrane context. Our initial report of this latter approach utilized a synthetic PI(4,5)P2
analog to detect binding of the PH domain of -spectrin.96 This assay was shown to be
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effective for sensitive detection of the binding and inhibition of PIPn receptors. Due to
the diversity of PIPn targets exhibited by receptors, an important application of this
approach involves the efficient delineation of the PIPn-binding specificity of receptors.
Herein, we describe the utility of this assay for characterizing PIPn specificity through
studies focusing on the PH domain of the prominent receptor Akt.
The modified PIPn assay employs PIPn-TEG-biotin conjugates as the recognition
motif for binding studies, based upon our initial study that successfully employed
synthetic PI(4,5)P2–TEG–biotin structure 4.2.1c (Scheme 4.1). This ligand consists of
the PI(4,5)P2 headgroup with a phosphodiester moiety at the same position as the
parent PI(4,5)P2 lipids (1-position of the inositol ring). The phosphodiester linkage
connects to a six-carbon hydrophobic region that is designed to mimic the
hydrophobicity of the natural glycerolipid backbone, which is excluded. Next, a
tetraethylene glycol (TEG) linker is employed as a spacer between the headgroup
binding motif and the microplate surface to prevent non-specific binding. Lately, Iyer and
co-workers showed evidence of a long tether being critical in microplate studies with
streptavidin-coated plate as the shortening of this linker led to the drastic reductions in
binding.97 Lastly, the biotin portion of 4.2.1c is installed for high-affinity non-covalent
immobilization of these ligands onto streptavidin-coated microplates in an effort to avoid
non-specific binding interactions.
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Scheme 4.1 Microarray binding analysis for PIPn headgroups: the designed PIP ligand
was immobilized onto the streptavidin-coated plate through its biotin moiety; next, the
GST-fused -spectrin proteins were incubated with this PIP-coated plate to allow
binding to occur. The excess non-bound proteins were subsequently washed away. The
bound GST-fused -spectrin proteins was quantified by ELISA.
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Scheme 4.2 Synthesis of headgroup-biotin conjugates of all seven naturally
occuring phosphoinositide isomers.

In order to develop an assay that is suitable for characterizing the binding affinities
of all PIPn family members, we extended our previous approach to produce biotinylated
ligands corresponding to all seven PIPn headgroup isomers 4.2.1a–g (scheme 4.2).
With the amino-tagged PIPn headgroups (2.2.5-7, 4.2.2c, e, f, g) in hand55 (see chapter
2), we synthesized PIPn–TEG–biotin conjugates 4.2.1a–g by reacting ligands 4.2.2a–g
with synthetic biotin–TEG–succinimidyl ester. These conjugates were then used for
microplate studies.
We first sought to apply these compounds 4.2.1a–g for side-by-side microplate
binding analysis in order to directly compare all seven PIPn isomers and thus assess
receptor binding specificity. In the studies, we employed the PH domain of Akt due to
the key role this receptor plays in the cell survival cycle and since few binding studies
have been reported using all PIPn isomers. The GST-tagged PH domain of Akt was
expressed and purified as described previously by Nathan Lucas in the lab of our
collaborator, Dr. Wonhwa Cho.56 In the assay, compounds 4.2.1a–g were immobilized
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in separate rows of streptavidin-coated 96-well microplates (scheme 4.1). Next, the Akt
PH domain was introduced to allow for recognition, followed by detection via
chemiluminescence-based ELISA signal transduction using an HRP-tagged anti-GST
antibody. Each step of the assay was followed by washes to remove any unbound
species.
In this assay, Akt binding analysis was performed in two ways. On one hand, fixed
concentrations of each ligand of type 4.2.1a–g were immobilized in separate rows, and
each isomer was treated with varying concentrations of the Akt PH domain. The results
from this approach are shown in figure 4.1A. Here, the analogs corresponding to the
PIP3 (4.2.1a) and PI(3,4)P2 (4.2.1b) headgroups yielded sensitive dose-dependant
responses when incubating with relatively low concentrations of the Akt PH domain (0–
20 nM). The other isomers yielded low-to-no signal and thus essentially doubled as
negative controls for the experiment. On the other hand, varying concentrations of
4.2.1a–g were incubated in separate wells of the microplate, followed by treatment with
a fixed concentration of the Akt PH–GST, the results of which are shown in figure 4.1B.
In a similar fashion, 4.2.1a and 4.2.1b yielded dose-dependant responses with minimal
protein recruitment to the microplate surface observed for the other isomers. In the latter
binding studies, a dual curve response is observed, which can likely be attributed to the
combined equilibria of the binding of the receptor to the PIPn headgroup as well as the
binding of the PIPn–TEG–biotin ligand to the microplate surface. However, this format is
still effective for analyzing binding specificity via an experiment where the receptor
concentration is held constant, thus avoiding any concerns that non-specific protein–
surface binding may be occurring. The data shown in figure 4.1 represent the averages
of at least three analyses with error bars showing the standard error produced by
multiple runs, indicating the reliability and reproducibility of the assay.
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(A)

(B)

Figure 4.1 Results from Akt PH domain microplate binding results using analogs
corresponding to all seven PIPn headgroups: (A) fixed concentrations of each ligand
4.2.1a–g were immobilized and tested against various concentrations of the Akt PH
domain; (B) varying concentrations of 4.2.1a–g were immobilized and tested against
fixed concentrations of the Akt PH domain.
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These results are consistent with previous reports indicating Akt binding specificity of
PIP3 > PI(3,4)P2 > PI(4,5)P2. Thus, the phosphates at the 3- and 4-positions are
required for binding, while the 5-phosphate contributes as well. Similar trends were
observed through studies using full PIPn analogs including SPR, vesicle pelleting, and
tryptophan quenching assays.56,98,99 In the latter study, it was observed that full PIPn
structures bound with much higher affinity than the corresponding inositol phosphates
(InsPs), which contain a phosphate group at 1-position instead of the phosphodiesterlinked glycerolipid backbone. In the current study we observe strong binding to
headgroup analogs bearing the traditional phosphodiester but lacking the glycerolipid
scaffold. Thus, this provides further evidence for the importance of the phosphodiester
group in binding, as opposed to the lipid core, which appears to not significantly
contribute to the binding of this particular receptor.
As we observed in the previous report from our group, this surface-based study
resulted in higher receptor binding affinities than membrane- and solution-phase
analysis. In the current studies, receptor binding affinities for the surface, commonly
termed “Kd, surf”,88 were evaluated via Scatchard Plot analysis to be approximately 9 nM
for 4.2.1a and 12 nM for 4.2.1b. Despite the similar affinity constants for these
structures, ligand 4.2.1a clearly recruits more receptor to the microplate surface based
on the enhanced amplitude of the binding curves. These values represent higher
affinities than those previously observed for PIP3 (234 – 590 nM) and PI(3,4)P2 (350 –
570 nM) motifs.56,98,99 However, variations in observed binding strengths are to be
expected due to the different conditions used in the current assay. The primarily
variations in the current study are the truncated structures of the PIPn ligands and the
use of surfaces coated with the ligand motif, of which it is not clear which aspect or both
may be affecting the binding. For the latter case, while binding may simply be enhanced
by the increased charge of the coated surface, this may nevertheless be biologically
significant since many PIPn-binding interactions seem to occur when the lipid motif is
aggregated in some way, and indeed Akt has been reported to bind PIP3 localized in
lipid rafts.100,101 In future studies, we will seek to analyze the effect that ligand density on
the microplate surface has on receptor affinities to further characterize any clustering
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effects. Furthermore, we are currently attempting to perform this assay on a glass slide
with robotic pin printer to realize a true high-throughput microarray analysis. The aminotagged PIPn headgroups (2.2.5-7, 4.2.2c, e, f, g) are used instead of biotinylated
analogs 4.2.1a-g to be immobilized on an epoxy-coated glass slide (figure 4.2). These
amino-tagged PIPn headgroups (2.2.5-7, 4.2.2c, e, f, g) were printed on the glass slide
by pin printer. After incubation, the glass slide was washed and then incubated with Akt
protein. Excess proteins were washed away by buffer. Lastly, ELISA was performed,
followed immediately by fluorescent scanning.

Glass slide pin printer
OR1
HO
OR2
O
P O
OR3
O OH OH

=
NH2

1)
Epoxy-coated
glass slide

1)
Akt PH Domain
GST fusion

2) Wash

2) Wash

ELISA

R1, R2, R3 = H or PO32-

1)
Anti-GST primary antibody
2)

Fluorescent detection

Cy3 conjugated
Goat Anti-rabbit secondary antibody

Figure 4.2 Picture of a pin printer and demonstration of glass slide-based
microarray binding analysis for PIPn headgroups
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3. Conclusions
This report describes a microplate-based binding platform for characterizing protein–
PIPn binding interactions using synthetic headgroup ligands corresponding to all seven
naturally occurring PIPn isomers. This approach was applied for rapid side-by-side
analysis of the binding of the Akt PH domain to the seven headgroup isomers. Results
obtained from studies indicated highly sensitive detection of binding, and the ligand
specificity of Akt of PIP3 > PI(3,4)P2 > PI(4,5)P2 was characterized in an efficient
manner. This study also provides useful information regarding the structural features
required for Akt binding, as immobilized headgroups bearing the phosphodiester
linkage, but lacking the glycerolipid backbone of full PIPn structures, exhibited highaffinity receptor binding outside of a membrane environment.
The described assay will be highly beneficial for probing and perturbing protein–PIPn
binding for numerous reasons. First, this platform is amenable for high-throughput
screening to maximize the efficiency of analysis. In addition, the surface-based ligand
presentation involved in this assay can mimic the presentation of lipid motifs on the
surfaces of cell membranes, thus providing an effective model system for biological
recognition. Furthermore, surface deposition allows for the ligand density to be
controlled, allowing for ligand clustering effects to be analyzed. Finally, while traditional
binding assays are limited to in vitro binding studies using protein and ligand motifs in
solution, antibody-based signal transduction allows for the detection of a specific
receptor target, and could thus be used for target detection in a more complex biological
context, such as a cell extract. We are now pursuing to apply this platform to address
important issues in protein–PIPn binding interactions. At the same time, a glass slidebased microarray analysis to study the protein–PIPn binding more robotically is
underway.
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4. Materials and methods
Experimental
General Experimental. Generally, reagents were purchased from Acros, Aldrich or
Advanced ChemTech and used as received. Dry solvents were obtained from a Pure
Solv solvent delivery system purchased from Innovative Technology, Inc. Column
chromatography was performed using 230-400 mesh silica gel purchased from Sorbent
Technologies and C18 (17%) reverse phase SPE columns (6 mL, 2 g) purchased from
Silicycle. NMR spectra were obtained using a Varian Mercury 300 spectrometer and a
Bruker Avance 400 spectrometer. Mass spectra were obtained with JEOL DARTAccuTOF spectrometer and an ABI Voyager DE Pro MALDI spectrometer with high
resolution capabilities. Microplate chemiluminescence analysis was performed using a
BioTek Synergy 2 multidetection microplate reader. White reacti-bind high binding
capacity

(HBC)

streptavidin-coated

96-well

microplates

employed

for

chemiluminescence studies were purchased from Pierce Biotechnology (Rockford, IL).
Mouse monoclonal anti-GST tag HRP-conjugate was purchased from Millipore
(Billerica, Ma). Supersignal ELISA femto maximum sensitivity substrate was purchased
from Pierce Biotechnology (Rockford, IL). The GST-tagged PH domain of Akt was
expressed and purified as previously described.56 Synthetic procedures for modular
PIPn–amine conjugates 4.2.2a-g102, as well as biotin-TEG-succinimidyl ester 4.2.4 and
biotinylated PI(4,5)P2 analog 4.2.1c96 were previously described.
General Procedure for the synthesis of PIP-TEG-Biotin Conjugates 4.2.1a-g. To a
solution of biotin–succinimidyl ester 4.2.4 in 1 mL of N,N-dimethylformamide was added
the appropriate PIPn–amine of type 4.2.2a-g in triethylammonium bicarbonate (TEAB)
buffer. Next, 0.5–1.5 mL of tetrahydrofuran was added to the solution until it turned
clear. The reaction mixture was then stirred at room temperature for 10 h, at which time
the solvent was removed under reduced pressure. Next, acetone was added to the
residue, and the white solid that formed was filtered and washed with acetone three
times. The white solid was dissolved in deionized water and Chelex 100 resin (Sigma,
Na+ form) was added. This solution was then stirred for 3 h and loaded onto a C18
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reverse phase column (6 mL, 2 g). The corresponding fractions were lyophilized to yield
4.2.1a-g (47-99% yield).
1-(6-(14-Biotinamido-3,6,9,12-tetraoxatetradecanamido)hexyl sodium phosphate)1D-myo-inositol

3,4,5-tris-(disodium

phosphate)

(4.2.1a).

PI(3,4,5)P3–amine

conjugate 4.2.2a (8 mg, 0.013 mmol) and biotin succinimidyl ester 4.2.4 (46 mg, 0.080
mmol) yielded 4.2.1a as a white solid (8 mg, 57%). 1H NMR (300 MHz, D2O):  4.364.34 (m, 1H), 4.18-4.15 (m, 1H), 3.84 (s, 2H), 3.74-3.70 (m, 4H), 3.52-3.38 (m, 18H),
3.20-3.18 (m, 2H), 3.14-3.12 (m, 2H), 3.08-3.02 (m, 3H), 2.10-2.05 (m, 2H), 1.46-1.32
(m, 8H), 1.20-1.16 (m, 6H).

31

P NMR (121.5 MHz, D2O):  6.20 (1P), 5.11 (2P), 0.89

(1P). MALDI-MS [M+H]+: calcd for C32H63N4O25P4S 1059.2447, found 1059.2393.
1-(6-(14-Biotinamido-3,6,9,12-tetraoxatetradecanamido)hexyl sodium phosphate)1D-myo-inositol 3,4-bis-(disodium phosphate) (4.2.1b). PI(3,4)P2–amine conjugate
4.2.2b (10 mg, 0.019 mmol) and biotin succinimidyl ester 4.2.4 (84 mg, 0.146 mmol)
yielded 4.2.1b as a white solid (20 mg, 99%). 1H NMR (300 MHz, D2O):  4.38-4.36 (m,
1H), 4.20-4.17 (m, 1H), 4.13-3.99 (m, 2H), 3.83 (s, 2H), 3.76-3.60 (m, 4H), 3.48-3.38
(m, 18H), 3.17-3.13 (m, 2H), 3.02-3.00 (m, 1H), 2.77-2.73 (m, 1H), 2.56-2.52 (m, 1H),
2.04 (t, J = 6Hz, 2H), 1.44-1.30 (m, 8H), 1.18-1.10 (m, 6H).

31

P NMR (121.5 MHz,

+

D2O):  2.16 (1P), 1.24 (1P), -0.19 (1P). MALDI-MS [M+H] : calcd for C32H62N4O22P3S
979.2784, found 979.2723.
1-(6-(14-Biotinamido-3,6,9,12-tetraoxatetradecanamido)hexyl sodium phosphate)1D-myo-inositol 3,5-bis-(disodium phosphate) (4.2.1d). PI(3,5)P2 amine conjugate
4.2.2d (10 mg, 0.019 mmol) and biotin succinimidyl ester 4.2.4 (46 mg, 0.080 mmol)
yielded 1d as a white solid (17 mg, 72%). 1H NMR (300 M Hz, D2O):  4.44-4.39 (m,
1H), 4.27-4.22 (m, 1H), 4.07-4.05 (m, 2H), 3.88 (s, 2H), 3.76-3.70 (m, 4H), 3.58-3.42
(m, 18H), 3.21-3.18 (m, 2H), 3.08-3.03 (m, 1H), 2.83-2.77 (m, 1H), 2.60-2.58 (m, 1H),
2.08 (t, J = 6 Hz, 2H), 1.50-1.35 (m, 8H), 1.24-1.16 (m, 6H).

31

P NMR (121.5 MHz,

D2O):  1.64 (1P), 0.30 (1P), -0.31 (1P). MALDI-MS [M+H]+: calcd for C32H62N4O22P3S
979.2784, found 979.2639.
1-(6-(14-Biotinamido-3,6,9,12-tetraoxatetradecanamido)hexyl sodium phosphate)1D-myo-inositol 5-disodium phosphate) (4.2.1e). PI(5)P–amine conjugate 4.2.2e (10
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mg, 0.023 mmol) and biotin succinimidyl ester 4.2.4 (46 mg, 0.080 mmol) yielded 4.2.1e
as a colorless crystal (14 mg, 65%).

1

H NMR (300 MHz, D2O):  4.55-4.45 (m, 1H),

4.35-4.25 (m, 1H), 4.19-4.10 (m, 1H), 3.98-3.92 (m, 2H), 3.85-3.75 (m, 2H), 3.70-3.45
(m, 20H), 3.32-3.22 (m, 4H), 3.16-2.12 (m, 1H), 2.89-2.85 (m, 1H), 2.18-2.14 (m, 2H),
1.70-1.40 (m, 8H), 1.40-1.20 (m, 6H).

31

P NMR (121.5 MHz, D2O):  3.75 (1P), -0.30

+

(1P). MALDI-MS [M+H] : calcd for C32H61N4O19P2S 899.3121, found 899.2996.
1-(6-(14-Biotinamido-3,6,9,12-tetraoxatetradecanamido)hexyl sodium phosphate)1D-myo-inositol 4-disodium phosphate) (4.2.1f). PI(4)P–amine conjugate 4.2.2f (10
mg, 0.023 mmol) and biotin succinimidyl ester 4.2.4 (83 mg, 0.144 mmol) yielded 1f as
a colorless crystal (20 mg, 93%).

1

H NMR (300MHz, D2O):  4.48-4.36 (m, 1H), 4.21-

4.17 (m, 1H), 4.02-3.99 (m, 2H) 3.86-3.82 (s, 2H), 3.76-3.68 (m, 4H), 3.56-3.36 (m,
18H), 3.18-3.14 (m, 2H), 3.04-3.00 (m, 1H), 2.79-2.73 (m, 1H), 2.58-2.51 (m, 1H), 2.082.00 (t, J = 6Hz, 2H), 1.44-1.32 (m, 8H), 1.19-1.07 (m, 6H). ).

31

P NMR (121.5 MHz,

D2O):  3.99 (1P), -0.11 (1P). MALDI-MS [M+H]+: calcd for C32H61N4O19P2S 899.3121,
found 899.3103.
1-(6-(14-Biotinamido-3,6,9,12-tetraoxatetradecanamido)hexyl sodium phosphate)1D-myo-inositol 3-disodium phosphate) (4.2.1g). PI(3)P–amine conjugate 4.2.2a (12
mg, 0.027 mmol) and biotin–succinimidyl ester 4.2.4 (46 mg, 0.080 mmol) yielded
4.2.1g as a colorless crystal (12 mg, 47%). 1H NMR (300 MHz, D2O):  4.50-4.44 (m,
1H), 4.31-4.27 (m, 1H), 3.80 (s, 2H), 3.65-3.54 (m, 18H), 3.51-3.47 (m, 4H), 3.27-3.23
(m, 4H), 3.13-3.09 (m, 1H), 2.89-2.83 (m, 1H), 2.66-2.62 (m, 1H), 2.14 (t, J = 6Hz, 2H),
1.65-1.38 (m, 8H), 1.38-1.16 (m, 6H).

31

P NMR (121.5 MHz, D2O):  4.15 (1P), -0.08

(1P). MALDI-MS [M+H]+: calcd for C32H61N4O19P2S 899.3121, found 899.3007.
Akt PH domain microplate binding analysis using PIPn-biotin conjugates 4.2.1a–g.
Each binding study involved side-by-side analysis of each headgroup isomer through
immobilization onto separate rows of a streptavidin-coated 96-well microplate. First, the
wells to be used were incubated with 200 ul of the wash buffer for the experiment, which
consisted of 20 mM Tris buffer at pH 8.0 with 0.05% tween as a blocking additive to
avoid nonspecific surface adsorption, for 30 minutes. This was removed, followed by the
addition of 100 ul of solutions of biotin-TEG-PIPn ligands of type 4.2.1a–g in wash buffer
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into different rows. Binding experiments were run using either a fixed concentration of
4.2.1a–g (500 nM) or by varying the ligand concentration (0, 40, 80, 140, 160, 200, 240,
280, 320, 400, 450, 500 nM). These solutions were incubated for 1h, removed, and the
wells were washed with 3 x 250 ul wash buffer. Next, solutions of the Akt PH domain in
wash buffer were added. For experiments with fixed [1a–g], protein solutions with
varying concentrations (0, 1, 3, 5, 6, 7, 8, 9, 10, 12, 15, 20 nM) were added, while for
those with varying [1a–g], solutions with the same protein concentration (15 nM) were
added. These solutions were incubated for 1h, removed, and the wells were washed
with 3 x 250 ul wash buffer. Following this, 200 ul solutions of HRP-tagged anti-GST
antibody (100 ng/mL) in wash buffer were added to each well. After a 1 h incubation,
these solutions were removed, and the wells were washed with 3 x 250 ul wash buffer.
Chemiluminescence detection of bound antibody was next performed using supersignal
ELISA femto maximum sensitivity substrate. For detection, a 1:1 mixture of the
substrate and peroxide solutions were mixed, and 100 ul of the resulting solution was
added to each well. The microplate was then immediately placed in the microplate
reader, and the chemiluminescence at 425 nm was repeatedly measured for 10 m.
Several microplate readings from each experiment were then averaged, and the entire
experiment was rerun at least 3 times and averaged to produce the data depicted in
figure 4.1.
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5. CHAPTER 5: Modular Synthesis of
Bis(monoacylglycero)phosphate for Convenient Access to
Analogues Bearing Hydrocarbon and Perdeuterated Acyl Chains
of Varying Length.
1. Introduction
Bis(monoacylglycero)phosphates (BMPs), also known as lysobisphosphatidic acid
(LBPAs), are formed during the degradation of phosphatidylglycerol and cardiolipin and
then enriched in the acidic compartments of cells, namely endosomes and lysosomes.
In physiological conditions, BMP exists as the form of two isomers that are in
equilibrium with one another (figure 5.1). The acyl chain at the sn-2 position can rapidly
migrate to sn-3 position through acyl migration under either acidic or basic conditions.
However, both structures contribute to the natural form of BMPs.

Figure 5.1 Bis(monoacylglycero)phosphate (BMP)

This lipid has been the subject of significant interest for biochemists, cytologists, and
physiologists in the recent years because of the important role it plays in regulating
several biological pathways. For instance, membranes presenting BMP are known to
enhance the degradation of sphingolipids including glucosylceramide, ceramide, GM1,
and GM2.103,104 BMP also regulates cholesterol transport,105,106 which is aberrant in
Niemann-Pick type C disease, and the accumulation of anti-BMP antibodies is known to
alter cholesterol homeostasis.9 In addition, BMP is a known antigen of antiphospholipid
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antibodies associated with antiphospholipid syndrome.105 Finally, the transport of
stomatitus virus to late endosomes, the last step prior to cytoplasmic release of the
nucleocapsid and infection, has been shown to require the presence of BMP.107,108
BMP is a minimal lipid component in the whole cell whereas it makes up about 70%
of the inner membranes and 15% of the total membranes in late endosomes.
Therefore, the functions of endosomes are closely associated with the unique structure
of BMPs. BMPs tend to form monolayer membrane instead of bilayers membranes, and
thus are untouched by the main phospholipases that would destroy phosphatidylcholine
and phosphotidylethanolamine. BMPs, with the special pH-dependent fusogenic
properties are ideal candidates to regulate the dynamic properties of this internal
membrane mosaic and the concentration of BMPs controls the rate of ceramide104 and
the endosomal cholesterol levels. It is believed that BMP membrane structure controls
the membrane function. Therefore, BMPs are important in studying the membrane
properties.
The biosynthesis of BMPs starts from phosphatidylglycerol, and occurs primarily in
the endosomes (figure 5.2). In the first step, the sn-2 fatty acid chain is removed from
phosphatidylglycerol by a phospholipase A2. The resulting lysophosphatidylglycerol is
then acylated on the sn-2’ position of the head group glycerol to generate
lysobisphosphatidic acid through a transacylase reaction with lysophosphatidylglycerol
as both the acyl donor and acyl acceptor. Next, the removal of the fatty acid from
position sn-1 of the primary glycerol unit was followed by the esterification of position
sn-2 of the primary glycerol unit probably by a transacylation reaction with another
phospholipid as donor.
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Figure 5.2 Biosynthetic pathway of bis(monoacylglycero)phosphate (BMP)

The earlier successful synthetic work of BMPs benefited from the natural
biosynthetic pathways. The syntheses utilized chemo-enzymatic approaches through
reaction of 2 equiv of diacylglycerol with a phosphoryl dichloride, followed by acyl chain
removal using phospholipase A2. Lately, chemical synthesis has been achieved to
access BMPs from simple glycerol precursors.109 In these reports, the primary focus has
been the synthesis of (S,S)-2,2-BMP structures, in which methods were developed to
minimize acyl migration to successfully produce this target. In the generation of (S,S)3,3-BMPs, rationally induced acyl migration has been effective for the synthesis of this
regioisomer from the corresponding (S,S)-2,2-BMP structure.18,109
This chapter will describe a modular synthetic strategy that allows the access of
BMPs with various chain lengths at sn-3 positions. These molecules are being used to
study the impact of BMP chain length on membrane property studies, which are
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currently being performed by our collaborator, Dr. Gail Fanucci at the University of
Florida.
2. Results and discussion
Synthetic BMP analogs are of great value as chemical tools for understanding their
biological and structural effect. In the current study, we developed novel (S,S)-3,3-BMP
analogues bearing labeled acyl chains for use in characterizing the effect of this lipid on
membrane structure. For this purpose, a particularly advantageous structural design
involves the incorporation of perdeuterated acyl chains into the BMP structure. Lipid
probes with specifically deuterated domains are beneficial for structural studies
employing NMR and neutron scattering, and have previously been synthesized.
Furthermore, since we are interested in determining how the identities of the acyl chains
affect packing within a membrane environment, we sought to synthesize a number of
(S,S)-3,3-BMP analogs bearing different chain lengths of both normal saturated and
perdeuterated lipid tails.
The efficient production of a number of BMP analogues containing diversity in the
acyl chains would benefit from a modular synthesis in which the lipid tails are introduced
at a late stage. The initial synthetic approach we developed for this purpose is indicated
in

scheme

5.1.

This

route

commenced

with

commercially

available

and

enantiomerically pure (S)-acetonide-protected glycerol (5.2.2), which contains the
appropriate stereochemistry for the targeted (S,S)-3,3-BMP derivatives. Protection of
the hydroxyl group of 5.2.2 as a para-methoxybenzyl (PMB) ether was followed by
acetonide deprotection to produce diol 5.2.3, as previously described.110 Next, the
primary hydroxyl group of 5.2.3 was selectively protected as a mono-methoxytrityl
(MMT) ether to generate alcohol 5.2.4, and then a tert-butyldiphenylsilyl (TBDPS) group
was installed at the remaining secondary hydroxyl to produce fully protected glycerol
derivative 5.2.5. The MMT protecting group was next removed and the resulting alcohol
5.2.6, was converted to phosphodiester 5.2.7 using phosphoramidite chemistry. Finally,
PMB-deprotection generated diol 5.2.8 as a core scaffold for the production of a range
of derivatized BMPs.
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Scheme 5.1 Synthetic route to the core scaffold of BMPs

Compound 5.2.8 acts as a convenient modular precursor to BMP analogues as
different lipid tails can be appended to this diol, followed only by global deprotection to
the final targets (scheme 5.2). Here, coupling chemistry was used to introduce all
saturated acyl chains of even length between 12 and 18 carbons in both normal
saturated and perdeuterated form to produce protected (S,S)-3,3-BMP phosphotriester
intermediates 5.2.9a–h. These specific acyl chain motifs were selected to study the
effect of the length of the lipid tail on biological and physiochemical properties, and
because the corresponding perdeuterated precursors of these fatty acids are
commercially available. Finally, global deprotection using TBAF was achieved to access
5.2.10 a–h,106 consisting of a number of (S,S)-3,3-BMP probes with acyl chains of
varying lengths composed of either perdeuterated or natural hydrocarbon acyl chains.
The final deprotection step proceeded in high yield for the formation of certain
derivatives, such as bis-palmitoyl derivative 5.2.9c (91%). However, this yield tended to
decrease with compounds with shorter acyl chains, likely due to problems in isolating
these compounds as a result of their amphiphilic nature. Other than this challenge, the
described synthesis is effective, with most steps proceeding in ~85 to 95% yield.
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Scheme 5.2 Synthetic route to eight BMP analogs

Since BMPs are known to undergo acyl chain migrations, it is important to confirm
the identity of the products from the deprotection producing 5.2.10a–h. In previous
reports of acyl chain migrations, sn-2-to-sn-3 migration has primarily been noted,
suggesting that the primary driving force for this transformation is the relief of steric
strain upon the shift to the less substituted sn-3 position. In fact, quantitative sn-2-to-sn3 migration has been reported in the synthesis of BMPs and other glycerolipids under
certain conditions.110 Based on this evidence, the reverse sn-3-to-sn-2 migration was
not expected to be problematic in the deprotection of 5.2.9a–h. This was confirmed via
1

H NMR analysis, as the typical chemical shifts for the hydrogens on the (S,S)-3,3-BMP

isomer (~ 3.9– 4.2) dominated the spectra of 5.2.10a–h (see 1H NMR spectra in the
experimental section), with minimal of the characteristic peaks of the (S,S)-2,2-isomer
(~ 3.8,  5.0), both of which have been previously described.109 Thus, this approach is
effective for accessing a range of analogues of the (S,S)-3,3-isomer of BMP.
3. Materials and methods
General experimental: Generally, reagents were purchased from Acros or Aldrich and
used as received. Perdeuterated fatty acids were purchased from Cambridge Isotopes.
Dry solvents were obtained from a Pure Solv solvent delivery system purchased from
Innovative Technology, Inc. Column chromatography was performed using 230–400
mesh silica gel purchased from Sorbent Technologies. NMR spectra were obtained
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using a Bruker AC250 spectrometer updated with a TecMag data collection system, a
Varian Mercury 300 spectrometer, and a Bruker Avance 400 spectrometer. Mass
spectra were obtained with either a JEOL DART-AccuTOF spectrometer or a Voyager
DE MALDI-TOF spectrometer, each with high resolution capabilities. Optical rotation
values were obtained using a Perkin–Elmer 241 polarimeter.
NMR spectra of the following compounds can be accessed online through our published
paper.111
3-O-(4-Methoxybenzyl)-1-O-((4-methoxyphenyl)diphenylmethyl)-sn-glycerol
(5.2.4). Enantiomerically pure alcohol 5.2.2 was purchased from Acros Organics,
converted to diol 5.2.3 using a literature procedure, and the product matched previous
characterizations.77,112 Diol 5.2.3 (0.080 g, 0.377 mmol) was then dissolved in dry
pyridine (5 mL), to which was added 4-methoxytrityl chloride (0.233 g, 0.754 mmol) and
4-dimethylaminopyridine (0.005 g, 0.038 mmol). The solution was stirred at rt for 24 h.
The reaction mixture was then quenched with methanol (0.5 mL), and the solvent was
removed under reduced pressure. The resulting residue was purified by column
chromatography with silica gel and a gradient solvent of 10–40% ethyl acetate/hexanes
to yield 5.2.4 as a white solid (0.171 g, 94%). []D296K 0.3 (c 3.0, CH3OH/CHCl3 (v/v
1:1)); 1H NMR (300 MHz, CDCl3):  7.41 (d, J=6.0 Hz, 4H), 7.16–7.30 (m, 10H), 6.83
(dd, 1J=12.0 Hz, 2J=9.0 Hz, 4H), 4.45 (s, 2H), 3.91–4.02 (m, 1H), 3.80 (s, 3H), 3.78 (s,
3H), 3.49–3.60 (AB of ABX, JAX=6 Hz, JAB=12 Hz, JBX=6 Hz, 2H), 3.15–3.24 (AB of
ABX, JAB=9 Hz, JAX=6 Hz, JBX=6 Hz, 2H), 2.40 (d, J=6.0 Hz, 1H);

13

C NMR (100.6 MHz,

CDCl3):  159.2, 158.5, 144.3, 135.4, 130.3, 130.0, 129.3, 128.3, 127.8, 126.9, 113.7,
113.1, 86.3, 72.9, 71.2, 69.9, 64.4, 55.2, 55.1; MALDI-HRMS [M+Na]+ calcd: 507.2142,
found: 507.2153.
2-O-(tert-Butyldiphenylsilyl)-3-O-(4-methoxybenzyl)-1-O-((4methoxyphenyl)diphenylmethyl)-sn-glycerol (5.2.5)
Alcohol 5.2.4 (0.866 g, 2.89 mmol), tert-butyldiphenylsilyl chloride (0.984 g, 3.58 mmol)
and imidazole (0.393 g, 3.58 mmol) were combined in dry pyridine (60 mL), and the
reaction was allowed to stir at rt for 24 h. The reaction mixture was then concentrated
and the resulting crude was purified by column chromatography with silica gel and a
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gradient solvent of 5–15% ethyl acetate/hexanes to yield crude 5.2.5 as a colorless oil.
Compound 5.2.5 was generally passed on to the next step without complete purification
due to difficulties in removing all byproducts. However, a sample of this compound was
isolated to homogeneity for the purpose of characterization. []D296K 0.85 (c 1.0,
CHCl3); 1H NMR (400 MHz, CDCl3):  7.64 (d, J=8 Hz, 2H), 7.59 (d, J=8 Hz, 2H), 7.18–
7.37 (m, 16H), 7.04 (d, J=8 Hz, 2H), 6.76 (dd, 1J=16 Hz, 2J=8 Hz, 4H), 4.21–4.29 (AB,
JAB=12 Hz, 2H), 3.96–4.05 (m, 1H), 3.78 (s, 3H), 3.76 (s, 3H), 3.41–3.58 (AB of ABX,
JAB=16 Hz, JAX=8 Hz, JBX=8 Hz, 2H), 3.13–3.22 (m, 2H), 1.02 (s, 9H);

13

C NMR

(100.6 MHz, CDCl3):  158.9, 158.3, 144.6, 135.9, 135.8, 133.9, 130.6, 130.4, 129.4,
129.0, 128.5, 127.6, 127.4, 126.6, 113.5, 112.9, 86.1, 72.6, 72.0, 71.5, 65.0, 55.2, 55.1,
30.9, 27.0, 19.3; MALDI-HRMS [M+Na]+ calcd: 745.3320, found: 745.3336.
2-O-(tert-Butyldiphenylsilyl)-3-O-(4-methoxybenzyl)-sn-glycerol (5.2.6)
Crude compound 5.2.5 from the previous procedure and camphorsulfonic acid (0.102 g,
0.44 mmol) were dissolved in 75 mL methanol/methylene chloride mixture (v/v 2:1), and
the solution was allowed to stir at rt for 3 h. The solvent was then removed under
reduced pressure, and the residue was purified by column chromatography with silica
gel and a gradient solvent of 5–35% ethyl acetate/hexanes to yield 5.2.6 as a colorless
oil (0.732 g, 87% from 5.2.4). []D296K +28.6 (c 1.50, CHCl3); 1H NMR (300 MHz, CDCl3):
 7.63–7.69 (m, 4H), 7.32–7.41 (m, 6H), 7.10 (d, J=9.0 Hz, 2H), 6.81 (d, J=9.0 Hz, 2H),
4.24–4.32 (AB, JAB=12 Hz, 2H), 3.88–3.96 (m, 1H), 3.78 (s, 3H), 3.61–3.65 (AB,
JAB=6 Hz, 2H), 3.38–3.53 (AB of ABX, JAB=9 Hz, JAX=6 Hz, JBX=6 Hz, 2H), 2.09 (t,
J=6.0 Hz, 1H), 1.06 (s, 9H); 13C NMR (100.6 MHz, CDCl3):  159.1, 135.8, 133.4, 130.0,
129.9, 129.8, 129.2, 127.7, 127.6, 113.7, 72.9, 71.9, 71.3, 64.8, 55.2, 27.0, 19.3;
MALDI-HRMS [M+Na]+ calcd: 473.2119, found: 473.2093.
2-Cyanoethyl bis-(3-O-(4-methoxybenzyl)-2-O-(tert-butyldiphenylsilyl)-sn-glycer-1yl) phosphate (5.2.7)
Alcohol 5.2.6 (1.19 g, 2.53 mmol) and bis-N,N-diisopropylamino cyanoethyl phosphine
(0.381 g, 1.27 mmol) were stirred in 10 mL dry methylene chloride. 1H-tetrazole (5.6 mL
of a 0.45 M solution in acetontrile, 2.52 mmol) was added and the solution was allowed
to stir at rt for 48 h. To the stirred reaction mixture, tert-butylhydroperoxide (0.50 mL,
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5.06 mmol) was added. After 1 h, the reaction was quenched by adding 50 mL of
saturated sodium thiosulfate aqueous solution. Next, the resulting solution was
extracted with methylene chloride (280 mL), and the organic layers were combined
and dried with magnesium sulfate. The solvent was then removed under reduced
pressure, and the resulting residue was purified by column chromatography with silica
gel and a gradient solvent of 20–60% ethyl acetate/hexanes to yield 5.2.7 as a colorless
oil (1.09 g, 84%). []D296K +12.2 (c 7.25, CHCl3); 1H NMR (300 MHz, CDCl3):  7.65 (d,
J=9.0 Hz, 8H), 7.30–7.43 (m, 12H), 7.09 (d, J=6.0 Hz, 4H), 6.81 (d, J=6.0 Hz, 4H),
4.22–4.29 (m, 4H), 3.88–4.06 (m, 8H), 3.78 (s, 6H), 3.34–3.44 (m, 4H), 2.43 (t,
J=6.0 Hz, 2H), 1.05 (s, 18H);

13

C NMR (100.6 MHz, CDCl3):  159.2, 136.0, 133.7,

133.3, 130.0, 129.3, 127.8 127.7, 113.8, 73.0, 71.0, 70.9, 70.3, 70.0, 69.0, 68.9, 61.6,
60.5, 55.4, 27.0, 19.4, 14.3;

31

P NMR:  0.534; MALDI-HRMS [M+Na]+ calcd:

1308.4168, found: 1308.4135.
2-Cyanoethyl bis-(2-O-(tert-butyldiphenylsilyl)-sn-glycer-1-yl) phosphate (5.2.8).
Phosphotriester 5.2.7 (1.09 g, 1.07 mmol) was dissolved in methylene chloride (20 mL)
and water (1 mL), and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 1.21 g,
5.35 mmol) was added. The reaction was then allowed to stir at rt for 12 h. Next, 60 mL
of 10% sodium bicarbonate solution was added, which was extracted with methylene
chloride (280 mL). The organic layers were then combined, concentrated, and the
residue was purified by column chromatography with silica gel and a gradient solvent of
5–20% acetone/methylene chloride to give 5.2.8 as a colorless oil (0.762 g, 92%).
[]D296K 12.6 (c 13.4, CHCl3); 1H NMR (300 MHz, CDCl3):  7.63–7.68 (m, 8H), 7.32–
7.48 (m, 12H), 3.95–4.15 (m, 6H), 3.85 (t, J=6.0 Hz, 2H), 3.48–3.58 (m, 4H), 2.57 (t,
J=6.0 Hz, 2H), 2.49 (br s, 1H), 1.06 (s, 18H);

13

C NMR (100.6 MHz, CDCl3):  135.9,

135.8, 133.2, 130.2, 128.1, 128.0, 116.4, 71.9, 71.8, 67.6, 67.5, 62.5, 62.0, 27.1, 19.4;
31

P NMR:  0.378; MALDI-HRMS [M+Na]+ calcd: 798.3018, found: 798.2960.

General procedure for the synthesis of compounds of type 5.2.9
Fatty acid (4 equiv for normal fatty acid; 2.5 equiv for deuterated fatty acid) was
dissolved in methylene chloride. N,N-Dicyclohexylcarbodiimide (4 equiv for normal fatty
acid or 3 equiv for deuterated fatty acid) and 4-dimethylaminopyridine (4 equiv for
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normal fatty acid or 3 equiv for deuterated fatty acid) were added to the solution. The
reaction mixture was allowed to stir for 10 min, followed by the addition of
phosphotriester 5.2.8. The solution was then allowed to stir for 12 h at rt, at which point
the precipitate that formed was filtered off and the solvent was removed under reduced
pressure. The residue was purified by column chromatography with silica gel and a
gradient solvent of 30–40% ethyl acetate/hexanes to yield 5.2.9a–h.
2-Cyanoethyl bis-(2-O-(tert-butyldiphenylsilyl)-3-stearyl-sn-glycer-1-yl) phosphate
(5.2.9a)
Phosphotriester 5.2.8 (0.114 g, 0.147 mmol) and stearic acid (0.167 g, 0.588 mmol)
yielded 5.2.9a as a colorless oil (0.171 g, 89%). []D296K +1.66 (c 9.4, CHCl3); 1H NMR
(300 MHz, CDCl3):  7.60–7.70 (m, 8H), 7.34–7.47 (m, 12H), 3.87–4.12 (m, 12H), 2.51
(t, J=6.0 Hz, 2H), 2.07–2.18 (m, 4H), 1.46–1.55 (m, 4H), 1.25 (s, 56H), 1.05 (s, 18H),
0.88 (t, J=6.0 Hz, 6H);

13

C NMR (100.6 MHz, CDCl3):  173.1, 135.6, 135.5, 132.9,

132.7, 129.8, 129.7, 127.6, 127.5, 115.8, 69.5, 67.9, 64.2, 61.5, 29.5, 29.1, 29.0, 26.6,
24.6, 22.5, 19.2, 19.1, 13.9;

31

P NMR:  0.759; MALDI-HRMS [M+Na]+ calcd:

1330.8237, found: 1330.8277.
2-Cyanoethyl

bis-(2-O-(tert-butyldiphenylsilyl)-3-stearyl-D35-sn-glycer-1-yl)

phosphate (5.2.9b). Phosphotriester 5.2.8 (0.200 g, 0.258 mmol) and deuterated
stearic acid D35 (0.212 g, 0.663 mmol) yielded 5.2.9b as a colorless oil (0.280 g, 71%).
[]D296K +1.44 (c 1.9, CHCl3); 1H NMR (300 MHz, CDCl3):  7.66 (t, J=6.0 Hz, 8H), 7.34–
7.47 (m, 12H), 3.88–4.14 (m, 12H), 2.51 (t, J=6.0 Hz, 2H), 1.05 (s, 18H);

13

C NMR

(100.6 MHz, CDCl3):  173.4, 135.8, 135.7, 133.1, 132.9, 130.0, 129.9, 127.8, 127.7,
116.0, 69.8, 69.7, 68.1, 68.0, 64.3, 61.7, 28.6, 28.4, 28.2, 28.0, 27.8, 26.8, 19.4, 19.3;
31

P NMR:  0.752; MALDI-HRMS [M+Na]+ calcd: 1401.2636, found: 1401.2641.

2-Cyanoethyl
phosphate (5.2.9c).

bis-(2-O-(tert-butyldiphenylsilyl)-3-palmitoyl-sn-glycer-1-yl)
Phosphotriester 5.2.8 (0.200 g, 0.258 mmol) and palmitic acid

(0.265 g, 1.03 mmol) yielded 5.2.9c as a colorless oil (0.266 g, 82%). []D296K +0.14 (c
13.3, CHCl3); 1H NMR (300 MHz, CDCl3):  7.67 (t, J=6.0 Hz, 8H), 7.34–7.48 (m, 12H),
3.82–4.14 (m, 12H), 2.51 (t, J=6.0 Hz, 2H), 2.06–2.19 (m, 4H), 1.46–1.57 (m, 4H), 1.26
(s, 48H), 1.05 (s, 18H), 0.88 (t, J=6.0 Hz, 6H);
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13

C NMR (100.6 MHz, CDCl3):  173.8,

136.3, 136.2, 133.6, 133.5, 133.4, 130.5, 130.4, 128.3, 128.2, 116.6, 70.3, 70.1, 68.6,
68.5, 64.9, 64.8, 62.2, 30.2, 30.0, 29.9, 29.8, 29.6, 27.3, 25.3, 23.2, 19.8, 14.6;

31

P

NMR:  0.752; MALDI-HRMS [M+Na]+ calcd: 1274.7611, found: 1274.7509.
2-Cyanoethyl

bis-(2-O-(tert-butyldiphenylsilyl)-3-palmitoyl-D31-sn-glycer-1-yl)

phosphate (5.2.9d).

Phosphotriester 5.2.8 (0.125 g, 0.161 mmol) and deuterated

paltimic acid D31 (0.116 g, 0.403 mmol) yielded 5.2.9d as a colorless oil (0.180 g,
85%). []D296K +1.56 (c 6.2, CHCl3); 1H NMR (300 MHz, CDCl3):  7.66 (t, J=6.0 Hz, 8H),
7.34–7.45 (m, 12H), 3.87–4.15 (m, 12H), 2.51 (t, J=6.0 Hz, 2H), 1.05 (s, 18H); 13C NMR
(100.6 MHz, CDCl3):  173.6, 136.1, 136.0, 133.3, 133.2, 133.1, 130.2, 128.0, 116.3,
70.0, 69.9, 68.3, 64.6, 64.5, 62.0, 61.9, 28.6, 28.5, 28.4, 28.3, 27.0, 19.7, 19.6, 19.5; 31P
NMR:  0.752; MALDI-HRMS [M+Na]+ calcd: 1337.1168, found: 1337.1210.
4.7.5.

2-Cyanoethyl

phosphate (5.2.9e).

bis-(2-O-(tert-butyldiphenylsilyl)-3-myristoyl-sn-glycer-1-yl)
Phosphotriester 5.2.8 (0.128 g, 0.165 mmol) and myristic acid

(0.151 g, 0.660 mmol) yielded 5.2.9e as a colorless oil (0.177 g, 90%). []D296K +1.64 (c
2.1, CHCl3); 1H NMR (300 MHz, CDCl3):  7.66 (t, J=6.0 Hz, 8H), 7.33–7.47 (m, 12H),
3.89–4.16 (m, 12H), 2.52 (t, J=6.0 Hz, 2H), 2.12–2.16 (m, 4H), 1.50–1.54 (m, 4H), 1.26
(s, 40H), 1.05 (s, 18H), 0.88 (t, J=6.0 Hz, 6H);

13

C NMR (100.6 MHz, CDCl3):  173.3,

135.8, 135.7, 132.9, 130.0, 129.9, 127.8, 127.7, 116.1, 69.8, 69.6, 68.1, 68.0, 64.4,
64.3, 61.7, 33.9, 31.9, 29.1, 26.8, 24.8, 22.7, 19.3, 14.1;

31

P NMR:  0.752; MALDI-

HRMS [M+Na]+ calcd: 1218.6985, found: 1218.6965.
4.7.6. 2-Cyanoethyl bis-(2-O-(tert-butyldiphenylsilyl)-3-myristoyl-D27-sn-glycer-1yl) phosphate (5.2.9f). Phosphotriester 5.2.8 (0.120 g, 0.155 mmol) and deuterated
myristic acid D27 (0.099 g, 0.387 mmol) yielded 5.2.9f as a colorless oil (0.164 g, 85%).
[]D296K +1.46 (c 1.6, CHCl3); 1H NMR (300 MHz, CDCl3):  7.66 (t, J=6.0 Hz, 8H), 7.33–
7.47 (m, 12H), 3.86–4.15 (m, 12H), 2.51 (t, J=6.0 Hz, 2H), 1.06 (s, 18H);

13

C NMR

(100.6 MHz, CDCl3):  173.6, 136.1, 136.0, 133.3, 133.2, 133.1, 130.3, 130.2, 128.0,
116.3, 70.0, 69.9, 68.3, 64.5, 62.0, 34.2, 28.3, 25.2, 19.7, 19.6, 19.5;

31

P NMR: 

0.759; MALDI-HRMS [M+Na]+ calcd: 1273.0084, found: 1,273.0082.
2-Cyanoethyl bis-(2-O-(tert-butyldiphenylsilyl)-3-lauroyl-sn-glycer-1-yl) phosphate
(5.2.9g). Phosphotriester 5.2.8 (0.122 g, 0.157 mmol) and lauric acid (0.126 g,
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0.629 mmol) yielded 5.2.9g as a colorless oil (0.158 g, 88%). []D296K +1.86 (c 5.3,
CHCl3); 1H NMR (300 MHz, CDCl3):  7.66 (t, J=6.0 Hz, 8H), 7.32–7.44 (m, 12H), 3.87–
4.16 (m, 12H), 2.51 (t, J=6.0 Hz, 2H), 2.06–2.18 (m, 4H), 1.50–1.54 (m, 4H), 1.26 (s,
32H), 1.05 (s, 18H), 0.88 (t, J=6.0 Hz, 6H);

13

C NMR (100.6 MHz, CDCl3):  173.6,

136.1, 136.0, 133.3, 133.1, 130.3, 130.2, 128.0, 116.3, 70.0, 69.9, 68.3, 64.6, 62.0,
31

61.9, 29.9, 29.7, 29.6, 29.5, 29.4, 27.0, 25.0, 22.9, 19.5, 14.4;

P NMR:  0.759;

+

MALDI-HRMS [M+Na] calcd: 1162.6359, found: 1162.6335.
2-Cyanoethyl

bis-(2-O-(tert-butyldiphenylsilyl)-3-lauroyl-D23-sn-glycer-1-yl)

phosphate (5.2.9h). Phosphotriester 5.2.8 (0.122 g, 0.157 mmol) and deuterated lauric
acid D23 (0.088 g, 0.393 mmol) yielded 5.2.9h as a colorless oil (0.172 g, 92%). []D296K
+1.60(c 1.9, CHCl3); 1H NMR (300 MHz, CDCl3):  7.66 (t, J=6.0 Hz, 8H), 7.33–7.46 (m,
12H), 3.86–4.18 (m, 12H), 2.51 (t, J=6.0 Hz, 2H), 1.05 (s, 18H);

13

C NMR (100.6 MHz,

CDCl3):  173.6, 136.1, 136.0, 133.1, 130.2, 128.0, 116.3, 70.0, 69.9, 68.3, 64.5, 62.0,
61.9, 34.2, 28.5, 28.3, 28.0, 27.0, 19.7, 19.6, 19.5;

31

P NMR:  0.759; MALDI-HRMS

[M+Na]+ calcd: 1208.9000, found: 1208.9042.
General procedure for the synthesis of compound 5.2.10
Phosphotriester 5.2.9 (1 equiv) and tetrabutylammonium fluoride trihydrate (TBAF, 15–
20 equiv) were dissolved in 5 mL of THF, and the reaction was allowed to stir at rt
overnight. The solvent was then removed under reduced pressure, and the resulting
residue was dissolved in 100 mL of methanol/chloroform mixture (v/v 1:4), and
extracted with 40 mL of 8 mM aqueous ammonium acetate solution. Next, the organic
layer was concentrated, and the resulting residue was purified by column
chromatography

with

20 g

silica

gel

and

a

gradient

solvent

of

5–16%

methanol/methylene chloride to yield a yellowish solid as the crude product. The crude
product was then washed with water and then methanol to provide a white solid, which
was dissolved in methanol/chloroform mixture (v/v 1:4) and filtered. The filtrate was then
concentrated under reduced pressure to yield 9 as a white powder.
Bis-(3-stearyl-sn-glycer-1-yl) phosphate ammonium salt (5.2.10a). Phosphotriester
5.2.9a (0.094 g, 0.0719 mmol) was treated with tetrabutylammonium fluoride trihydrate
(0.340 g, 1.08 mmol) in 5 mL THF and yielded 5.2.10a as a white powder (0.046 g,
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80%). []D296K +0.33 (c 1.2, MeOH/CHCl3); 1H NMR (300 MHz, CD3OD/CDCl3):  3.75–
4.35 (m, 10H), 2.30–2.40 (m, 4H), 1.58–1.66 (m, 4H), 1.27 (s, 56H), 0.83–0.92 (m, 6H);
13

C NMR (100.6 MHz, CD3OD/CDCl3):  174.1, 68.4, 66.6, 64.7, 33.8, 31.7, 29.5, 29.4,

29.3, 29.1, 29.0, 24.6, 22.4, 13.7;

31

P NMR:  2.483; MALDI-HRMS [C42H83O10P+Na]+

calcd: 801.5616, found: 801.5597.
Bis-(3-stearyl-D35-sn-glycer-1-yl)

phosphate

ammonium

salt

(5.2.10b).

Phosphotriester 5.2.9b (0.062 g, 0.0450 mmol) was treated with tetrabutylammonium
fluoride trihydrate (0.213 g, 0.675 mmol) in 5 mL THF and yielded 5.2.10b as a white
powder (0.034 g, 87%). []D296K +2.03 (c 3.2, MeOH/CHCl3); 1H NMR (300 MHz,
CD3OD/CDCl3):  3.78–4.28 (m, 10H), 1.27 (s, 7H), 0.83–0.92 (m, 2H);

31

P NMR: 

2.813; MALDI-HRMS [C42H12D70O10PNa+Na]+ calcd: 893.9848, found: 893.9797.
Bis-(3-palmitoyl-sn-glycer-1-yl)

phosphate

ammonium

salt

(5.2.10c).

Phosphotriester 5.2.9c (0.266 g, 0.213 mmol) was treated with tetrabutylammonium
fluoride trihydrate (1.00 g, 3.19 mmol) in 5 mL THF and yielded phosphate 5.2.10c as a
white powder (0.143 g, 91%). []D296K +0.36 (c 1.4, MeOH/CHCl3); 1H NMR (300 MHz,
CD3OD/CDCl3):  3.70–4.30 (m, 10H), 2.28–2.42 (m, 4H), 1.55–1.68 (m, 4H), 1.27 (s,
48H), 0.80–0.95 (m, 6H);

13

C NMR (100.6 MHz, CD3OD/CDCl3):  174.0, 66.5, 66.4,

64.7, 33.7, 31.7, 29.5, 29.3, 29.1, 29.0, 28.7, 24.6, 22.4, 13.6;

31

P NMR:  2.806;

MALDI-HRMS [C38H75O10P+Na]+ calcd: 745.4990, found: 745.4944.
Bis-(3-palmitoyl-D31-sn-glycer-1-yl) phosphate ammonium salt (5.2.10d)
Phosphotriester 5.2.9d (0.180 g, 0.137 mmol) was treated with tetrabutylammonium
fluoride trihydrate (0.648 g, 2.05 mmol) in 5 mL THF and yielded phosphate 5.2.10d as
a white powder (0.051 g, 46%). []D296K +0.27 (c 4.1, MeOH/CHCl3); 1H NMR (300 MHz,
CD3OD/CDCl3):  3.85–4.28 (m, 10H), 1.18–1.35 (m, 2H);

31

P NMR:  2.483; MALDI-

HRMS [C38H12D62O10PNa+Na]+ calcd: 829.8367, found: 829.8643.
Bis-(3-myristoyl-sn-glycer-1-yl)

phosphate

ammonium

salt

(5.2.10e).

Phosphotriester 5.2.9e (0.177 g, 0.148 mmol) was treated with tetrabutylammonium
fluoride trihydrate (0.700 g, 2.22 mmol) in 5 mL THF and yielded phosphate 5.2.10e as
a white powder (0.046 g, 45%). []D296K +0.96 (c 1.2, MeOH/CHCl3); 1H NMR (300 MHz,
CD3OD/CDCl3):  3.85–4.18 (m, 10H), 2.36 (t, J=9.0 Hz, 4H), 1.55–1.70 (m, 4H),
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1.27(s, 40H), 0.89 (t, J=6.0 Hz, 6H);

13

C NMR (100.6 MHz, CD3OD/CDCl3):  174.4,

68.7, 66.7, 65.0, 34.1, 32.0, 29.6, 29.3, 24.9, 22.7, 14.0;

31

P NMR:  1.804; MALDI-

HRMS [C34H67O10P+Na]+ calcd: 689.4370, found: 689.4360.
Bis-(3-myristoyl-D27-sn-glycer-1-yl)

phosphate

ammonium

salt

(5.2.10f).

Phosphotriester 5.2.9f (0.265 g, 0.212 mmol) was treated with tetrabutylammonium
fluoride trihydrate (0.969 g, 3.07 mmol) in 5 mL THF and yielded phosphate 5.2.10f as a
white powder (0.030 g, 19%). []D296K +0.31 (c 2.3, MeOH/CHCl3); 1H NMR (300 MHz,
CD3OD/CDCl3):  3.85–4.25 (m, 10H), 1.20–1.36 (m, 5H);

31

P NMR:  1.931; MALDI-

HRMS [C34H12D54O10PNa+Na]+ calcd: 765.7282, found: 765.7543.
Bis-(3-lauroyl-sn-glycer-1-yl) phosphate ammonium salt (5.2.10g). Phosphotriester
5.2.9g (0.158 g, 0.139 mmol) was treated with tetrabutylammonium fluoride trihydrate
(0.875 g, 2.77 mmol) in 5 mL THF and yielded phosphate 5.2.10g as a white powder
(0.039 g,

45%).

[]D296K

+0.23

(c

2.0,

MeOH/CHCl3);

1

H

NMR

(300 MHz,

CD3OD/CDCl3):  3.82–4.25 (m, 10H), 2.36 (t, J=9.0 Hz, 4H), 1.55–1.70 (m, 4H), 1.28
(s, 32H), 0.89(t, J=6.0 Hz, 6H);

13

C NMR (100.6 MHz, CD3OD/CDCl3):  173.9, 68.2,

66.2, 64.6, 33.6, 31.5, 29.1, 28.8, 24.4, 22.2, 13.3;

31

P NMR:  2.413; MALDI-HRMS

[C30H58O10PNa+Na]+ calcd: 655.3558, found: 655.3541.
Bis-(3-lauroyl-D23-sn-glycer-1-yl)

phosphate

ammonium

salt

(5.2.10h).

Phosphotriester 5.2.9h (0.260 g, 0.219 mmol) was treated with tetrabutylammonium
fluoride trihydrate (1.38 g, 4.38 mmol) in 5 mL THF and yielded phosphate 5.2.10d as a
white powder (0.029 g, 20%). []D296K +0.60 (c 2.0, MeOH/CHCl3); 1H NMR (300 MHz,
CD3OD/CDCl3):  3.85–4.25 (m, 10H), 1.20–1.38 (m, 15H);

31

P NMR:  2.490; MALDI-

HRMS [C30H12D46O10PNa+Na]+ calcd: 701.6450, found: 701.6435.
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6. CHAPTER 6. Synthesis of lysophosphatidylcholine (LPC) to
facilitate the research in the role of lysophospholipase A-I in
lysophosphatidic acid (LPA) production.
1. Introduction
Lysophosphatidic acid (LPA) is an important lipid that is involved in many biological
processes, such as cell proliferation and survival, cell migration and invasion, tumor
progression, wound healing and many others.16,17 However, the biosynthetic pathway(s)
to produce LPA in biological fluids has not yet been fully understood. In other to
investigate this issue, our collaborators Ms. Alyssa Bolen and Dr. Gabor Tigyi purified a
phospholipase A1 (PLA1) from thrombin-activated human platelets. This PLA1 was
indentified by proteomic studies as acyl-protein thioesterase 1, a novel PLA1. It was
observed that the addition of this enzyme greatly increased the production of sn-2esterified polyunsaturated lysophosphatidylcholines (LPCs) and the corresponding
LPAs in blood. Since LPCs are precursors of LPAs in biosynthetic pathways and the
conversion of LPCs into LPAs rely on lysophospholipase D or autotaxin (ATX), they
extended the investigation to study ATX’s regioisomeric preference on LPC (sn-1 LPC
v.s. sn-2 LPC, see figure 6.1). In order to do so, 2-oleyl-sn-glycero-3-phosphocholine
was needed to be synthesized with ether linkage to prevent acyl chain migration. We
set out to synthesize this molecule to support their research work.
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Figure 6.1 Lysophosphatidylcholine (LPC)

Scheme 6.1 Synthesis of sn-2 lysophosphatidylcholine
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2. Results and Discussion
The synthetic route to 2-Oleoyl-sn-glycero-3-phosphocholine is shown in scheme
6.1. The synthesis began with 3-O-(4-Methoxybenzyl)-sn-glycerol 5.2.3, which contains
a built-in stereo center needed for the targeted compound, 2-Oleoyl-sn-glycero-3phosphocholine 6.1.1. The selective primary alcohol protection of compound 5.2.3 with
tert-butyldiphenyl chlorosilane was followed by etherization of the secondary alcohol
with oleyl triflate to afford 6.1.3. The PMB deprotection of 6.1.3 led to compound 6.1.4.
The one-pot phosphorylation of 6.1.4 afforded 6.1.5. Compound 6.1.5 was surprisingly
found with ethyl cyano protecting group removed from the phosphodiester. Followed up
by mass spectrometry, this was found to happen during the purification process. The
removal of the silyl protecting group of 6.1.5 by TBAF yielded the targeted product 6.1.1.
It is worthy to mention that a similar but different scheme was performed with the silyl
group deprotected first and PMB deprotection as the final step. This has led to the
extreme difficulty of final purification. The slightly revised synthetic scheme has given
pure product with very easy purification steps as mentioned above. The racemic
compound 6.1.1 has also been previously synthesized in a different way.113,114
Using this synthetic sn-2 LPC, it was found that ATX preferred the sn-1 over the
sn-2 regioisomer of LPC. Therefore, a LPA production pathway in blood is proposed as
follows: 1) activated platelets release PLA1; 2) PLA1 produces sn-2 LPCs; 3) these
newly produced sn-2 LPCs undergo acyl migration to yield sn-1 LPCs, which are the
preferred substrates of ATX. 4) ATX cleaves the sn-1 LPCs to generate sn-1 LPA
species.
General experimental.
Generally, reagents were purchased from Acros, Aldrich or AK Scientific, Inc., Alfa
Aesar and used as received. Dry solvents were obtained from a Pure Solv solvent
delivery system purchased from Innovative Technology, Inc. Column chromatography
was performed using 230–400 mesh silica gel purchased from Sorbent Technologies.
NMR spectra were obtained using a Varian Mercury 300 spectrometer. Mass spectra
were obtained with a Voyager DE MALDI-TOF spectrometer. Optical rotation values
were obtained using a Perkin–Elmer 241 polarimeter.
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3-O-(4-Methoxybenzyl)-1-O-(tert-Butyldiphenylsilyl)-sn-glycerol (6.1.2). Diol 5.2.3
was prepared from S-glycerol acetonide (purchased from AK Scientific, Inc.) according
to a known procedure,77 same compound has also been prepared by our group.111 Diol
5.2.3 (0.430 g, 2.026 mmol) was stirred in dry DMF (20 mL). To this solution, tertbutyldiphenyl chlorosilane (0.525 mL, 2.026 mmol) was added, followed by imidazole
(0.359 g, 5.270 mmol). The reaction mixture was stirred at room temperature overnight.
The solvent was then concentrated at a reduced pressure. The resulting residue was
dissolved in CHCl3 (100 mL) and extracted by H2O (50 mL x 2). The organic layer was
collected, dried by magnesium sulfate and condensed to yield the crude product, which
was then purified by column chromatography with silica gel and a gradient solvent of
15–35% ethyl acetate/hexanes to yield 4 as a colorless oil (0.73 g, 80%). The product
matched previous characterizations.111
1

H NMR (300 MHz, CDCl3):  7.62–7.65 (m, 4H), 7.34–7.42 (m, 6H), 7.20-7,25 (m, 2H),

6.84-6.87 (m, 2H), 4.45 (s, 2H), 3.88–3.92 (m, 1H), 3.79 (s, 3H), 3.69–3.71 (m, 2H),
3.50-3.54 (m, 2H), 2.47 (d, J=6.0 Hz, 1H), 1.06 (s, 9H); MALDI-HRMS [M+Na]+ calcd:
473.2119, found: 473.2093.
1-O-(tert-Butyldiphenylsilyl)-2-oleyl-3-O-(4-Methoxybenzyl)-sn-glycerol

(6.1.3).

Compound 6.1.2 (0.660 g, 1.465 mmol) was combined with oleyl triflate (2.900 g, 7.240
mmol) (prepared from a known precedureand proton sponge (1.10 g, 5.15 mmol) in dry
dichloromethane (40 mL). The solution was heated to reflux and stirred overnight. The
solvent was then removed under reduced pressure to yield the crude product 6.1.3,
which was purified by column chromatography with silica gel and a gradient solvent of
5–10% acetone/hexanes to yield 6.1.3 as a yellowish oil (0.714 g, 71%).
1

H NMR (300 MHz, CDCl3):  7.66–7.75 (m, 4H), 7.32–7.40 (m, 6H), 7.22-7.30 (m, 2H),

6.83-6.91 (m, 2H), 5.35-5.41 (m, 2H), 4.47-4.52 (m, 2H), 3.73-3.80 (m, 3H), 3.38 -3.70
(m, 7H), 2.04 (m, 4H), 1.58 (m, 2H), 1.33 (m, 24H), 1.03-1.06 (m, 9H), 0.90-0.94 (m,
3H);

13

C NMR (100.6 MHz, CDCl3):  159.14, 135.99, 135.64, 133.57, 129.90, 129.48,

129.21, 129.13, 127.66, 127.43, 113.69, 113.59, 79.48, 73.02, 71.38, 69.71, 63.50,
55.16, 32.70, 31.99, 30.18, 29.78, 29.72, 29.58, 29.33, 26.20, 22.76, 19.25, 14.21;
MALDI-HRMS [M+Na]+ calcd: 700.4881, found: 700.4892.
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1-O-(tert-Butyldiphenylsilyl)-2-oleoyl-sn-glycero-3-phosphocholine

(6.1.5).

Compound 6.1.3 (0.325 g, 0.463 mmol) was combined with 2,3-dichloro-5,6dicyanobenzoquinone (0.315 g, 1.389 mmol) in dichloromethane (10 mL) and H2O (1
mL). The reaction mixture was stirred at room temperature. After 10 hours, saturated
sodium bicarbonate (100 mL) was added to quench the solution, which was then
extracted twice by chloroform (100 mL x 2).

The organic layers were dried by

magnesium sulfate and condensed to yield the crude product 6.1.4, which was carried
on to the next step without further purification. Crude compound 6.1.4 was combined
with bis-N,N-diisopropylamino cyanoethyl phosphine (0.205 g, 0.606 mmol), 1Htetrazole (0.740 mL of a 0.45 M solution in acetontrile, 0.333 mmol) in dichloromethane
(10 mL) and the solution was allowed to stir at room teperature for 1 h. To this stirred
solution, choline tosylate (0.334 g, 1.212 mmol) 1H-tetrazole (2.690 mL of a 0.45 M
solution in acetontrile, 1.212 mmol) were added and the solution was allowed to stir at
room temprerature for another 12 h. To this solution, tert-butylhydroperoxide (0.470 mL,
4.848 mmol) was added. After 1 h, the reaction was quenched by adding 50 mL of
saturated sodium thiosulfate aqueous solution. Next, the resulting solution was
extracted with methanol/methylene chloride (v/v 1:4, 80 mL2), and the organic layers
were combined and dried with magnesium sulfate. The solvent was then removed under
reduced pressure, and the resulting residue was purified by column chromatography
with silica gel and a gradient solvent of 5–30% methanol/dichloromethane to yield 6.1.5
as a colorless oil (0.060 g, 17 % yield over 2 steps).
1

H NMR (300 MHz, CDCl3):  7.65–7.69 (m, 4H), 7.26–7.38 (m, 6H), 5.32-5.35 (m, 2H),

4.14-4.18 (m, 2H), 3.89-3.91 (m, 2H), 3.49-3.74 (m, 2H), 3.28-3.30 (m, 2H), 3.22 (s, 9H),
1.99-2.01 (m, 4H), 1.47-1.49 (m, 2H), 1.19-1.23 (m, 24H), 1.02 (s, 9H), 0.86 (t, J=6.0 Hz,
3H); 31P NMR:  0.59; MALDI-HRMS [M+Na]+ calcd: 746.4939, found: 746.4946.
2-Oleoyl-sn-glycero-3-phosphocholine (6.1.1). Compound 6.1.5 (0.060 g, 0.080
mmol) and tetrabutylammonium fluoride trihydrate (TBAF, 0.126 g, 0.40 mmol) were
dissolved in THF (10 mL), and the reaction was allowed to stir at rt overnight. The
solvent was then removed under reduced pressure, and the resulting residue was
purified by column chromatography with 3 g of silica gel and a gradient solvent of 10–
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50% methanol/chloroform to yield 6.1.1, but mixed with TBAF. The crude product 6.1.1
was then stirred with sodium form in H2O for 3 h. The solution was directly loaded onto
a C18 reverse phase column. The column was eluted with H2O-methanol and the pure
product 6.1.1 came out with 80% methanol/H2O. The fractions with 6.1.1 were collected
and condensed to yield a off-white paste compound 6.1.1 (0.025 g, 62 %). The product
matched previous characterizations.113,114
1

H NMR (300 MHz, CD3OD/CDCl3, v/v 1:2):  5.33-5.36 (m, 2H), 4.4-4.28 (m, 2H), 3.96

(m, t, J=6.0 Hz, 2H), 3.49-3.74 (m, 5H), 3.34-3.36 (m, 2H), 3.21 (s, 9H), 1.99-2.04 (m,
4H), 1.52-1.59 (m, 2H), 1.25-1.32 (m, 24H), 0.86 (t, J=6.0 Hz, 3H);
MALDI-HRMS [M+Na]+ calcd: 508.3762, found: 508.3768.
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31

P NMR:  4.01;

7. Chapter 7. Miscellaneous synthetic probes and compounds

1. Synthesis of rhodamine 6G and rhodamine B.
For a collaborative research project with Dr. Jon Camden, we synthesized
rhodamine 6G and deuterated rhodamine 6G for single molecular imaging in SERS.
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Scheme 7.1 Synthesis of various rhodamines.

A combination of two reported procedures was adopted to synthesize the rhodamine
compounds.115,116
General procedure to synthesize rhodamine 7.1.1a-b. o-Ethylamino-p-cresol and
phthalic anhydride (for 7.1.1a) or phthalic anhydride (D4) (for 7.1.1b) were combined in
16 mL 1,2-dichlorobenzene. The reaction was refluxed at 180 C with Dean-Stark
apparatus overnight. The reaction was then cooled to room temperature and diethyl
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sulfate and sodium hydroxide was added. The reaction mixture was stirred at 100-110 C
overnight. The solvent was then removed under reduced pressure. The crude was
purified by column chromatography with a gradient solvent system of 6-10%
methanol/dichloromethane with 1% triethylamine. The collected product was then dried
and was re-dissolved in 5 mL ethanol. 10 mL of 14% potassium bromide was added
and the solution was stirred at room temperature overnight. Ethanol was then removed
and the rhodamine bromide salt was filtered to yield rhodamine 7.1.1a-b.
Rhodamine 6G (7.1.1a). o-Ethylamino-p-cresol (410 mg, 2.712 mmol) and phthalic
anhydride (200 mg, 1.350 mmol), diethyl sulfate (0.256 mL, 1.04 mmol) and sodium
hydroxide (36 mg, 0.67 mmol) was used. 5 mL Ethanol and 10 mL of 14% potassium
bromide used to precipitate the rhodamine bromide salt as greenish needles 7.1.1a (70
mg).
1

H NMR (300 MHz, CDCl3)  8.31 (d, J = 9 Hz, 1H), 7.837.74 (m, 2H), 7.34-7.27 (m,

1H), 6.73 (s, 2H), 6.65 (s, 2H), 4.03 (q, J = 6 Hz, 2H), 3.64-3.55 (m, 4H), 2.31 (s, 6H),
1.40 (t, J = 9 Hz, 6H), 0.99 (t, J = 6 Hz, 3H). MALDI-HRMS [M + H]+ calcd for 423.2329;
found, 423.2320.
Rhodamine 6G (D4) (7.1.1b). o-Ethylamino-p-cresol (205 mg, 1.356 mmol) and
phthalic anhydride (103 mg, 0.678 mmol), diethyl sulfate (0.1 mL, 0.702 mmol) and
sodium hydroxide (18 mg, 0.450 mmol) was used. 5 mL Ethanol and 10 mL of 14%
potassium bromide used to precipitate the rhodamine bromide salt as greenish needles
7.1.1a (40.5 mg).
1

H NMR (300 MHz, CDCl3)  7.12 (t, J = 6 Hz, 2H), 6.73 (s, 2H), 6.65 (s, 2H), 4.04 (q, J

= 6 Hz, 2H), 3.62-3.53 (m, 4H), 2.30 (s, 6H), 1.41 (t, J = 9 Hz, 6H), 1.01 (t, J = 6 Hz,
3H).
Rhodamine B (7.1.2). 3-Dimethylaminophenol (286 mg, 2.08 mmol) and 1,2,4benzene-tricarboxylic anhydride (200 mg, 1.04 mmol) were combined in 16 mL 1,2dichlorobenzene. The reaction was refluxed at 180 C with Dean-Stark apparatus
overnight. The reaction was then cooled to room temperature and the precipitate was
filtered off. The solvent was then removed under reduced pressure. The crude was
purified by column chromatography with a gradient solvent system of 10-25%
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methanol/dichloromethane to yield rhodamine B 6.6.2. The product was further purified
on a C18 reverse-phase column (2 g) The collected product was then dried and was redissolved in 5 mL ethanol. 10 mL of 14% potassium bromide was added and the
solution was stirred at room temperature overnight. Ethanol was then removed and the
rhodamine bromide salt was filtered to yield rhodamine 7.1.1a-b.
1

H NMR (300 MHz, D2O)  8.00-7.97 (m, 2H), 7.75-7.73 (m, 2H), 7.09-7.02 (m, 2H),

6.69-6.67 (m, 1H), 2.96 (s, 12H). MALDI-HRMS [M + H]+ calcd for 431.1601; found,
431.1726.
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2. Synthesis of Inositol (1,4,5)-Trisphosphate (InsP3).
In a collaborative project with Chi-Linh Do-Thanh in our group to deveplop a
fluorescent bis-cyclen tweezer receptor for inositol (1,4,5)-trisphosphate, I synthesized
inositol (1,4,5)-trisphosphate as the binding target of the tweezer.
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Scheme 7.2 Synthesis of Inositol (1,4,5)-Trisphosphate (InsP3).
The synthesis started with D-myo inositol. The preparation until 1D-2,3,6-O-Tris(benzyloxymethyl)-myo-inositol 4,5-bis-(dibenzyl phosphate) (7.2.2) was previously
reported.96,102 Phosphorylation of the last free alcohol yielded compound 7.2.3 which
then underwent a global protecting group deprotection to form the inositol (1,4,5)trisphosphate 7.2.1.
1D-2,3,6-O-Tris-(benzyloxymethyl)-myo-inositol

1,4,5-tis-(dibenzyl

phosphate)

(7.2.3). To a solution of 7.2.2 (67 mg, 0.063 mmols) and 1-H-tetrazole (0.56 mL, 0.253
mmol, 0.45 M in acetonitrile) in methylene chloride (15 mL) under nitrogen gas was
added dibenzyl N,N-diisopropylphosphoramidite (0.30 mL, 0.91 mmol), and the mixture
was then stirred at rt for 10 h. The reaction solution was then cooled to 0 °C, and mCPBA (158 mg, 5786%) was added. The mixture was stirred at this temperature for 60
min and then slowly warmed to rt after the removal of the cooling bath. The solution was
next diluted to 100 mL with methylene chloride and washed with saturated aqueous
sodium bicarbonate (2  60 mL), and the resulting aqueous phase was extracted once
more with methylene chloride (60 mL). The organic phases were dried with magnesium
sulfate, filtered, and concentrated, and the residue was then purified by chromatography
on silica gel (15-35% acetone/hexanes) giving tris-phosphodiester 7.2.3 (75 mg, 90%)
as a syrup. []D296K 24.3 (c = 1.0, CHCl3); 1H NMR (300 MHz, CDCl3)  7.217.28 (m,
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45H), 4.915.10 (m, 16H), 4.684.88 (m, 3H), 4.62-4.66 (m, 2H), 4.564.62 (m, 3H),
4.444.56 (m, 2H), 4.36-4.42 (m, 2H), 4.29 (t, 1H), 4.20 (t, 1H);

31

P NMR (161.8 MHz,

CDCl3)  0.091. MALDI-HRMS [M + Na]+ calcd for C72H75O18P3, 1343.41; found,
1343.44.
(-)-D-myo-Inositol 1,4,5-trisphosphate hexakis sodium salt (7.2.1). To a solution of
1D-2,3,6-O-Tris-(benzyloxymethyl)-myo-inositol 1,4,5-tis-(dibenzyl phosphate) (7.2.3, 75
mg, 0.057 mmol) in methanol (50 mL) was added palladium hydroxide on charcoal (15
mg). The mixture was then stirred under 1 atm of hydrogen (balloon) for 3 days at rt.
Next, the catalyst was removed by filtration, and the residue was with washed with
methanol. The solvent was the removed under vacuum, and the crude product was
dissolved in water and stirred for 3 h with Chelex 100 resin (Sigma, Na+ form). The resin
was removed by filtration, and the filtrate was lyophilized to give InsP3 (2, 29 mg, 94%)
as a white solid. Characterizations were in agreement with previously reported
values.117
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3. Synthesis of phosphatidylinositol (3,4,5)-trisphosphate.
In order to obtain a phosphatidyinositol polyphosphate with lipid backbone that can
be incorporated into liposome, we designed a rapid synthetic route to access lipid as
such using the amino-tagged PIPns that we have at hand.
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Scheme 7.3 Synthesis of phosphatidylinositol (3,4,5)-trisphosphate.

First of all, the lauric acid was activated into an NHS ester which was reacted with
amino-tagged PI(3,4,5)P3 to generate PI(3,4,5)P3 7.3.1.
Phosphatidylinositol (3,4,5)-trisphosphate (7.3.1). Lauric acid (200 mg, 1.0 mmol)
was dissolved in 10 mL THF. To this solution was added N-hydroxy succinimide (115
mg, 1.0 mmol) and DCC (206 mg, 1.0 mmol). The reaction was stirred at room
temperature overnight. The by-product DCU was filtered off and the filtrate was
concentrated to yield the crude NHS ester which was then purified through a short silica
gel column with a solvent system of 1:20 acetone/dichloromethane to yield the pure
NHS ester as a white solid (239 mg, 85%). The lauryl NHS ester (18 mg, 0.064 mmol) in
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1 mL DMF was added amino-tagged PI(3,4,5)P3 (10 mg, 0.013 mmol) in 1 mL TEAB
(1M, pH=7.5). About 0.5 mL of THF was added to this solution. The reaction was stirred
at room temperature overnight. The solvent was then removed under reduced pressure.
The yielded crude was washed by acetone (10 mL x3) and then dissolved in 5 mL
deionized water. The solution was filtered and the filtrate was lyophilized to generate
compound 7.3.1 as a white solid (7 mg, 58%).
1

H NMR (300MHz, D2O)  4.23-4.21 (m, 2H), 3.88-3.77 (m, 6H), 3.02-3.00 (m, 2H),

2.06-2.04 (m, 2H), 1.46-1.40 (m, 6H), 1.19-1.10 (m, 18H), 0.70-0.69 (m, 6H).
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P NMR

(161.8 MHz, D2O)  4.57, 3.25, 2.56, 0.75. MALDI-HRMS [M + Na]+ calcd for 804.1903;
found 804.4795.
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4. Synthesis of phosphatidylinositol (3, 5)-bisphosphate fluorescein conjugate.
A soluble PI(3,5)P2-fluorescein conjugate was requested by our collaborator, Dr. Jon
Andresen from the University of Missouri-Kansas City. Adopting the modular PIPns
probe synthetic strategy, we derivatized the amino-tagged PI(3,5)P2 into 5(6)carboxyfluorescein tagged PI(3,5)P2 conjugate.
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Scheme 7.4 Synthesis of PI(3,5)P2 fluorescein conjugate.

Phosphatidylinositol (3,5)-bisphosphate (7.4.1). 5(6)-carboxyfluorescein (50 mg,
0.133 mmol) was dissolved in a mixture of 1 mL THF and 1 mL DMF. To this solution
was added N-hydroxy succinimide (31 mg, 0.266 mmol) and DCC (55 mg, 0.266 mmol).
The reaction was stirred at room temperature for 1.5 hours. The solvent was then
removed under reduced pressure. The crude was washed by ethyl ether (20 mL x3).
The solid was then dissolved in 10 mL chloroform and filtered. The filtrate was
concentrated to yield the CBF-NHS ester, which was next dissolved in 1 mL DMF. To
this solution was added amino-tagged PI(3, 5)P3 (4.5 mg, 0.0072 mmol) in 1 mL TEAB
(1M, pH=7.5). About 0.5 mL of THF was added to the solution. The reaction was stirred
at room temperature overnight. The solvent was then removed under reduced pressure.
The yielded crude was washed by cold acetone (10 mL x3) and then dissolved in 5 mL
deionized water with 200 mg sodium form. The solution stirred at room temperature for
3 hours and then was directly loaded onto a C18 reverse-phase column (2 g). The
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column was eluted with deionized water (10 mL). The combined water fractions were
lyophilized to generate compound 7.4.1 as an orange solid (3.6mg, 50%).
1

H NMR (300MHz, D2O)  8.13-7.93 (m, 2H), 7.49-7.47 (m, 1H), 7.19-7.18 (m, 2H),

6.70-6.54 (m, 4H), 4.40-4.39 (m, 2H), 3.98-3.84 (m, 6H), 3.13-3.11 (m, 2H), 1.60-1.30
(m, 8H).

31

P NMR (161.8 MHz, D2O) 2.40, 0.83, -0.87. MALDI-HRMS [M + H]+ calcd

for 878.1222; found 878.1215.
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5. Synthesis of azido-tagged lipids.
Originally, we designed azido-tagged lipids (compound 7.5.1 & 7.5.2) to be used in the
liposome immobilization studies. However, better results were observed with the
triazole-linked azido lipids rather than the amide-linked ones. This may be caused by
the lower hydrophilicity of amide than triazole. Here, I include the synthetic procedures
of these lipids as a reference for any other similar synthetic projects.
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Scheme 7.5 Synthesis of azido-tagged lipids.
Benzyl (2,3-dihydroxypropyl)carbamate (7.5.4). 3-Amino-1,2-propanediol 7.5.3 (1.0
g, 11.0 mmol) was dissolved in 25 mL toluene, along with phthalic anhydride (1.55 g,
10.5 mmol). The reaction was heated to 135oC with Dean-Stark apparatus overnight.
The reaction was extracted by chloroform (200 mL)/saturated sodium chloride solution
(150 mL x 3). The organic layer was collected, dried by magnesium sulfate, filtered and
concentrated to yield product 7.5.4 as a white solid (1.10 g, 47%).
2,3-Bis(hexadecyloxy)propan-1-amine (7.5.6). Diol 6.5.4 was dissolved in 15 mL cold
DMF. To this solution was added sodium hydride under nitrogen. The reaction was
stirred at 0 C for 15 minutes then room temperature for 10 minutes. 1Bromohexadecane (1.7 mL, 5.43 mmol) was added to the solution which was then
refluxed at 135 C overnight. The reaction wan then cooled to room temperature and
quenched by 1 mL water. The solvent was removed under reduced pressure. The crude
was extracted by dichloromethane (200 mL)/saturated sodium chloride solution (150 mL
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x 3). The organic layer was dried by magnesium sulfate, filtered and concentrated to
yield the crude product 7.5.5, which was directly used in the next reaction without
further purification. Crude 7.5.5 was dissolved in 25 mL methanol along with 2 mL
hydrazine monohydrate. The reaction was refluxed overnight. Then the solvent was
removed under reduced pressure. The crude was purified by column chromatography
using

a

gradient

solvent

system

of

2-10%

ammonia

saturated

methanol/dichloromethane to yield amine 7.5.6 as an off-white solid (306 mg, 60% from
7.5.4).
Azido-TEG-ether-lipids (7.5.1). Azido acid 7.5.6 (51 mg, 0.185 mmol) was combined
with DCC (50 mg, 0.241 mmol), DMAP (29 mg, 0.241 mmol) in 5 mL dichlormethane.
The reaction was stirred at room temperature for 20 minutes. Then amine 7.5.6 (100 mg,
0.185 mmol) was added to the solution. The reaction was stirred at room temperature
overnight. The solvent was then removed under reduced pressure. The yielded crude
was purified by column chromatography using a gradient solvent system of 50-100%
ethyl acetate/hexane then 5% methanol/dichloromethane to yield lipid 7.5.1 as a white
solid (32 mg, 22%).
Azido-TEG-ester-lipids (7.5.2). 3-Amino-1,2-propanediol 7.5.3 (247 mg, 2.706 mmol)
was combined with azido acid 6.5.7 (500 mg, 1.804 mmol), EDCI (517 mg, 2.706 mmol),
HOBt (366 mg, 2.706 mmol), triethylamine (0.4 mL, 2.706 mmol) in 5 mL dry DMF. The
reaction was stirred at room temperature overnight. The solvent was then removed
under reduced pressure. The crude was purified by column chromatography using a
gradient solvent system of 5-20% methanol/dichloromethane with 1% acetic acid to
yield diol 7.5.8. Diol 6.5.8 was dissolved in 30 mL chloroform. To this solution was
added paltimic acid (1.85 g, 7.216 mmol), DCC (1.49 g, 7.216 mmol) and DMAP (0.88
g, 7.216 mmol). The reaction was stirred at at room temperature overnight. The solvent
was then removed under reduced pressure. The crude was purified by column
chromatography using a gradient solvent system of 10-20% acetone to chloroform to
yield lipid 7.5.2 (643 mg, 43% from 7.5.3).
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